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HIV-associated lipodystrophy syndrome (HALS) is characterised by abnormalities of 
body fat distribution and metabolism resulting from adipocyte dysfunction. This thesis 
examines the hypothesis that antiretroviral drugs (ARVs) alter PPAR-γ, which 
contributes to adipocyte dysfunction. We hypothesise that conjugated linoleic acid 
(CLA) isomers, as putative PPAR-γ ligands, will attenuate adipocyte dysfunction and 
HALS.  
In vitro, ritonavir (RTV; 20 μM) was the most potent ARV and significantly decreased 
triglyceride storage (P < 0.001), perilipin (P = 0.003) and Cidea expression (P < 0.001), 
PPAR-γ expression (P = 0.014) and nuclear binding (P = 0.03), and adiponectin 
secretion (P < 0.001) compared with control. Microarray analysis revealed adipocyte 
differentiation as a top pathway affected by RTV (P = 0.007).  
The addition of both c9,t11 and t10,c12 (100 μM) to RTV-treated cells in vitro 
significantly increased triglyceride accumulation compared with control (P < 0.001). 
c9,t11 increased PPAR-γ nuclear binding (P = 0.038), while t10,c12 decreased perilipin 
expression (P = 0.004) and adiponectin expression (P = 0.038) and protein secretion (P 
= 0.003). Although c9,t11 had positive effects on adipocyte function, t10,c12 enhanced 
the detrimental effects of RTV.  
The prevalence of HALS was found to be 29% among a cohort of UK patients with 
HIV. Receiving a first line ARV regimen was associated with reduced odds of 
developing HALS (OR 0.28, P = 0.003).  
A study was conducted to investigate the effect of CLA (3 g/d) versus placebo (high-
oleic sunflower oil) on abdominal obesity in HIV-infected men. Five of 478 patients 
were eligible and completed the study. No difference in WC was detected between the 
groups after 12 weeks of supplementation. Information collected as part of this study 
will help inform future polyunsaturated fatty acid interventions among HIV patients. 
The findings of this thesis are discussed in the context of existing scientific literature in 
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TNF-α  tumour necrosis factor-alpha 
Tregs  regulatory T cells 
TZD  thiazolidinedione  
T2DM  type 2 diabetes mellitus 
t10,c12 trans-10,cis-12 conjugated linoleic acid 
UCP  uncoupling protein  
VAT  visceral adipose tissue 
VEGF  vascular endothelial growth factor 
WAT  white adipose tissue 
WHO  World Health Organisation 
WHR  waist-to-hip ratio 
WC   waist circumference  
ZDV  zidovudine 






















Chapter 1  
 
Introduction 




HIV associated lipodystrophy syndrome (HALS) is a complication of human 
immunodeficiency virus (HIV) infection and antiretroviral drugs (ARVs) (Galescu et 
al., 2013).  The prevalence of HALS in UK HIV populations and the causal factors 
associated with it are currently unknown. HALS may occur as a result of antiretroviral 
drug-induced adipocyte dysfunction, particularly down-regulation of peroxisome 
proliferator-activated receptor gamma (PPAR-γ) (Caron et al., 2009). Conjugated 
linoleic acid (CLA) isomers are putative PPAR-γ ligands (Belury et al., 2002).  The aim 
of this thesis was to investigate the contribution of ARVs to adipocyte dysfunction and 
the role of CLA isomers in mitigating this adipocyte dysfunction in vitro, and to explore 
the prevalence of lipodystrophy in a London-based HIV population, the factors 
associated with it and the role of CLA supplementation in improving aspects of 
lipodystrophy in vivo.  
 
 
1.1 Human immunodeficiency virus  
In 1981, five cases of Pneumocystis carinii pneumonia were presented to the United 
States Centre for Disease Control in homosexual men who had also presented with 
decreased CD4+ T cell count resulting in a deficit in cell-mediated immunity (Gottlieb 
et al., 1981). The men were later found to be suffering from an acquired immune 
deficiency syndrome (AIDS), caused by a retrovirus named human T-lymphotropic 
virus type III / lymphadenopathy-associated virus (Sarngadharan et al., 1984), now 
referred to as HIV. 
 
The latest global prevalence figure for HIV is 35.3 million, with 6,300 new infections 
per day in 2012, of which ninety-five percent were in individuals from low- and middle-
income countries (World Health Organisation, 2014a). In 2013, over two thousand new 
cases of HIV were diagnosed in the UK, which brings the total number of new 
diagnoses to 131,327 in over two decades (Public Health England, 2014). The UK HIV 
population represents less than one percent of the HIV/AIDS burden worldwide, while 
sixty-eight percent of the global HIV/AIDS population is located in Sub-Saharan Africa 
(World Health Organisation, 2010). Since 2005, mortality from HIV/AIDS has declined 
by 30%, which was accompanied by and partly attributed to a 24-fold increase in the 




There are currently twenty-four ARVs from five different drug classes licensed for use 
in the European Union (EU; Table 1.1). Drugs within each ARV class differ in their 
mode of action and effects on the stages of HIV replication (Figure 1.1). Nucleoside 
reverse transcriptase inhibitors (NRTIs) interact with the substrate binding site of HIV 
reverse transcriptase (RT) (Kakuda, 2000). Nucleotide reverse transcriptase inhibitors 
(NtRTIs) require only two steps of phosphorylation, as opposed to three with the 
NRTIs, but work in a similar way to NRTIs (Gilead Sciences Inc, 2001). Non-
nucleoside reverse transcriptase inhibitors (NNRTIs) differ from NRTIs in that they 
bind specifically with a non-substrate binding site of the RT enzyme, disrupting the 
enzymes catalytic site. Protease inhibitors (PIs) inhibit the protease enzyme, thus 
preventing the cell from cleaving the proteins into active viral particles (Wynn et al., 
2004). Fusion inhibitors block the attachment, co-receptor binding and fusion of the 
viral particle and prevent viral capsid entry into the host cell (Greenberg and Cammack, 
2004). C-C chemokine receptor type 5 (CCR5) inhibitors inhibit CCR5 signalling, are 
antagonists of the CCR5 receptor and prevent viral entry into the host cell (Dorr et al., 
2005). Integrase inhibitors are the newest class of ARVs and work by inhibiting the 
insertion of the HIV-1 pro-viral DNA into the host cell genome (De Clercq, 2010).   
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Table 1.1 Antiretroviral drugs currently licensed in the EU 
Generic name Trade name 
Fixed dose combinations  
Lamivudine (3TC) / abacavir  Kivexa 
3TC/ zidovudine (ZDV) Combivir 
Emtricitabine (FTC)/ tenofovir Truvada 
3TC/abacavir/ ZDV Trizivir 
FTC/rilpivirine/ tenofovir Eviplera 
FTC/ tenofovir/ efavirenz Atripla 
Elvitegravir/ cobicistat/ FTC/ tenofovir Stribild  
NRTIs  
3TC Epivir 
Abacavir  Ziagen 
ZDV  Retrovir  
FTC Emtriva 
NtRTIs  
Tenofovir  Viread 
NNRTIs  
Efavirenz  Sustiva 
Etravirine  Intelence 
Nevirapine  Viramune  








CCR5 inhibitor  
Maraviroc Celsentri 
Integrase inhibitor  










Figure 1.1 Mode of action of antiretroviral drugs  (Adapted from (National Institute of 














In 1987, zidovudine (ZDV) became the first ARV approved by the Food and Drug 
Administration (FDA) for the management of HIV/AIDS (Food and Drug 
Administration, 2011). The development of successive ARVs would give rise to the 
first combination with ZDV and dideoxycytidine (McLeod and Hammer, 1992). 
Combination drug therapy, also known as highly active antiretroviral therapy 
(HAART), consists of at least two ARVs, most commonly NRTIs, PIs and NNRTIs 
(Shafer and Vuitton, 1999). For those with access to ARVs, HIV infection has been 
transformed into a manageable, chronic condition. HAART introduction has led to a 
significant reduction in mortality among people living with HIV/AIDS (Palella et al., 
1998). However, the beneficial impact of HAART is marred to some extent by the 
adverse effects associated with its use. HIV infection and HAART are associated with 
the development of adverse neurological, gastrointestinal, hepatobilliary, respiratory, 
endocrine, reproductive, renal, skeletal and cardiovascular (CV) / metabolic effects 















Figure 1.2 Spectrum of HIV complications (Adapted from (NAM., 2012))   
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1.2 HIV-associated lipodystrophy syndrome  
HALS is one of the complications of HAART and was first described by Carr and 
colleagues in 1998 (Carr et al., 1998a). HALS has since become the most prevalent sub-
type of acquired lipodystrophy (LD) (Garg, 2011). HALS is characterised by 
lipoatrophy (LA) in the face and extremities, lipohypertrophy (LH) in the abdomen and 
dorsocervical region, accompanied by dyslipidaemia, insulin resistance (IR), impaired 
glucose tolerance, hypertension (HTN), endothelial dysfunction, and altered cytokine 
and adipokine production (Galescu et al., 2013). A recent systematic review and meta-
analysis found that HIV-infected individuals receiving HAART had a two-fold 
increased risk of cardiovascular disease (CVD) compared with healthy individuals 
(Islam et al., 2012). An increased risk of acute myocardial infarction has also been 
shown in HIV-infected individuals receiving ARVs, particularly the PI ritonavir (RTV), 
which was associated with a greater than two-fold increased risk (Durand et al., 2011). 
Though ARVs, particularly PIs and NRTIs, are considered the main drivers of HALS, 
the virus itself (Agarwal et al., 2013)
 
and host genetics (Marzocchetti et al., 2011),  may 
also contribute to its pathogenesis. 
 
 
1.2.1 Clinical characteristics of HALS  
 
1.2.1.1 Lipoatrophy  
LA in HIV is characterised by loss of subcutaneous (SC) fat (Carr et al., 1998a) and is 
distinctly different from traditional HIV wasting, which is characterised by a decrease in 
lean body mass (Grinspoon et al., 1996). LA is seen mainly in the face (facial LA), 
arms, legs and buttocks (peripheral LA) (Saint-Marc et al., 2000, Lichtenstein et al., 
2003). Facial LA usually presents as malar or temporal wasting (Omolayo, 2008). 
Peripheral LA is often accompanied by prominent superficial veins, which contribute to 
the emaciated appearance observed in these individuals (Bergersen et al., 2005). It has 
been shown that at least 30% of limb fat needs to be lost before LA becomes clinically 
evident (Podzamczer et al., 2009). Although LA was originally attributed to PIs (Carr et 
al., 1998a), a recent systematic review concluded that NRTIs are the main contributor 
(de Waal et al., 2013). Older NRTIs such as stavudine (d4T) are associated with a 
significantly greater rate of limb fat loss in HIV-infected men compared with other 
drugs (Mallon et al., 2003). The World Health Organisation (WHO) now recommends 
ZDV- or tenofovir (TDF)-based first line regimens in favour of d4T due to the long 
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term toxicities associated with d4T which include LA (World Health Organisation, 
2013).  Other risk factors associated with LA include older age, a decrease in body mass 
index (BMI) of ≥ 2 kg/m2, white race, low recent CD4 cell count percentage, low nadir 
CD4 count or percentage, and a diagnosis of AIDS (Lichtenstein et al., 2001). 
Generally, morphological alterations associated with HALS including LA tend to occur 
later in the course of treatment. One study showed that patients treated with a NRTI or a 
PI for less than three months did not develop LA (Ho et al., 1999). In accordance with 
these findings, Carr et al estimated the mean time to developing LD as ten months after 
commencing PI therapy (Carr et al., 1999). A recent study found that 28% of a cohort of 
2,131 patients developed LA after 1-5 years of receiving HAART (Leclercq et al., 
2013). 
 
1.2.1.2 Lipohypertrophy  
LH is characterised by adipose tissue accumulation mainly in the intra-abdominal (Carr 
et al., 1998a, Dinges et al., 2005) and dorsocervical regions (Lo et al., 1998, Roth et al., 
1998). Other features of LH may include breast enlargement, observed in both males 
and females (Bernasconi et al., 2002, Savès et al., 2002, Mutimura et al., 2007), 
accumulation of adipose tissue on the anterior region of the neck (Palella et al., 2006), 
side of the neck (Mutimura et al., 2007), under the axillae (Palella et al., 2006) and in 
the suprapubic region (Guaraldi et al., 2007), and localised or generalised lipomas 
(Miller et al., 2003).  LH in the context of HIV/HAART is distinct from simple 
accumulation of visceral adipose tissue (VAT), as it is associated with a decrease, rather 
than an increase, in subcutaneous adipose tissue (Dinges et al., 2005). Interestingly, 
central obesity is the most commonly identified form of LH seen among HALS patients 
(Loonam and Mullen, 2012).  
 
Factors associated with the development of LH in the context of HIV and HAART 
include being female (Jacobson DL et al., 2005), older age, white race, type 2 diabetes 
mellitus (T2DM) and CD4 count > 300 (Nguyen et al., 2008), CD8 cell activation 
(Guaraldi et al., 2013), total cholesterol (TC) ≥ 5 mmol/L and triglycerides (TG) ≥ 1.75 
mmol/L (Nguyen et al., 2008). PIs (indinavir (IDV), abacavir, nelfinavir) and NNRTIs 
(efavirenz) have also been shown to be associated with LH (Nguyen et al., 2008). 
Interestingly, greater levels of VAT and a higher prevalence of metabolic syndrome 
(MetS), T2DM and CVD risk have been found in men with a high TG/high waist 
circumference (WC) ratio (Janiszewski et al., 2011).  Recently, it has been observed that 
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central obesity in HIV-infected individuals is associated with physical frailty (Shah et 
al., 2012) and neurocognitive impairment possibly as a result of cerebral degeneration 
associated with inflammation and IR (McCutchan et al., 2012). 
 
 
1.2.1.3 Dyslipidaemia  
The incidence of dyslipidaemia is higher in HIV-infected individuals receiving HAART 
compared with treatment-naive individuals and non-HIV-infected individuals (Tripathi 
et al., 2013). The prevalence of dyslipidaemia in HIV has been shown to vary from 24% 
to 72% (Loonam and Mullen, 2012). Dyslipidaemia in HIV-infected individuals arises 
as a result of HIV infection, as well as treatment with HAART (Grunfeld et al., 1989, 
Pinto Neto et al., 2013). HAART is associated with the development of an atherogenic 
lipid profile including elevated TC, low-density lipoprotein cholesterol (LDL-C) and 
TG (Duro et al., 2013).  Interestingly, the same researchers found increased levels of 
high density lipoprotein cholesterol (HDL-C) in patients treated for 3 years with an 
NNRTI containing regimen (Duro et al., 2013). This protective effect of NNRTI on 
HDL-C has also been demonstrated in other studies (van der Valk et al., 2001, Friis-
Moller et al., 2003). Data from HIV negative healthcare workers treated 
prophylactically with HAART following sharps injury showed elevated TC and LDL-C 
after only four weeks of treatment (Allan and Behrman, 2001). Although one study 
found no effect of HAART duration on risk of dyslipidaemia (Duro et al., 2013), data 
from large cohort studies (Friis-Moller et al., 2003, Young et al., 2005, Domingo et al., 
2008), cross-sectional studies (Ceccato et al., 2011, Feleke et al., 2012) and prospective 
studies (Heath et al., 2001, Heath et al., 2002) demonstrate an association between 
increasing duration of HAART and risk of dyslipidaemia.  Age and sex (Leitner et al., 
2006), race (Foulkes et al., 2006) and genetic factors (Egana-Gorrono et al., 2013) have 
also been shown to be associated with risk of dyslipidaemia in HIV.  
 
Dyslipidaemia in HIV-infected individuals may be diagnosed using recommendations 
for the general population, i.e. using the National Cholesterol Education Programme 
Adult Treatment Panel III (NCEP) guidelines (Gkrania-Klotsas and Klotsas, 2007). The 
authors of this paper recommended that fasting lipid profile tests be offered to patients 




1.2.1.4 Atherosclerosis  
Atherosclerosis is characterised by the formation of plaques in large- and medium-sized 
arteries and is an initial step in the development of CVD (Gibellini et al., 2013). 
Atherosclerotic plaques form within the sub-endothelial intima structure when LDL and 
lipoprotein remnants become trapped, are modified and then activate the endothelium. 
The activated endothelium and modified LDL induce chronic inflammation and are 
associated with an increase in monocyte recruitment and differentiation to macrophages. 
In the presence of chronic inflammation, activated macrophages produce cytokines, 
chemokines and proteases, which lead to the formation of foam cells and migration of 
smooth muscle cells into the endothelial intima. As the atherosclerotic plaque increases 
in size, it induces vascular damage and eventually, rupture of the plaque and thrombosis 
may lead to a coronary event (Gibellini et al., 2013). Atherosclerotic plaques, by 
definition, are “lesions of the intima characterised by necrotic and calcified regions 
containing accumulated, modified lipids, inflamed smooth muscle cells, leukocytes and 
foam cells” (Gibellini et al., 2013).   
 
HIV-infected men have a higher prevalence of subclinical coronary atherosclerosis 
compared with non-infected men with similar demographics and risk factors for heart 
disease (59% vs. 34%) (Lo et al., 2010). LD was found to predict endothelial 
dysfunction (Masiá, 2010), which is a critical step in the progression of atherosclerosis 
in HIV (Shankar and Dube, 2004). Data from the AIDS Clinical Trials Group show a 
rapid improvement in endothelial function in previously naive patients randomised to 
treatment (Torriani et al., 2008). Similarly, a study in patients receiving HAART found 
no association between HAART and endothelial function measured using flow-
mediated dilatation (Dubé et al., 2010). Contrary to this, a study of 37 adults receiving 
HAART showed increased endothelial dysfunction in those taking PIs compared to 
those who were not (Stein et al., 2001). Atherosclerosis progression, as measured by 
carotid intima media thickness, was found to be increased as a result of HAART (van 
Vonderen et al., 2009, Vigano et al., 2010). Other factors associated with 
atherosclerosis in HIV include TC, LDL-C and longer duration of HAART, which 
predict plaque burden (Lo et al., 2010), lower nadir CD4 count which is associated with 
coronary stenosis of greater than 50% (Post et al., 2014) and long term HIV infection, 




1.2.1.5 Endothelial dysfunction 
Endothelial dysfunction is one of the proposed underlying mechanisms involved in the 
development of CVD in HIV (López et al., 2012). Untreated HIV infection has been 
associated with greater endothelial dysfunction (Arildsen et al., 2013). Brachial artery 
flow mediated dilatation (FMD) provides a measure of blood flow through the blood 
vessel, as well as vessel dilation, and has been shown to be normalised upon initiation 
of HAART in HIV-infected individuals with low FMD readings compared with controls 
(Arildsen et al., 2013). A recent study showed a decrease in biomarkers for endothelial 
damage in treatment-naive patients with HIV after 12 weeks of HAART (Mata-Marín et 
al., 2013). Type of HAART has been shown to play a role, as was shown in one study 
where worsening endothelial function was observed in patients treated with the NNRTI 
efavirenz compared with PIs at 12 months (Gupta et al., 2012). HAART duration, 
associated with a higher circulating lipopolysaccharide (LPS) concentration, was also 
shown to be a predictor of FMD in patients with HIV (Blodget et al., 2012). In a study 
of ninety-six HIV-infected individuals, no association was found between endothelial 
function assessed by brachial FMD and any body composition measure, HAART use, 
PI use, CD4 cell count, and HIV RNA levels (Dubé et al., 2010). Although this study 
failed to find an association for PI use in vivo, work in human aortic endothelial cells 
has shown PI to mediate endothelial dysfunction, which was ameliorated by the addition 
of troglitazone, an anti-diabetic drug and potent PPAR-γ agonist (Mondal et al., 2013).  
 
1.2.1.6 Hypertension 
HTN is a major modifiable risk factor for CVD and is prevalent in up to 43% of patients 
with HIV (Myerson et al., 2014). In some studies, rates of 30%, similar to the general 
population (Joffres et al., 2013), have been reported (De Socio et al., 2014). In a cohort 
of London-based HIV patients, raised systolic blood pressure (SBP) was identified in 
18% of patients (Elgalib et al., 2011). HTN in HIV is associated with both LA and LH 
(Crane et al., 2009). Patients classified as having isolated LH and mixed forms of LD 
were shown to have a higher prevalence of HTN compared with those with LA and with 
no LD. HTN associated with LH is suggested to be mediated by increased BMI (Crane 
et al., 2009).  
 
A recent, multicentre, cross-sectional study of 1,182 HIV patients found a number of 
factors to be predictive of HTN including age ≥ 50 years, male sex, BMI ≥ 25 kg/m2, 
central obesity, family history of CVD, previous CV events, T2DM and MetS, as well 
31 
 
as duration of HIV infection, duration of HAART, and low nadir CD4 cell count (De 
Socio et al., 2014). Contrary to these findings, Elgalib et al (2011) found that higher 
CD4 cell count was associated with raised SBP in their cohort of 1,022 London-based 
patients. The role of HAART in mediating HTN is unclear as some studies associate 
HTN with longer duration of HAART (De Socio et al., 2014), while others found no 
association between HAART and HTN (Thiébaut et al., 2005, Medina-Torne et al., 
2012) and use of some NNRTI was found to lower the risk of HTN (Thiébaut et al., 
2005). Recently, alcohol abuse has been independently associated with HTN in patients 
with HIV (Ikeda et al., 2013).  
 
1.2.1.7 Cardiovascular disease  
As discussed in previous sections, both HIV and HAART alter the profile of traditional 
CV risk factors (see Figure 1.3) and increase the risk of CVD in HIV-infected 
individuals (Bergersen et al., 2004). The role of viraemia in CVD was demonstrated by 
El-Sadr et al (2008) who found that patients randomised to episodic use of HAART 
based on CD4 count had higher rates of CVD compared with patients with 
uninterrupted HAART who maintained viral suppression.  With respect to ART, 
increased CVD risk was found to be associated with each additional year of exposure to 
PIs (IDV and lopinavir) (Friis-Moller et al., 2007, Bavinger et al., 2013) and NRTIs 
(abacavir) (Bavinger et al., 2013), but not NNRTIs (Friis-Moller et al., 2007), newer 
generation PIs, CCR5 antagonists, or integrase inhibitors (Longenecker and Triant, 
2014). Data from a London-based cohort show an association between duration of first 
line HAART and a coronary heart disease (CHD) risk of ≥ 10% (Elgalib et al., 2011).  
However, the role of HAART in mediating CVD in HIV was recently reviewed and 
findings suggest that use of HAART, even at higher CD4 counts, may reduce CVD risk 











The risk of CV events increases in patients with MetS compared with those without 
(22.2% vs. 7.4%) (Alvarez et al., 2010). However, family history has been shown to be 
a greater predictor of CVD risk than T2DM, HTN and smoking in HIV-infected 
individuals (Calvo-Sánchez et al., 2013). Ten-year CVD risk is frequently estimated 
using the Framingham equations; however, the Data collection on Adverse events of 
Anti-HIV Drug study equation is the only tool specifically designed to predict CVD risk 
in HIV-infected populations (Nery et al., 2013). The PROCAM study equation is also 
used to predict 10-year CVD risk, but, again, is not specific for HIV-infected 
individuals (Nery et al., 2013). Using the Framingham equations, a London-based study 
of HIV positive adults identified an average of 6% risk of CVD with a median risk of 
4% in men and 1.4% in women. Caucasians had a three-fold increase in the prevalence 
of CVD risk > 20% compared with other ethnicities and raised TC was the greatest risk 





















Traditional risk factors cannot fully explain the increased risk of CVD in HIV. The role 
of immune activation and inflammation in the pathogenesis of CVD in HIV has recently 
been reviewed (Triant, 2013).  Acute phase proteins such as IL-6 and C-reactive protein 
(CRP), as well as biomarkers of coagulation (D-dimer) are associated with CVD risk 
factors in HIV (Duprez et al., 2012, Hileman et al., 2014). Treated HIV-infected 
patients demonstrate increased monocyte expression of pro-inflammatory IL-1β 
compared with uninfected individuals (19.5% vs. 1.9%), which is predictive of high 
plasma IL-6 (Jalbert et al., 2013).  The presence of obesity in patients with HIV has an 
additive effect on inflammatory biomarkers resulting in higher serum IL-6 and 
macrophage inflammatory protein 1-α compared with non-obese patients (Koethe et al., 
2013). Recent evidence indicates that despite virological suppression in patients 
receiving HAART, markers of inflammation and immune activation persist, which may 
contribute to chronic inflammation (Reingold et al., 2008, French et al., 2009).  
Moreover, a higher prevalence of atherosclerosis (78% vs. 42%) and immune activation 
has been demonstrated among elite controllers (controlled HIV infection in the absence 
of therapy) compared with uninfected controls (Pereyra et al., 2012). Both of these 
factors argue for an effect of HIV disease parameters in the pathogenesis of CVD.  
 
1.2.1.8 Altered adipokine and cytokine expression  
Altered expression and secretion of adipokines is a characteristic feature of HALS 
(Paruthi et al., 2013). Adiponectin, leptin, resistin and interleukin-6 (IL-6) are some of 
the main adipokines affected in HALS. Adiponectin is a relatively abundant plasma 
adipokine with anti-inflammatory actions involved in the regulation of glucose 
metabolism and peripheral insulin sensitivity (Ouchi et al., 2011). Adiponectin 
concentration in HALS was found to be 40% lower than in healthy controls and 43% 
lower than HIV-infected individuals without HALS (Bezante et al., 2009). This finding 
of hypoadiponectinaemia in HALS has been demonstrated by a number of groups 
(Lindegaard et al., 2004, Samaras et al., 2007, Luo et al., 2009, Veloso et al., 2012). 
Adiponectin levels in HALS correlate negatively with glucose, IR and TG (Veloso et 
al., 2012) and have been associated with current or previous d4T use (Lindegaard et al., 
2004). Pro-inflammatory adipokines leptin, resistin and IL-6 are significantly altered in 
HALS, which may contribute to inflammation, a key step in the pathogenesis of HALS 
(Caron-Debarle et al., 2010a). Furthermore, recent evidence points towards an 
association between inflammation in HIV and declines in functional performance as 




Leptin is an important regulator of lipid metabolism, insulin action and energy 
homeostasis (Ouchi et al., 2011). Circulating plasma leptin reflects adiposity in HIV, 
where patients with LA have lower leptin levels (1.76 ng/ml) compared with patients 
with LH (9.10 ng/ml) and those without LD (3.14 ng/ml) (Nagy et al., 2003). Leptin 
replacement therapy was found to improve dyslipidaemia (Mulligan et al., 2009) and 
glycaemia (Sekhar et al., 2012) in patients with LA suggesting a role for 
hypoleptinaemia in the pathogenesis of these abnormalities in HALS.  
 
Resistin is another pro-inflammatory adipokine, originally suggested to be the link 
between obesity and IR (Steppan et al., 2001). A recent cross-sectional study of 100 
patients found that LA was associated with a 20% increase in resistin compared with 
patients without HALS (Arama et al., 2014). In contrast, no association was found 
between serum resistin levels and LA, LH or mixed syndrome in a cross-sectional study 
of 227 patients (Barb et al 2005). Differences might be explained by the way in which 
HALS was defined in each study; Barb et al used three blinded investigators to 
determine fat distribution based on measured body composition, while Arama et al did 
not measure body fat and relied on a questionnaire to identify the presence or absence of 
features of HALS. Plasma resistin levels have been shown to correlate with IR in HALS 
(Escote et al., 2011) and single nucleotide polymorphisms (SNPs) in the resistin gene 
have been found to be associated with HALS (Ranade et al., 2008, Escote et al., 2011). 
Both of these factors indicate the potential implication of resistin in HALS, although its 
exact role has yet to be determined.  
 
Adipose tissue produces a significant proportion of circulating IL-6, which acts as a 
pro-inflammatory cytokine and is thought to link obesity-associated inflammation with 
IR (Ouchi et al., 2011). Plasma IL-6 has been shown to correlate with IR in HALS 
(Vigouroux et al., 2003) and serum IL-6 concentrations were increased in HALS 
compared with subjects without HALS and healthy controls (Johnson et al., 2004). 
Other studies have shown no difference in plasma IL-6 between those with HALS and 
those without (Kannisto et al., 2003, Saumoy et al., 2008). In subcutaneous adipose 
tissue (SCAT) biopsy samples from HALS patients, IL-6 mRNA expression was found 
to be significantly higher compared with patients without HALS (Kannisto et al., 2003) 
and healthy controls (Jan et al., 2004). Another study found no difference in SCAT 
expression of IL6 in patients with HALS compared to healthy controls, but 
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interestingly, IL-6 expression in VAT was significantly decreased  (Gallego-Escuredo et 
al., 2013).  
 
1.2.1.9 Insulin resistance and type 2 diabetes mellitus  
T2DM in HIV-infected individuals was relatively uncommon prior to the antiretroviral 
therapy (ART) era (Bradbury and Samaras, 2008). Following the introduction of PIs, a 
greater number of reported glucose disorders began to emerge in HIV infected 
individuals (Dubé et al., 1997, Eastone and Decker, 1997, Visnergarwala et al., 1997). 
In a recent study, patients with LD (defined by fat mass ratio) had significantly higher 
plasma glucose, insulin, HbA1c and IR compared with those without LD (Freitas et al., 
2012). Accordingly, patients with LD had a higher prevalence of impaired fasting 
glucose (15.7% vs. 5%), impaired glucose tolerance (21.4% vs. 19%) and T2DM 
(21.4% vs. 14%) than patients without LD. Impaired glucose tolerance was also more 
prevalent among patients with abdominal LD in this study, compared with those without 
a high WC (30.9% vs. 16.2%).  IR has been identified in up to 66 % of HIV-infected 
patients stable on HAART (Arama et al., 2013). Another study compared 6816 HIV-
infected individuals with the same number of non-HIV infected controls and found a 
higher incidence of T2DM among non-HIV infected individuals compared with infected 
(13.6 vs. 11.4 per 1000 person-years) (Tripathi et al., 2014). Risk factors for T2DM in 
HIV have been found to include older age, female gender, non-white race/ethnicity, 
higher BMI, higher TG, lower TC, pre-existing HTN, hepatitis C virus (HCV) infection, 
longer duration of HIV infection and lower nadir CD4 (Galli et al., 2012, Tripathi et al., 
2014).  
 
Diagnosis of glucose disorders in HALS has been made on the basis of guidelines from 
the International Diabetes Federation (IDF) (International Diabetes Federation, 2005) 
and the American Diabetes Association (American Diabetes Association and Expert 
Committee on the Diagnosis and Classification of Diabetes Mellitus, 2003). According 
to these guidelines, impaired glucose tolerance is defined as a fasting glucose (FG) of 
greater than 5.6 mmol/L and a value of greater than 7 mmol/L is indicative of diabetes. 
Recent European AIDS Clinical Society guidelines recommend testing patients for FG 
at HIV diagnosis, before the start of HAART and annually thereafter (Lundgren et al., 
2008). Society guidelines for diagnosing diabetes and its pre-stages are based on those 
from the WHO 2006 and the IDF (Table 1.2) (World Health Organisation and 





Table 1.2 Diagnosis of diabetes and its pre-stages 
Diabetes 
Any one of the following:  
FG ≥ 7 mmol/L              
2-hour plasma glucose ≥ 11.1 mmol/L                 
75 g OGTT with FG ≥ 7 mmol/L                        
Glycated haemoglobin (HbA1c) ≥ 6.5%               
Random plasma glucose ≥ 11.1 mmol/L in the presence of classical diabetes symptoms 
Impaired fasting glucose 
FG 6.1 – 6.9 mmol/L and if measured 
2-hour plasma glucose < 7.8 mmol/L 
Impaired glucose tolerance 
FG < 7 mmol/L and 
2-hour plasma glucose ≥ 7.8 mmol/L and < 11.1 mmol/L 
OGTT, oral glucose tolerance test. FG, fasting glucose.  
 
 
1.2.1.10 Energy dysregulation  
Energy dysregulation is another characteristic of HALS and has been investigated in a 
few studies, the results of which are summarised in Table 1.3. A meta-analysis of 
studies investigating energy expenditure in HIV found that resting energy expenditure 
per kg lean body mass (REE/LBM) was significantly higher in HIV-infected individuals 






Table 1.3 Energy expenditure in HALS 
Reference Subjects Change in energy expenditure  




14.6% and 32.5% increased REE compared 
with PI-treated without HALS and PI-naive 
without HALS, respectively.  




67.8 % and 56.4% increased REE compared 
with HIV positive without HALS and 
healthy subjects, respectively.  










11% increased REE compared with HIV+ 
subjects without HALS 
PI, protease inhibitors. REE, resting energy expenditure. HALS, HIV-associated 
lipodystrophy syndrome. HAART, highly active antiretroviral therapy.   
 
 
Sutinen and Yki-Jarvinen (2007) showed that the increased energy expenditure found in 
their subjects with HALS was accompanied by an 18.6% higher total caloric intake 
compared with those without HALS (2,289 kcal/d vs. 1,861 kcal/d). In addition to 
increased REE, studies by Kosmiski et al have shown that 3 days of eu-energetic 
feeding (energy requirements = REE x activity factor of 1.3), which should not induce a 
change in REE, resulted in a significantly higher REE among HIV positive adults with 
LD compared with healthy controls (33 vs. 28 kcal/kg lean body mass (LBM) 
(Kosmiski et al., 2007b). The same researchers found that three days of hypo-energetic 
feeding (energy requirements = 50% less than eu-energetic period) induced a 7.5% 
reduction in REE and three days of hyper-energetic feeding (energy requirements = 
50% more than eu-energetic period) caused a 4.3% increase in REE in HIV positive 
adults with LD but not in patients without LD or healthy controls (Kosmiski et al., 
2007a). The group concluded that individuals with LD have higher REE per kg LBM 
than those without LD, short-term caloric restriction reduces REE and short-term over-
feeding increases REE in those with LD. The authors suggest that hypermetabolism 
associated with LD and a form of adaptive thermogenesis invoked to dissipate calories 
that cannot be stored in a normal manner underlie these observations. Data from the 
Nutrition for Healthy Living study also show increased REE in individuals receiving 
HAART compared to those not receiving HAART (Mangili et al., 2006), while 
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Vassimon et al (2012) demonstrated a 22% and 56% increased fasting carbohydrate 
oxidation in HALS compared with men without HALS and healthy controls, 
respectively. Additionally, lipid oxidation in men with HALS was 23% and 53% lower 
in HALS compared with men without HALS and healthy controls, respectively. A 
recent study showed a 2% increase in REE in HAART-naive women, which remained 
elevated when on HAART, suggesting a role for the virus itself in instigating changes in 
REE (Mittelsteadt et al., 2013). 
 
1.2.2 Defining HALS  
It is almost two decades since HALS was first described (Carr et al., 1998a) and a 
precise definition for the syndrome has yet to be established. Carter et al. (2001) 
showed that the prevalence of HALS can vary between 19% - 65% as a result of 
differences in the definition of HALS. Furthermore, LA and LH have been shown to 
occur together as well as separately which has led to much confusion regarding the 
definition of the syndrome. Existing definitions for the syndrome include LA or LH, LA 
alone, LH alone or a combination of LA and LH.  A recent systematic review concluded 
that LA is a consequence of HAART, but LH is not as it occurs to the same degree in 
those receiving different HAART regimens, is not linked to any specific drugs, and can 
be improved by changes to lifestyle (de Waal et al., 2013). The authors of this study 
suggest that LH occurs only as a result of controlling HIV infection, which normalises 
the inflammatory profile.  
 
The main definitions used for the metabolic alterations associated with HALS include 
the NCEP guidelines (National Cholesterol Education Program Expert Panel on 
Detection Evaluation and Treatment of High Blood Cholesterol in Adults, 2002) (Worm 
et al., 2010), the IDF Guidelines (International Diabetes Federation, 2005) (Zannou et 
al., 2009), a combination of NCEP and IDF (Samaras et al., 2007), or the “Report of the 
National Heart, Lung, and Blood Institute/ American Heart Association Conference on 
Scientific Issues Related to Definition” (Grundy et al., 2004) (Jacobson et al., 2006).    
 
In a recent cohort study of more than 34,000 subjects from the general European 
population, the prevalence of the MetS was found to be 24.3% (Scuteri et al., 2014).  
Although the exact prevalence is unclear, prevalence of MetS in international HIV 
populations ranges from 11-45% (Paula et al., 2013). HIV-infected individuals with 
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HALS display features of the MetS including abdominal obesity, dyslipidaemia, IR, 
HTN, endothelial dysfunction, and a proinflammatory and prothrombotic state 
(International Diabetes Federation, 2006). However, unlike MetS in the general 
population, abdominal obesity in HALS may also occur alongside LA.    
 
Self-report and physician examinations are frequently used to diagnose HALS; 
however, these definitions have been shown to vary and the accuracy of these subjective 
methods is unclear (Loonam and Mullen, 2012). In addition to patient self-report and 
physician reports, anthropometric techniques such as skinfold thickness measurements 
are also used to identify body fat changes in HIV (Siqueira Vasimon et al., 2011). 
Skinfold measurements have been used to calculate fat mass ratio (FMR; ratio of the 
percentage of trunk fat mass to the percentage of the lower limb fat mass ) in HIV and 
have been shown to be particularly useful among HIV-infected individuals in resource 
poor settings (Asha et al., 2011). Bioelectrical impedance analysis (BIA) is used to 
measure body composition in HIV, and is useful in measuring total fat mass (Freitas et 
al., 2011). BIA has been shown to be more precise than skinfold measurements, can be 
repeated and is a non-invasive way of determining total fat mass (Siqueira Vasimon et 
al., 2011, Perez-Matute et al., 2013). Dual energy x-ray absorbtiometry (DXA) was 
used early in the post-HAART era to determine body composition (Grinspoon et al., 
1999) and over a decade later, continues to be used to evaluate fat mass in HIV (Freitas 
et al., 2012). Computed tomography (Freitas et al., 2012) and whole body magnetic 
resonance imaging (Lake et al., 2011) have been used to investigate abnormalities of 
body composition in HIV-infected individuals. Although these measures provide 
accurate body composition data, the cost associated with their use negates their use in 
routine clinical practice. Sonography has been used by some researchers to define 
HALS (Signorini et al., 2012) and has been shown to be accurate in measuring intra-
abdominal fat, waist-to-hip ratio (WHR) and subcutaneous leg fat (Padilla et al., 2007). 
However, the same researchers showed that skinfold measurements and WHR had 
greater reproducibility than ultrasonography.  
 
In 2003, Carr and colleagues proposed an objective definition for HALS based on age, 
sex, duration of HIV infection, HIV disease stage, WHR, serum anion gap, HDL-C 
concentration, trunk to peripheral fat ratio, percentage leg fat, and intra-abdominal to 
extra abdominal fat ratio (Carr, 2003). Table 1.4 shows the case definition and scoring 
system used. A diagnosis of LD is made by deriving a total LD score by adding the 
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individual scores for each variable, and then subtracting a constant value of 43. If the 
final score is at least zero or greater then the patient can be diagnosed with LD, while a 
score of less than zero indicates no LD. This definition requires anthropometric 
variables from DXA and CT, which reduces its utility in clinical practice. Other 
research groups have also determined fat mass distribution objectively by creating 
standard values for a fat mass ratio (FMR; ratio of the percentage of the trunk fat mass 
to the percentage of the lower limb fat mass) in uninfected men and applying it to HIV-
infected men (Bonnet et al., 2005). Using variables from DXA another group defined 
gender-specific FMR cut offs as 1.961 for men and 1.329 for women, which provide 
another objective method of defining HALS (Freitas et al., 2010).  










< 40 years 





< 4 years 









WHR (0.1) Multiply by 29 
Metabolic  
HDL-C (0.1 mmol/L) Multiply by -14 
Anion gap (1 mmol/L) Multiply by 1 











Trunk/limb fat ratio (1.0) Multiply by 5 










 (Adapted from Carr et al 2003) 
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1.2.3 Molecular pathogenesis of HALS  
One of the first proposed mechanisms underpinning HALS was “abnormal lipid release 
or storage perhaps via adipocyte apoptosis” (Carr et al., 1998b). Since then, a definitive 
association between disturbances in adipose tissue metabolism and HALS has been 
established including altered adipocyte differentiation, insulin sensitivity, adipokine 
secretion and mitochondrial toxicity (Giralt et al., 2011). Both PIs and NRTIs have been 
shown to cause disturbances in adipocyte function (Stankov et al., 2010, Zha et al., 
2013). Research aimed at improving adipose tissue function has focused on adipogenic 
transcription factors as key modifiable factors. PPAR-γ is one such transcription factor 
and has been shown to be significantly down regulated in response to ARVs, as well as 
in adipose tissue biopsies from HALS patients (Caron et al., 2009). Two PPAR-γ 
isoforms exist: PPAR-γ1 which is found in almost all tissues except muscle and PPAR-
γ2 which is found primarily in adipose tissue and the intestine. The studies reported in 
this thesis refer to the PPAR-γ2 isoform identified in adipose tissue. 
 
1.2.3.1 Peroxisome proliferator-activated receptor gamma  
PPAR-γ is a ligand-activated transcription factor and is expressed in abundance in 
adipose tissue (Desvergne and Wahli, 1999). PPAR-γ forms a heterodimer with 
retinoid-X-receptor (RXR) (PPAR:RXR) for DNA binding to the peroxisome 
proliferator response element (PPRE). The unbound PPAR-RXR is activated by a 
ligand and binds to the PPRE. The PPRE-bound heterodimer targets a coactivator-
acetyltransferase complex to the promoter, which acetylates the histone tails and 
modifies promoter chromatin at the transcription initiation site region. Transcription 
factors are recruited to the accessible promoter and transcription is initiated (see Figure 
















































Figure 1.4 Model for transcriptional activation by PPARs  




1.2.3.1.1 PPAR-γ in adipogenesis  
PPAR-γ has a number of important metabolic roles in adipose tissue (Figure 1.5) and is 
a major determinant of the adipocyte phenotype (Tontonoz et al., 1994). Through the 
process of adipogenesis, PPAR-γ activation induces differentiation of fibroblast-like 
pre-adipocytes into mature, lipid-enriched adipocytes (Otto and Lane, 2005). Activation 
of PPAR-γ induces the expression of another transcription factor CAAT-enhancer 
binding protein (CEBP)-α, and once expressed, CEBP-α and PPAR-γ positively regulate 
each other’s expression during the adipogenic cascade via a positive feedback loop 
(Otto and Lane, 2005). These two transcription factors remain elevated throughout 
differentiation and the life of the mature adipocyte (Rosen, 2005). Other members of the 
CEBP family (CEBP-β and CEBP-δ) are expressed early in adipogenesis and induce the 
expression of CEBPα and PPAR-γ, both of which induce the terminal stages of 
differentiation.  
 
During terminal differentiation, CEBP-α, PPAR-γ and sterol regulatory element binding 
protein (SREBP)-1c are involved in activating adipogenic genes responsible for 
maintaining the adipocyte phenotype (Otto and Lane, 2005). Adiponectin is one such 
target gene responsible for insulin signalling in adipocytes (Iwaki et al., 2003). Others  
include adipocyte lipid binding protein (aP2), fatty acid transport protein, 
phosphoenolpyruvate carboxykinase (PEPCK), as well as lipoprotein lipase (LPL) 
(Desvergne and Wahli, 1999). Lipid droplet-associated proteins, such as perilipin and 
cell death-inducing DFFA-like effector a (Cidea), were also found to have PPRE in 
their promoter regions and are involved in maintaining lipid droplet size once 
adipogenesis has proceeded  (Targett-Adams et al., 2005, Viswakarma et al., 2007). 
PPAR-γ also appears to up-regulate the expression of glucose transporters, such as 
glucose transporter type 4 (GLUT4), which mediates insulin-stimulated glucose 






Figure 1.5 Multiple roles of PPAR-γ in adipose tissue  
(Adapted from (Ahmadian et al., 2013). HFD, high fat diet. TZD, thiazolidinedione. 
STAT, signal transducer and activator of transcription. ACBP, acyl-CoA-binding 
protein. CD36, cluster of differentiation 36. ACS, acyl-CoA-synthetase. GyK, 
glycerokinase. PI3K, phosphoinositide-3-kinase. CAP, c-Cbl associating protein. IRS, 




1.2.3.1.2 Role of PPAR-γ in inflammation 
PPAR-γ mediates its anti-inflammatory effects in a number of ways. PPAR-γ down-
regulates the transcriptional activity of nuclear factor kappa-light-chain-enhancer of 
activated B cells (NF-κB) leading to repression of macrophage inflammatory genes 
(Monsalve et al., 2013). PPAR-γ ligands have been useful in helping to elucidate the 
mechanisms underlying the anti-inflammatory effects of the transcription factor. These 
include repression of pro-inflammatory cytokine and chemokine production from 
dendritic cells, repression of  interferon gamma (IFN-γ) expression in activated T-cells 
and repression of chemokine expression in macrophages (Figure 1.6) (Straus and Glass, 
2007). Recently, PPAR-γ was also found to regulate a novel population of regulatory T 
cells (Tregs) in VAT in mice (Cipolletta et al., 2012), which control VAT inflammation 





Figure 1.6 Anti-inflammatory actions of PPAR ligands  
(Adapted from (Straus and Glass, 2007). CD1, cluster of differentiation 1a.  
CCR7, C-C chemokine receptor 7. VCAM, vascular cell adhesion molecule.   
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1.2.3.1.3 Role of PPAR-γ in insulin sensitivity  
During the early stages of adipogenesis, insulin triggers the induction of PPAR-γ. Once 
activated, PPAR-γ induces insulin-dependent GLUT4 expression, which transports 
glucose across the cell membrane, thereby regulating tissue glucose uptake (Wu et al 
1998). Adipocyte dysfunction has been suggested to play a central role in the 
development of altered glucose homeostasis and IR; therefore, adipocyte dysfunction 
occurring as a result of down-regulated PPAR-γ is likely to contribute to IR (Figure 
1.7). Support for this comes from in vitro studies of 3T3-L1 adipocytes, where PPAR-γ 
inhibition leads to reduced insulin-stimulated glucose uptake mediated by GLUT4 and 
GLUT1 (Liao et al., 2007), as well as reduced insulin receptor and insulin receptor 
substrate (Tamori et al., 2002).  
 
In mouse models, fat-specific ablation of PPAR-γ results in increased blood glucose and 
serum insulin, as well as IR (Wang et al., 2013).  Circulating free fatty acids (FFA) are 
associated with IR and PPAR-γ activation has been shown to lead to a reduction in FFA 
by increasing the number of small, insulin-sensitive adipocytes with greater lipid 
storage capacity (Saraf et al., 2012). The insulin sensitising effect of PPAR-γ may also 
be mediated by activation of target genes, such as adiponectin (Iwaki et al., 2003). 
PPAR-γ is a target for the family of anti-diabetic drugs thiazolidinediones (TZDs) 
(Lehmann et al., 1995). Pioglitazone, a member of the TZD family, was recently shown 
to decrease fasting plasma glucose and improve IR in patients with T2DM compared 
with placebo. This was accompanied by a significant increase in plasma adiponectin and 
a decrease in IL-6 suggesting that the insulin sensitising effect of this PPAR-γ ligand 







Figure 1.7 Putative role of PPAR-γ in insulin resistance (Adapted from (Saraf et al., 
2012). ATGL, adipose triglyceride lipase. HSL, hormone sensitive lipase. PI-3 kinase, 
phosphoinositide-3 kinase. IRS, insulin receptor substrate. TNF-α, tumour necrosis 
factor alpha. 
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1.2.3.1.4 PPAR-γ and HALS  
As discussed previously, PPAR-γ is crucial in maintaining adipocyte function, glucose 
homeostasis and inflammatory profile. Mutations in the PPARG gene are associated 
with LD and symptoms of the MetS in humans (Ludtke et al., 2007). It is not surprising, 
therefore, that a role for PPAR-γ in the aetiology of HALS has been proposed (Caron et 
al., 2009). Down-regulation of PPAR-γ occurs as a result of HIV infection, as well as 
with the use of ARVs. HIV accessory protein, viral protein R, has been shown to 
suppress PPAR-γ activation in vitro in 3T3-L1 adipocytes by interacting with the ligand 
binding domain of the receptor (Shrivastav et al., 2008, Agarwal et al., 2013). HIV-1 
Nef protein has also been shown to decrease the expression of PPAR-γ in human 
macrophages and T-cells (Otake 2004).  
 
ARVs have been shown to decrease PPAR-γ expression and protein levels in some, but 
not all studies. A number of studies in mouse adipocytes, including a microarray 
analysis, have shown a significant reduction in PPAR-γ gene expression in response to 
PIs, NRTIs and NNRTIs (Caron et al., 2001, Caron et al., 2004, Pacenti et al., 2006, 
Viengchareun et al., 2007, Díaz-Delfín et al., 2011, Minami et al., 2011, Díaz-Delfín et 
al., 2012). In these studies, RTV was a particularly potent inhibitor of PPAR-γ at doses 
up to 20 µM, but this finding is not confirmed by all studies  (Grigem et al., 2005, Kim, 
2006, Adler-Wailes et al., 2008). Similar findings for PPAR-γ down-regulation are 
observed for PIs and NRTIs in human pre-adipocytes derived from HIV-negative 
donors (Vernochet et al., 2005, Saillan-Barreau et al., 2008, Caso et al., 2010).  
 
Adipose tissue biopsy samples from healthy, non-obese subjects show that PPAR-γ 
mRNA expression is significantly lower in VAT compared with SCAT (Lefebvre et al., 
1998). In the context of HIV, patients with LA have lower mRNA concentrations of 
PPAR-γ and a 70% reduction in PPAR-γ protein concentration in SCAT compared with 
healthy controls (Bastard et al., 2002a). Similar findings have been observed in other 
studies and are accompanied by lower expression of PPAR-γ target gene adiponectin, as 
well as lower leptin, and increased IL-6 and tumour necrosis factor α (TNF-α) (Jan et 
al., 2004). PPAR-γ expression in SCAT was found to be significantly lower in HAART 
recipients compared with treatment-naive individuals (Pace et al., 2003) and in patients 
with LD compared with those without LD (Kannisto et al., 2003). Interestingly, a six 
month interruption of PI therapy has been shown to significantly improve PPAR-γ 
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expression in SCAT samples from HIV-infected patients, suggesting that the effects on 
PPAR-γ may be reversible (Kim et al., 2007c).  
 
The mechanisms underlying the reduction in PPAR-γ expression in response to ARVs 
reported in the majority of studies are not yet clear. The mitogen activated protein 
kinase/ extracellular signal-regulated protein kinase (MAPK/ERK) signalling pathway 
may play a role, as activation of the pathway enhances PPAR-γ expression (Prusty et 
al., 2002), and ARVs such as IDV and efavirenz have been shown to suppress ERK 
phosphorylation (Hong-Brown et al., 2004) and active ERK signalling (Dong et al., 
2013).  
 
1.2.3.2 Adiponectin  
Adiponectin is a 30kDa protein secreted exclusively by adipocytes, which exists as 
three oligomeric isoforms (trimeric, hexameric and high molecular weight (HMW)) 
secreted into circulation as complexes (Scherer et al., 1995). The biological activity of 
adiponectin is mediated by the HMW form (Caselli et al., 2014). Adiponectin exerts its 
biological effects by binding to ubiquitously expressed receptors AdipoR1 and 
AdipoR2, as well as T-cadherin. Several endoplasmic reticulum molecules regulate the 
synthesis and secretion of adiponectin, and once in circulation, post-translational 
modifications maintain adiponectin stability (Caselli et al., 2014).   
 
1.2.3.2.1 Regulation of adiponectin transcription  
PPAR-γ positively regulates adiponectin gene expression through a PPRE in the 
adiponectin promoter (Iwaki et al., 2003). Synthetic PPAR-γ agonists, TZDs, have been 
shown to increase adiponectin transcription in 3T3-L1 adipocytes (Mineo et al., 2007) 
and in human subjects (Riera-Guardia and Rothenbacher, 2008). Weaker PPAR-γ 
agonists such as marine polyunsaturated fatty acids (PUFA) have also been shown to 
increase adiponectin mRNA and protein secretion in 3T3-L1 adipocytes (Oster et al., 
2010). Similarly, conjugated linoleic acid (CLA) isomers have been shown to alter 
adiponectin expression via PPAR-γ-dependent mechanisms (Miller et al., 2008). 
Proinflammatory cytokines TNF-α and IL-6 negatively regulate adiponectin expression, 




1.2.3.2.2 Adiponectin, insulin sensitivity and HALS  
Adiponectin is secreted by adipocytes in response to insulin via a phosphoinositide 3-
kinase (PI3K)-dependent mechanism (Blumer et al., 2008). In humans, raised 
adiponectin has been shown to increase insulin sensitivity (Gao et al., 2013). 
Adiponectin exerts its insulin sensitising effects by increasing glucose uptake by 
skeletal muscles (Liu and Sweeney, 2014), inhibiting gluconeogenic enzymes and 
glucose production in the liver and increasing insulin gene expression and secretion in 
pancreatic beta cells (Tao et al., 2014). Adiponectin also works indirectly to decrease 
plasma FFA and reduce ectopic lipid accumulation by stimulating acetyl-CoA 
carboxylase and fatty acid β-oxidation (Yamauchi et al., 2002). Recently, a novel 
adapter protein APPL1 has been identified as a key mediator of the insulin sensitising 
effects of adiponectin in these tissues (Cheng et al., 2014). Proinflammatory cytokines 
such as TNF-α suppress adiponectin transcription and induce IR by promoting the 
expression of insulin-like growth factor binding protein-3 (Kim et al., 2007b).  
 
Adiponectin has been investigated extensively in HALS, where hypoadiponectinaemia 
is a common finding (Mynarcik et al., 2002, Kosmiski et al., 2003a, Bezante et al., 
2009, Luo et al., 2009, Veloso et al., 2012). Plasma adiponectin levels in patients with 
LD are significantly lower compared with individuals without LD and healthy controls 
(1.6 vs. 3.4 μg/ml and 1.6 vs. 6.7 μg/ml, respectively) (Kosmiski et al., 2003a). 
Adiponectin concentration has been observed to change over time in individuals with 
LD, increasing up until 6 months after initiation of HAART and then decreasing 
substantially over time until month 30, when the reduction is maintained (Luo et al., 
2009).  
 
Adiponectin concentration has been shown to positively correlate with measures of fat 
distribution (Kosmiski et al., 2003a), insulin sensitivity (Mynarcik et al., 2002) and 
negatively correlated with IR, BMI, WHR, TG and high sensitivity-CRP (Vigouroux et 
al., 2003). Use of older ARVs is associated with hypoadiponectinaemia (Lindegaard et 
al., 2004). Adipose tissue biopsy samples from patients with peripheral LA show a 2-
fold lower adiponectin mRNA expression compared with healthy individuals (Jan et al., 
2004). Another study demonstrated increased adiponectin expression in adipose tissue 
from patients switching from older (d4T) to newer (raltegravir) ARVs (Domingo 2014). 
In vitro, treatment with ARVs has shown inconsistent results: RTV in particular has 
been shown to reduce adiponectin mRNA expression and secretion by up to 50% in 
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3T3-L1 and Simpson Golabi Behmel Syndrome (SGBS) adipocytes (Grigem et al., 
2005, Kim, 2006, Pacenti et al., 2006, Lagathu, 2007, Adler-Wailes et al., 2008, Díaz-
Delfín et al., 2011), and has been suggested to occur as a result of increased oxidative 
stress (Lagathu, 2007) and negative feedback by inflammatory cytokines (Luo et al., 
2009).  However, in other studies ARVs increase adiponectin expression (Díaz-Delfín et 
al., 2011), or have no effect (Jones et al., 2008).  
 
1.2.3.3 Perilipin  
Perilipin-1 (Plin1) is expressed in white adipose tissue (WAT) and is one of five 
members of the perilipin, adipophilin and TIP47 family of proteins, responsible for 
protecting the lipid droplet from lipolysis. Plin1 covers the surface of the lipid droplet 
and has recently been suggested to be involved in increasing lipid droplet size (Sztalryd 
and Kimmel, 2014). Plin1 expression is regulated by the PPAR:RXR heterodimer via a 
PPRE in the Plin1 promoter (Dalen et al., 2004). PPAR-γ agonists have differential 
effects on Plin1 expression; synthetic PPAR-γ agonist rosiglitazone increased Plin1 
expression in rat SCAT (Kim et al., 2007a), while natural putative PPAR-γ agonist, 
docosahexanoic acid (DHA), reduced Plin1 expression by 49% in 3T3-L1 adipocytes 
compared with control (Barber et al., 2013). In a recent randomised controlled trial, a 
diet high in saturated fat and a diet supplemented with omega-3 PUFA (n-3 PUFA) 
were both shown to decrease Plin1 expression in SCAT samples from MetS patients 
(Camargo et al., 2014). The authors suggest a reduction in PPAR-γ may be responsible 
for this effect. The beneficial role of Plin1 has been demonstrated in animal models, 
where over-expression of adipose Plin1 in mice fed a high fat diet results in resistance 
to obesity and improved insulin sensitivity (Miyoshi et al., 2010).  
 
In the context of HALS, Plin1 expression is negatively altered by ARVs. PI treatment 
decreased Plin1 expression in human SCAT, but not VAT (Leroyer et al., 2011). A 
similar study in rats treated with PIs showed decreased Plin1 expression in fat isolated 
from SC fat pads (56.8%) and perigonadal fat pads (20.5%) (Kovsan et al., 2008). 
Similar findings are observed in vitro, with 3T3-L1 adipocytes and preadipocyte cell 
lines from rats showing decreased Plin1 expression in response to PIs (Rudich et al., 
2001, Adler-Wailes et al., 2005, Kovsan et al., 2008).  The effects of ARV on depot 
specific expression of Plin1 may be one mechanism underlying LA observed in patients 




1.2.3.4 Cell-death inducing DFFA-like effector a 
Cidea is another lipid droplet-associated protein expressed mainly in adipocytes, which 
promotes lipid storage in large lipid droplets (Xu et al., 2012). Cidea is thought to 
facilitate enlargement of lipid droplets by destabilising phospholipids at contact sites 
between lipid droplets, thereby allowing lipid exchange and transfer (Gong et al., 2011). 
Mice deficient in Cidea have a lean phenotype with significantly reduced adipose tissue 
(Wu et al., 2014). The Cidea gene promoter contains a PPRE and transcription has been 
shown to be regulated by PPAR-γ (Puri et al., 2008). Interestingly, natural putative 
PPAR-γ agonists, eicosapentanoic acid (EPA) and DHA have been shown to reduce 
Cidea expression in 3T3-L1 adipocytes (Barber et al., 2013). In the context of HIV, 
Cidea has been shown to be decreased in microarray analysis of adipocytes treated with 
10 μM RTV (Adler-Wailes et al., 2008). One study has investigated the expression of 
Cidec, another member of the Cide family, in human preadipocyte cells treated with the 
PI, saquinavir, and found it to be significantly decreased (Bociaga-Jasik et al., 2013).  
 
1.2.3.5 Leptin 
Leptin was first discovered in 1994 as a product of the mouse Ob gene (Zhang et al., 
1994) and since then has been a target in efforts to tackle obesity. Leptin is a 16 kDa 
polypeptide secreted by WAT, which circulates at concentrations reflective of SCAT 
stores (Pan et al., 2014). Although obesity and IR are associated with hypoleptinaemia, 
increased leptin levels have been identified in some obese patients, which has been 
suggested to occur as a result of leptin resistance (Post et al., 2014). The role of leptin in 
counteracting obesity is mediated via leptin receptors located in the brain, which 
regulate feeding behaviour and energy expenditure (Pan et al., 2014). Leptin also 
modulates adipocyte metabolism directly via leptin receptors located on the adipocyte, 
as well as indirectly via the action of insulin on adipocytes (Harris, 2014).  
 
Leptin increases in proportion to decreasing adipose tissue stores and is therefore of 
interest in HALS, where abnormalities of body fat distribution are characteristic 
features. In vitro, ARVs have been shown to significantly reduce leptin expression in 
human adipocytes (Díaz-Delfín et al., 2011, Díaz-Delfín et al., 2012). RTV, a PI, also 
decreases leptin levels in mice (Vyas et al., 2010). In contrast, treatment of SC 
adipocytes from HIV-negative men with RTV increased leptin secretion (Jones et al., 
2008). Leptin levels have been shown to be significantly reduced in patients with HALS 
compared with those without HALS and uninfected controls (3.5 vs. 4.6 vs. 8.2 ng/ml, 
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respectively) (Veloso et al., 2012).  However, other groups have shown raised leptin 
levels to be associated with increased WC (de Luis et al., 2012) and IR (Arama et al., 
2013) and a three-fold increased risk of peripheral LA, but not abdominal LH (Calmy et 
al., 2008). Conflicting findings may reflect the fact that leptin levels correlate with body 
fat stores, which are altered in different adipose tissue depots in HALS.  
 
Leptin administration has been investigated in an effort to correct hypoleptinaemia in 
HALS. Leptin administration in mice was found to reverse RTV-induced elevations in 
plasma TC, while in the same study a PUFA-rich diet had no effect (Riddle et al., 
2003). In patients with HALS, recombinant human leptin administration decreased 
VAT by 32% and TG, TC and LDL-C by 39%, 15% and 20%, respectively, after 6 
months (Mulligan et al., 2009). Similar findings for leptin administration and TC have 
been demonstrated by others in hypoleptinaemic, hypertriglyceridaemic patients with 
HALS (Sekhar et al., 2012). Although results are somewhat inconsistent, evidence 
exists to support a role for leptin in the pathogenesis of body fat abnormalities in HALS.   
 
1.2.3.6 Resistin  
Resistin is a 12.5 kDa cysteine-rich protein secreted in rodents by adipocytes and in 
humans by macrophages (Steppan et al., 2001, Park and Ahima, 2013). Resistin 
expression in mice is regulated by PPAR-γ, which is illustrated by the suppression of 
resistin gene expression in 3T3-L1 adipocytes by PPAR-γ agonists, TZDs (Chung et al., 
2006).  Resistin was originally postulated to be the link between obesity and IR, and 
studies have shown improved insulin sensitivity and glucose levels associated with loss 
of resistin in obesity. Furthermore, resistin is secreted by adipocytes and macrophages 
in response to chronic inflammation, a characteristic feature of obesity and T2DM 
(Stofkova, 2010). Serum resistin has been shown to correlate with degree of VAT and 
was shown by some (Degawa-Yamauchi et al., 2003), but not all (Lee et al., 2003) 
studies to be higher in obese individuals.  
 
In the context of HIV, plasma resistin levels have been shown to be significantly greater 
in HIV-infected individuals without LD compared with those with LD and uninfected 
individuals (4.21 vs. 3.64 vs. 2.74 ng/ml, respectively), and in patients with isolated LA 
compared with those with a mixed form of LD (4.64 vs. 3.27 ng/ml) (Escote et al., 
2011). These findings are supported by another group (Arama et al., 2014). PPAR-γ 
agonist rosiglitazone was previously shown to decrease serum resistin (12.17 to 10.23 
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ng/ml) in HIV-infected individuals with LA and hyperinsulinaemia (Kamin et al., 
2005). Furthermore, a SNP in the resistin gene was recently found to increase the risk of 
metabolic complications associated with ARVs (Ranade et al., 2008). Although these 
studies demonstrate a role for resistin in HALS, others have found no association 
between serum resistin and any form of LD or metabolic abnormality in HIV-infected 
individuals receiving HAART (Barb et al., 2005). It is clear that resistin is involved in 
HALS, but the degree of involvement and its specific role remains to be elucidated.   
 
1.2.3.7 Interleukin-6 
IL-6 is a single 21-28 kDa polypeptide chain found to have both pro- and anti-
inflammatory properties. In humans, 15-35% of circulating IL-6 derives from adipose 
tissue and is primarily secreted by non-adipose cells such as macrophages (Eder et al., 
2009). IL-6 transcription is regulated by NF-κB and CEBP-α, and is also subject to 
post-translational modifications (Rincon, 2012). Additionally, TNF-α and adiponectin 
have been shown to regulate IL-6 production in adipocytes, via NF-κB, PPAR-γ and 
CEBP-β mediated mechanisms (Ito et al., 2009, Zoico et al., 2009).  
 
The role of IL-6 in IR is unclear. IL-6 has been shown to inhibit the action of insulin in 
adipocytes and mice, and IL-6 knockout mice have disrupted glucose metabolism. 
Furthermore, IL-6 secretion in skeletal muscle is increased following exercise, which is 
associated with improved insulin sensitivity (Pal et al., 2014). IL-6 is increased in obese 
individuals compared with lean controls and decreases in response to weight loss 
(Bastard et al., 2000). Recently, it has been shown that increased IL-6 in VAT enhances 
diet-induced obesity and inflammation by suppressing Tregs, a novel population of T 
cells, which regulate inflammation and IR (Priceman et al., 2013).  
 
The importance of IL-6 in HIV is demonstrated by the observation that IL-6 levels at 
the time of seroconversion predict HIV disease progression (Hamlyn et al., 2014). HIV-
infected patients have higher plasma IL-6 compared with uninfected controls (2.6 vs. 
1.4 pg/ml) and a higher prevalence of SNPs in the IL-6 gene (Saumoy et al., 2008). 
Patients with LD were found to have higher plasma IL-6 compared with those without 
LD (1.5 vs. 1.13 pg/ml) (Crawford et al., 2013). The role of HAART in mediating 
increases in IL-6 was demonstrated by Kim et al (2007c) who showed that interruption 
of HAART for 6 months resulted in fewer IL-6 expressing cells in adipose tissue. In 
vitro, treatment with PIs (IDV, nelfinavir, lopinavir, RTV) and NRTI (d4T and ZDV) 
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increases IL-6 expression in human adipocytes (Lagathu, 2007), a finding corroborated 
by others in both human and murine adipocytes (Grigem et al., 2005, Jones et al., 2005, 
Lagathu et al., 2005, Kim, 2006).  
 
In vivo, SCAT from HALS patients shows a three-fold increase in IL-6 mRNA 
compared with healthy controls (Lihn et al., 2003). This finding is supported by other 
groups (Kannisto et al., 2003, Johnson et al., 2004, Saumoy et al., 2008, Gallego-
Escuredo et al., 2013) and was found to be associated with apoptosis (Jan et al., 2004). 
Interestingly, a recent study found reduced IL-6 protein expression in VAT from 
patients with LD compared with uninfected controls (Gallego-Escuredo et al., 2013). 
Regardless of the presence or absence of LD, serum IL-6 was found to be positively 
associated with VAT and negatively associated with lower limb SCAT (Johnson et al., 
2004). IL-6 has also been shown to correlate positively with WHR in patients with HIV 
(Vigouroux et al., 2003). Treatment with PPAR-γ agonist rosiglitazone for 24 weeks 
resulted in a three-fold reduction in IL-6 expression in SCAT from HALS patients 
(Sutinen et al., 2004), highlighting the role of PPAR-γ in IL-6 regulation.  In summary, 
IL-6 expression is altered in HALS which may be due to a combination of host genetic 
factors, HIV infection itself and HAART. Increased circulating levels may contribute to 
inflammation in HALS.  
 
1.2.3.8 Mitochondrial toxicity 
Mitochondrial toxicity is another mechanism involved in the pathogenesis of LA in 
HIV. Unlike classical mitochondrial disease, which is caused by a mutation in nuclear 
or mitochondrial DNA, mitochondrial toxicity in HIV is caused by NRTI-induced 
inhibition of mitochondrial DNA polymerase γ, a key enzyme responsible for DNA 
replication. NRTIs have a high affinity for mitochondrial polymerase γ and are 
incorporated during mitochondrial DNA replication resulting in chain termination of 
mitochondrial polymerase γ (Gardner et al., 2013). HIV RT has also been shown to 
have a high affinity for mitochondrial polymerase γ. Human studies in support of this 
show an association between HIV infection and increased mitochondrial toxicity 
independent of ART and LD (Garrabou et al., 2011), but an association has also been 
found for ART (McComsey et al., 2008). PIs and NNRTIs also cause mitochondrial 
toxicity without affecting polymerase γ, which has been recently suggested to occur via 





1.2.4 Management of HALS  
 
1.2.4.1 Medication and surgery 
Current pharmacological management of HALS focuses on the correction of 
dyslipidaemia, T2DM, HTN and abdominal obesity. Guidelines from the European 
AIDS Clinical Society (EACS) for the management of dyslipidaemia in HIV (Lundgren 
et al., 2008) are summarised in Table 1.5. If initial management with diet and lifestyle 
proves ineffective, switching ART is recommended, followed by use of statins. 
Switching to more “lipid-friendly” ART is often used to manage dyslipidaemia. 
Common switch strategies include switching to atazanavir from another PI, which has 
been shown to improve TG and TC, switching from thymidine analogues to TDF-based 
regimens within the NRTI family and switching from PI to NNRTI (Lake and Currier, 
2010). 
 
Table 1.5 Management of dyslipidaemia in HIV  
Lipid abnormality First treatment option Additional therapy 
LDL-C > 5 mmol/L Statin + Ezetimibe 
LDL-C > 5 mmol/L  
& TG 5-10 mmol/L 
Statin + fibrate (/nicotinic acid 
derivative) 
TG 2.3-10 mmol/L Diet; no alcohol  - 
TG > 10 mmol/L Fibrate + omega 3 acid ester (or 
nicotinic acid derivative) 
HDL-C < 0.9 mmol/L Fibrate + nicotinic acid derivative 
Adapted from (Lundgren et al., 2008). LDL-C, low-density lipoprotein cholesterol. TG, 
triglyceride. HDL-C, high-density lipoprotein cholesterol.  
 
 
Pharmacological interventions to control glucose in T2DM include metformin, TZDs 
and insulin. TZDs are potent PPAR-γ agonists and have been shown to improve 
metabolic and body composition abnormalities in HALS including ameliorating IR, 
increasing HDL-C, decreasing TG (Walli et al., 2000, Slama et al., 2008), increasing 
SCAT and decreasing VAT (Walli et al., 2000, Raboud et al., 2010). However, some 
studies demonstrated negative effects of TZDs on TC and LDL-C (Walli et al., 2000), 
as well as no effect on LA (Carr et al., 2004). Other drugs acting via a PPAR-γ 
dependent mechanism include the anti-inflammatory drug leflunomide, which was 
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found to significantly improve LA and dyslipidaemia associated with RTV (Mencarelli 




) is a growth hormone releasing factor and is the only drug 
approved for the treatment of abdominal obesity associated with ART. However, its use 
is associated with side-effects, which include worsening glycaemic control, and so the 
benefits should be weighed against the risks of growth hormone treatment (Sivakumar 
et al., 2011).  
 
Surgery is frequently used to correct body fat abnormalities associated with HALS. 
Facial LA is probably the most stigmatising feature of HALS and its correction 
typically involves the use of biodegradable or non-biodegradable fillers, or fat 
transplantation (Guaraldi et al., 2011). LH of the neck and trunk can be corrected using 
ultrasonic liposuction and excisional lipectomy (Hultman et al., 2007). As with all 
surgical interventions, there is a risk of post-operative complications.   
 
1.2.4.2 Exercise  
Exercise also forms part of the EACS guideline for the management of metabolic 
diseases in HIV and has recently been shown to be an independent protective factor 
against LD (Della Justina et al., 2014). A recent systematic review of randomised 
controlled trials found that resistance exercise increased LBM and reduced body weight, 
while aerobic exercise reduced body weight, body fat and WHR in adults with HIV 
(Gomes-Neto et al., 2013). These findings are confirmed by an earlier systematic review 
and meta-analysis which also found decreased WC in response to aerobic exercise 
compared with control (-2.60 cm vs. +0.03 cm) (Fillipas, 2010). Furthermore, trunk fat 
was found to decrease significantly after 6 weeks of moderate-intensity exercise in HIV-
infected men with greater than 20% body fat compared with non-intervention controls 
(33.7% vs. 32.2%) (Dudgeon et al., 2012). In terms of metabolic abnormalities, TC, TG, 
FG and insulin were all found to be reduced in response to exercise (Fillipas, 2010). 
Overall, it appears that exercise may be beneficial in improving lipid and glucose 




1.2.4.3 Diet  
Nutrition plays an important role in maintaining health in HIV-infected individuals. 
However, according to a consensus statement from the American Dietetic Association, 
evidence for the role of diet in mitigating HALS is limited (American Dietetic 
Association, 2010). The effect of diet in mitigating the metabolic and morphological 
abnormalities of HALS has been investigated in a number of intervention studies 
(Table 1.6).  
 
An early case report showed reduced abdominal fat and improved metabolic profile in 
one male with LD after 4 months of a low-fat, low-glycaemic index, high fibre diet plus 
exercise (Roubenoff et al., 2002). Another group found that a low fat diet for 6 months 
was beneficial in reducing TC by 10% and TG by 23% among HIV-infected individuals 
with hyperlipidaemia (Barrios et al., 2002). In contrast, another study found increased 
TG (+1.3 mmol/L) and no effect on TC following a low-fat diet for 1 year (Ng et al., 
2011). Another study showed that a low fat diet in combination with aerobic exercise 
for 12 weeks significantly reduced body weight (-2 kg), body fat percentage (-5%) and 
WHR in hyperlipidaemic HALS patients (Terry et al., 2006). A 24-week trial of low fat 
diet combined with exercise and niacin (up to 2 g/d) caused a significant increase in 
plasma HDL-C (+0.11 mmol/l) and reduced TC:HDL-C ratio (4.9 vs. 4.3) in patients 
treated with HAART (Balasubramanyam et al., 2011). A 12 month intervention with the 
NCEP diet (25-35% total energy from fat, < 7% from saturated fat, 50-60% of energy 
from carbohydrate, 15% from protein and 20-30 g/d fibre) decreased plasma TG (-0.38 
mmol/l) and reduced the proportion of patients with a dyslipidaemic lipid profile 
compared with control (21% vs. 68%) (Lazzaretti et al., 2012).  
 
In terms of a Mediterranean-style diet, adherence to the diet, as defined by a high 
Mediterranean Diet Score, was found to have no effect on serum lipids in one study 
(Turčinov et al., 2009) and was positively associated with HDL-C and marginally 
negatively associated with TG in another study (Tsiodras et al., 2009). Moreover, a pilot 
randomised controlled trial (RCT) investigating the effects of a Mediterranean diet in 
LD patients showed increased TC (+0.52 mmol/l) after 12 months (Ng et al., 2011). 
Overall, existing evidence appears to indicate the potential benefit of a diet high in fibre, 
low in saturated fat, which includes polyunsaturated fat, and which corresponds with a 
Mediterranean style dietary pattern in mitigating aspects of HALS.  
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Table 1.6 Dietary interventions to improve metabolic abnormalities in HIV 
Reference Design Type of intervention Subject characteristics Duration Outcome 
Diet      
Barrios et al (2002) PIS  Low fat diet 230 HIV+, receiving ART, 
with dyslipidaemia. 
6 m ↓TC, TG & weight 
 
Lazzeretti et al 
(2012) 
RCT NCEP diet (low-fat, high 
fibre) 
43 randomised to ART + diet; 
40 randomised to ART only 
12 m ↓ TG (25%); ↓ dyslipidaemia 
vs. control (21 vs. 68%) 




Modified Mediterranean diet 
vs. low-fat, low-cholesterol 
diet 
 
48 HIV+ 12 m Mediterranean: no Δ TG, ↑ TC. 
Low fat: no Δ TC, ↑ TG  
 
Roubenoff et al 
(2002) 
CR Moderate fat, low GI, high 
fibre diet + exercise three 
times per week. 
 
1 HIV+, M, receiving ART. 4 m ↓ total & trunk fat, LDL-C, 
TC, glucose & IR.  
Terry et al (2006) 
 
RCT Low fat diet + aerobic 
exercise/ low fat diet only  
30 HIV+, 20M, HALS, 
receiving ART. 
 
12 w ↓ body weight, body fat & 
WHR in two groups 






Diet & exercise + niacin 
(2g/d)  
191 HIV+, ↑TG 24 w ↑ HDL-C & adiponectin  
Benedini et al  
(2009) 
RIT 2 g/d L-acetylcarnitine 9 HIV+/9 healthy controls, 
receiving PI/NRTI 
 
8 m ↑ % leg fat 
Calmy et al (2010) 
 
PRT 36 g uridine t.d.s HIV+, M, LA+ 60 d No ∆ limb fat mass 
Marcel et al (2011) RPS 19 g/d Spirulina (algae) vs. 
soybean 
33 HIV+, insulin resistant 8 w Improved insulin sensitivity 






Table 1.6 continued 
Reference Design Intervention/ placebo Subjects/ controls Duration Outcome 
McComsey et al 
(2007) 
POL 36 g uridine t.d.s. every 
other day  
14 HIV+, 11M, receiving 
ART, LA+. 
16w + 16 w 
washout 
LA scores by patient and 
physician improved  
Oliveira et al (2013) RPCT 3 g/d n-3 PUFA or soy oil 83 HIV+, 64M, receiving 
ART 
24 w No effect on lipids or WC 
Sutinen et al (2007) RDPCT 36 g uridine t.d.s. 20 HIV+, 17M, 10 cases, 10 
controls, receiving ART, LA+ 
3 m ↑total limb fat, intra-abdominal 
fat & total body fat  
      
∆, change. PIS, prospective intervention study. ART, antiretroviral therapy, m, months. TC, total cholesterol. TG, triglyceride. RCT, controlled trial. NCEP, 
National Cholesterol Education Programme. CR, case report. GI, glycaemic index. M, male. LDL-C, low-density lipoprotein cholesterol. IR, insulin resistance. 
RCT, randomised controlled trial. HALS, HIV-associated lipodystrophy syndrome. w, weeks. WHR, waist:hip ratio. RDPCT, randomised, double blinded, 
placebo controlled trial. HDL-C, high-density lipoprotein cholesterol. RIT, randomised intervention trial. PI, protease inhibitors. NRTI, nucleoside reverse 
transcriptase inhibitors. PRT, prospective, randomised trial. t.d.s., ter die sumendum (three times a day). LA+, lipoatrophy. d, days. POL, prospective open label. 









Nutritional supplementation has also been investigated in HALS (Table 1.6). 
Supplementation with uridine has been shown to increase limb fat by 7% (18% to 25%) 
after 3 months. However, intra-abdominal and total fat were also significantly increased 
in the same study compared with placebo (+210 g vs. -80 g and +1920 g vs. 240 g, 
respectively) (Sutinen et al., 2007). Increases in lean body mass were demonstrated after 
24 weeks of the same supplement (Calmy et al., 2010). Findings from a recent 
systematic review show that nicotinic acid analogues significantly reduce TG (-0.54 vs. 
+0.65 mmol/l) and increase HDL-C (+0.08 vs. -0.03 mmol/l) compared with placebo, 
while chromium supplementation significantly improves IR and reduces TG (-0.78 vs. 
+0.14 mmol/l) in patients with LD compared with those without LD (Stradling et al., 
2012). Supplementation with 19 g/d Spirulina, a blue-green algae, significantly 
improved insulin sensitivity after 8 weeks compared with soybean in HIV-infected 
individuals (Marcel et al., 2011).  
 
N-3 PUFA, which are natural putative PPAR-γ agonists, have been investigated for 
their role in the prevention of dyslipidaemia in HIV. A recent systematic review and 
meta-analysis of seven studies investigating the effect of n-3 PUFA supplementation 
(0.3 g/d to 4.86 g/d for 12-24 weeks) on dyslipidaemia in HIV showed an overall 
significant reduction in fasting TG (-1.12 mmol/l) in the intervention group compared 
with control. N-3 PUFA supplementation also significantly reduced TC (-0.36 mmol/l), 
but had no effect on HDL-C and LDL-C (Stradling et al., 2012). More recently, a study 
of hypertriglyeridaemic HIV patients showed that 3.6 g/d of n-3 PUFA for 8 weeks 
significantly decreased TG (-0.38 vs. +0.45 mmol/l) and caused a 39% reduction in IL-6 
(-0.62 vs. +0.18 pg/ml) compared with a corn oil placebo (Metkus et al., 2013). In 
contrast, another study compared 3 g/d n-3 PUFA with 3 g/d soy oil for 24 weeks and 
found no significant effect on lipid parameters or WC (Oliveira et al., 2013). Although 
heterogeneity exists between the studies in terms of the study population, supplements 
used and duration, it appears that n-3 PUFA supplementation is beneficial in mitigating 




1.3 Conjugated linoleic acid  
 
1.3.1 Biosynthesis  
CLA is the term used to describe a group of at least 28 positional and stereo-isomers of 
linoleic acid with 18 carbons and two unsaturated double bonds separated by one single 
bond (Lawson et al., 2001). CLA isomers are formed by incomplete biohydrogenation 
of linoleic acid by the microorganism Butyrivibrio fibrisolvens in the rumen (Bauman et 
al., 1999). CLA can also be formed in bovine mammary tissue by the action of delta 9 –
desaturase on vaccenic acid (Griinari et al., 2000). The isomers differ in the location of 
their double bonds and position of the hydrogen atom. The hydrogen atom at each 
double bond can be positioned in the cis or trans configuration.  
 
The main naturally occurring isomer consists of two unsaturated double bonds located 
at positions 9 and 11 from the carboxylic end. CLA concentration of milk and animal 
fat can be enhanced by modifying the CLA content of animal feed to include marine 
algae or plant oils, adjusting the proportion of grazed grass in the diet and lowering 
forage: concentrate ratios (Lawson et al., 2001). Animal genetics may also play a role in 
determining CLA content of milk and animal fat.  Type of feed influences the extent of 
biohydrogenation in the rumen and therefore, the concentration of CLA (Lawson et al., 
2001). Grass fed animals have up to a 5-fold increased cis-9,trans-11 (c9,t11) 
concentration in their milk compared to animals fed a usual diet consisting of a 50:50 
mix of forage and grain (Dhiman et al., 2005).  Supplementation of the animal’s diet 
with plant oils high in linoleic acid (sunflower, soya bean and rapeseed) may also 
increase milk CLA composition (Lawson et al., 2001).   
 
1.3.2 Industrial synthesis  
Synthetic CLA supplements are used extensively in human studies and typically contain 
a mix of the two main isomers c9,t11 and trans-10,cis-12 (t10,c12) in a 1:1 ratio. The 
final concentration of CLA depends on the initial level of linoleic acid (Kapoor et al., 
2005). Synthetic CLA is either directly derived from safflower oil or undergoes 
enzymatic pre-processing to increase the content of linoleic acid. Alkaline treatment of 
the oil results in saponification and isomerisation (conjugation) leading to the formation 
of c9,t11 and t10,c12 in a 1:1 ratio. Subsequently, dilution and acidification of the 
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mixture, followed by washing, drying and distillation, results in the formation of FFA, 
which are finally re-esterified with glycerol (Kapoor et al., 2005, EFSA, 2010).  
 
1.3.3 Dietary sources  
The c9,t11 and t10,c12 isomers appear to be the most biologically active CLA isomers 
(Pariza et al., 2001). The c9,t11 isomer is more predominant in the diet, constituting 
90% of total CLA and is found mainly in meat and dairy products derived from 
ruminants (Mushtaq et al., 2010). The average intake of c9,t11 from dietary sources is 
estimated at 97.5 mg/day in the UK (Mushtaq et al., 2010) and 151-212 mg/d in the US 
(Ritzenthaler et al., 2001). The c9, t11 content of some of these food items can be found 
in Table 1.7.  
 
Table 1.7 Main dietary sources of c9,t11-CLA  (mg/100 g food)  
Milk and milk products 
Milk-full fat  7.1 
Milk- semi-skimmed  3.3 
Milk-skimmed - 
Double cream  176.2 
Crème fraiche 162.9 
Meat and meat products 
Minced lamb 276.8 
Beef rib eye steak 178.6 
Beef mince 51.2 
Butter and margarine 
Butter  201.0 
Olive oil  4.7 
Polyunsaturated margarine 3.5 
Cheese 




English Brie  94.9 
Goat’s cheese 71.3 




1.3.4 Biological activities  
The biological activities of CLA include modulation of immune and inflammatory 
responses, CVD protection, cancer prevention, bone health, and anti-obesity effects, 
which will be discussed below in greater detail. 
 
1.3.4.1 Immune and inflammatory responses 
The immunomodulatory and anti-inflammatory effects of CLA have been investigated 
in in vitro, animal and human studies. In macrophages, c9,t11 has been shown to exert 
anti-inflammatory effects by significantly suppressing membrane and lipid raft CD14 
and LPS-induced interferon regulatory factor-3 activation, as well as decreasing LPS 
stimulated endocytosis of toll like receptor 4, a protein involved in antigen detection 
and immune system activation (Dowling et al., 2013). Another study demonstrated a 
decrease in cell adhesion molecules in human vein endothelial cells treated with c9,t11 
and t10,c12 (Stachowska et al., 2012). The authors of this study suggest that this may be 
one mechanism underlying the anti-atherosclerotic effects of CLA. Human bronchial 
cells and eosinophils play an important role in inflammatory airways disease. CD69 and 
CD13 are induced by the activation of T lymphocytes and NK cells and are responsible 
for lymphocyte proliferation and function. c9,t11 has been shown to significantly reduce 
the activation markers in human bronchial cells and eosinophils. The effects of c9,t11 in 
this study were mediated through activation of PPAR-γ (Jaudszus et al., 2005). A study 
in mice showed that intestinal probiotic bacteria produced CLA, which decreased 
myeloid cell PPAR-γ leading to suppression of colitis (Bassaganya-Riera et al., 2012).  
 
A dietary intervention study investigating the effect of pecorino cheese for 10 weeks in 
healthy subjects found a reduction in inflammatory cytokines IL-6, IL-8 and TNF-α 
(Sofi et al., 2010). In overweight, mild asthmatics, 12 weeks of CLA supplementation 
(4.5 g/d mixed isomers) in addition to usual treatment resulted in a significant 
improvement in airway responsiveness (MacRedmond et al., 2010). In another study, 
twelve weeks of c9,t11 supplementation (2 g/d; 65% c9,t11 and 8.5% t10,12) in subjects 
with birch pollen allergy led to a decrease in the production of TNF-α and IFN-γ 
(Turpeinen et al., 2008). A study in healthy men showed that 2.2 g/d of an isomeric 
mixture of CLA isomers for 8 weeks reduced ex vivo peripheral blood mononuclear 
cells IL-2 secretion, a cytokine produced by T cells during an immune challenge 
(Mullen et al., 2007). CLA supplements have also been tried in certain disease states. In 
patients with Crohn’s disease, 6 g/d CLA reduced pro-inflammatory cytokine 
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production from CD4+ and CD8+ cells, and decreased disease activity (Bassaganya-
Riera et al., 2012).  In patients with active rheumatoid arthritis, CLA was shown to 
improve the clinical manifestations of the disease after 3 months of supplementation 
with 2 g/day of mixed CLA isomers (Aryaeian et al., 2009). Although these studies 
have demonstrated a beneficial effect of CLA, some have failed to find any effect (Smit 
et al., 2011), or have demonstrated a negative effect, particularly on levels of C-reactive 
protein (Gaullier et al., 2007).  To the best of our knowledge, no studies have 
investigated the effects of CLA on markers of immune function in HIV-infected 
individuals. 
 
1.3.4.2 Cardiovascular disease  
Unlike non-conjugated trans fatty acids found in snacks and fast food, ruminant trans 
fatty acids have shown beneficial effects in CVD (Bendsen et al., 2011). Evidence from 
animal studies has shown CLA to be beneficial in reducing atherosclerosis (Toomey et 
al., 2006, Mitchell et al., 2012), TG and TC (Hur et al., 2013), LDL-C and increasing 
HDL-C (Noto et al., 2006). However, results are conflicting, as some have shown CLA 
to increase TG and LDL-C (Verma and Kansal, 2013) and promote atherosclerotic 
lesion development (Reynolds et al., 2013). A number of studies in humans have 
investigated the effect of CLA mixed isomer supplementation on blood lipids (Table 
1.8). HDL-C was reduced in healthy overweight subjects (Gaullier et al., 2004) and 
obese men with MetS (Risérus et al., 2002), but increased in type 2 diabetics (Moloney 
et al., 2004) in response to mixed CLA isomer supplementation. Another study 
demonstrated increased TC:HDL-C ratio after a diet containing mixed CLA isomers  
(Wanders et al., 2010). A possible explanation for the inconsistencies in these studies 
may be the differences in doses of CLA used (3.4 - 28 g/d), differences in the study 
population (overweight and obese versus T2DM) or the effect of different CLA isomers 
(mixed isomers versus t10,c12 alone).  
 
The individual isomers were shown to have differential effects; t10,12 increased LDL-C 
: HDL-C and TC : HDL-C compared with c9,t11 (Tricon et al., 2004). CLA also 
increased concentrations of lipoproteins which have been linked to CVD including 
increased lipoprotein A compared with placebo (Gaullier et al., 2004, Gaullier et al., 
2007) and increased apolipoprotein B after a CLA diet compared with an oleic acid diet 
(Wanders et al., 2010). Beneficial effects of CLA have been demonstrated for heart rate 
(Gaullier et al., 2004), blood pressure (Iwata et al., 2007) and platelet aggregation (Sofi 
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et al., 2010). The latter dietary intervention study is one of few studies which provided a 
natural source of CLA in the form of 200 g/ week of pecorino cheese. In contrast, Raff 
et al (2006) in another dietary intervention study showed that a diet rich in both CLA 
isomers (c9,t11 and t10,c12) based on normal butter and an additional 5.5 g of CLA-oil 
for 5 weeks had no effect on arterial elasticity or blood pressure in healthy young men. 
Differences in study designs, duration and study populations, as well as concentrations 
and types of CLA supplementation may account for some of the differences observed in 
these studies.   
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Table 1.8 CLA interventions to improve cardiovascular risk profile 
Reference Design n / subjects Intervention Duration Findings 
Gaullier (2004)  DPCT 180/ OW (1) 4.5 g/d CLA (FFA) or (2) 4.5 g/d CLA 
(TAG) or (3) 4.5 g olive oil 
1 y (1) ↑ LDL (+0.22 mmol/l); (2) ↓ HDL 
(-0.09 mmol/l); No ∆ between groups 
Gaullier (2007) DPCT 118/ OW & obese 4 g/d CLA / 4.5 g olive oil 6 m ↓ body fat/↓WHR / ↓ HDL-C in CLA 
Iwata (2007) RDPCT 60/ OW men 3.4 g/d CLA or 6.8 g/d CLA or 10.8 g/d 
safflower oil 
12 w No difference in blood lipids between 
groups  
Moloney (2004) RDPCT 32/ T2DM 3 g/d CLA / blend palm & soya bean oil 8 w ↑ FG (+0.46 mmol/l) 
Raff (2006) RDB 
parallel 
60/ healthy men Substitute 115 g fat with butter & 5.5g 
CLA oil / eucaloric control diet with butter 
5 w No effect on blood pressure  
Riserus (2002) RDPCT 60/ obese  3.4 g/d CLA, or pure t10,c12, or placebo 12 w t10,c12 ↑ IR (19%) &↓ HDL  (4%) 
Tricon (2004) RDCr 39-49 healthy 3 doses c9,t11 (0.59, 1.19, and 2.38 g/d) or 
t10,c12 (0.63, 1.26, and 2.52 g/d) 
8 w*  t10,c12 ↑ LDL:HDL & TC:HDL. 
c9,t11 ↓ LDL:HDL & TC:HDL 
Sofi (2010) Crossover  10/ healthy 200 g/week CLA-rich cheese or placebo 
(regular cheese)  
10 w ↓ platelet aggregation (1.1%)  
Wanders (2010) RSMCr 61/ healthy 3 identical diets with 7% energy from (1) 
CLA mixed isomers, (2) industrial trans fat 
or (3) oleic acid  
9 w (1) 8.7% ↑ LDL-C; 10% ↑ TC:HDL-
C. (2) 11.6%  ↑ LDL-C & TC:HDL-C 
∆ , change. * 6 week washout. RDPCT, randomised double-blind placebo controlled trial. OW, overweight. CLA, conjugated linoleic acid. w, weeks. DPCT, 
double-blind placebo-controlled trial. FFA, free fatty acid. TAG, triacylglycerol. y, year. HDL, high density lipoprotein. m, months. WHR, waist:hip ratio. T2DM, 
type 2 diabetes mellitus. FG, fasting glucose. RDB, randomised double-blind. IR, insulin resistance. RDCr, randomised double blind crossover trial. LDL, low-






1.3.4.3 Cancer  
CLA isomers were first shown to inhibit epidermal neoplasia in mice in 1987 and since 
then the anti-cancer properties of CLA have been extensively investigated (Pariza et al., 
2001). CLA has been shown to display anti-cancer effects in vitro by a number of 
mechanisms including inducing apoptosis (Pierre et al., 2013), inhibiting activation of 
NF-κB (Rakib et al., 2013) and inhibiting fatty acid synthase (FASN), which is over 
expressed in carcinoma cells (Song et al., 2012).  
 
In support of these in vitro findings, numerous animal studies have identified reduced 
tumour incidence, metastasis and angiogenesis, as well as anti-oestrogenic effects in 
response to CLA (Bhattacharya et al., 2006). CLA has also been shown to reduce 
inflammatory mediators in human lung cancer cells (Oraldi et al., 2013). However, 
other studies in mice have shown that CLA supplementation promotes tumour 
progression and carcinogenesis (Meng et al., 2008), and down regulates the expression 
of adiponectin, leptin and PPAR-γ genes, which have been shown to be protective in the 
mammary gland (Flowers et al., 2010). Results for the effect of CLA on carcinogenesis 
are contradictory; t10,c12 has been shown to activate the NF-κB pathway, which 
promotes carcinogenesis in a model of intestinal cancer (Rajakangas et al., 2003), but it 
has also been shown to  inactivate NF-κB resulting in inhibition of human breast cancer 
cells (Rakib et al., 2013).  
 
Human studies also support the effects of CLA in cancer prevention (Table 1.9). 
Epidemiological data point towards a protective role of foods rich in CLA and reduced 
risk of colorectal (Larsson et al., 2005) and breast cancer (Aro et al., 2000, Mc Cann et 
al., 2004), even at 25-year follow up (Knekt et al., 1996). In contrast, CLA was found to 
either have no association/ no protective effect against breast cancer (Voorrips et al., 
2002, Rissanen et al., 2003) or to be negatively associated with breast cancer incidence 
(Hjartåker et al., 2010). CLA intervention studies in patients with a cancer diagnosis 
found significantly reduced markers of inflammation (TNF-α and hsCRP), tumour 
invasion and angiogenesis (matrix metalloproteinase 9) compared with placebo 
(Mohammadzadeh et al., 2013), as well as decreased breast tumour expression of spot 
14, a regulator of FASN (McGowan et al., 2013). However, one study found no 
association between CLA and prognostic factors, metastasis or death (Chajès et al., 
2002). In summary, it appears that CLA has potential cancer preventive effects, but the 
underlying mechanisms are still being uncovered. Further randomised controlled trials 
may be necessary to clarify the inconsistencies in the literature.     
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Table 1.9 CLA and cancer prevention 
Reference Design / cancer  
n case / n 
control 
Outcome / intervention  Duration Findings 
Aro (2000) CS /BrCa 195 / 208  Dietary CLA 3 y OR for BrCa = 0.4 for highest vs. lowest CLA 
quintile 
Hjartaker (2010) PC /BrCa 48,844   Childhood & adult milk 
consumption 
6.2y follow-up Childhood and adulthood milk consumption 
negatively associated with BrCa 
Knekt (1996) PO /BrCa 4,697  Dairy intake 25y follow-up Inverse association between milk intake and 
BrCa 
Larsson (2005) PC/ colorectal 60,708  High fat dairy foods 14.8y follow-up ≥ 4 servings high-fat dairy ↓ risk of colorectal 
Ca. Each ↑2 servings= 13% ↓ risk 
McCann (2004) CC /BrCa 1,122 / 2,036  Dietary CLA  5y follow-up Pre-menopausal, highest CLA tertile ↓ risk of 
ER-negative tumour 
Rissanen (2003) NCC/ BrCa 127 / 242  Serum CLA  10y follow-up  No association between serum CLA and BrCa 
(samples stored for 25y) 
Voorrips (2002) 
 
Cohort/ BrCa 941  Dietary CLA  6.3y follow-up Weak, positive association between CLA and 
BrCa 
Chajes (2003) Cohort/ BrCa 209  CLA in Br adipose tissue 7.5y follow-up No association between CLA and prognostic 
factors, metastasis or death 
McGowan (2013) OL/ BrCa 24  7.5 g/d 1:1 mixed isomer Up to 20 d ↓ breast tumour expression of Spot 14 
Mohammadzadeh (2013) RDPCT/ rectal Ca 34  3 g/d CLA (1:1) / placebo 
(sunflower oil) 
5 w ↓ TNF-α (-1.07 pg/ml); ↓ hsCRP (-0.84mg/l); ↓ 
MMP-9 (-78.1ng/ml) 
CS, cross sectional. BrCa, breast cancer.CLA, conjugated linoleic acid. y, years. OR, odds ratio. PO, prospective observational. PC, prospective cohort. CC, case 
control. ER, estrogen receptor. NCC, nested case control. OL, open label. d, days. RDPCT, randomised double blind placebo controlled trial. w, weeks. Ca, cancer. 






1.3.4.4 Bone health  
Numerous in vitro studies have demonstrated a beneficial effect of CLA on bone health. 
c9,t11 has been shown to inhibit osteoclast formation by 70% and a combination of 
c9,t11 and t10,c12 decreased osteoclast activity by 85-90%, which suggests CLA may 
inhibit bone resorption (Platt and El-Sohemy, 2009). A recent study found no effect of 
c9,t11 in murine mesenchymal stem cells, but t10,c12 decreased adipogenesis and 
increased osteoblastogenesis. Only the effect on adipogenesis was PPAR-γ mediated 
(Kim et al., 2013a). In animal studies, mice fed a t10,c12-containing diet had higher 
bone mineral density (BMD) in femoral, tibial and lumbar regions compared with those 
fed a diet of corn oil and c9,t11 (Rahman et al., 2011). t10,c12 also significantly 
decreased osteoclastogenic factors in serum of these animals. In mice, CLA in 
combination with fish oil (Halade et al., 2010) and exercise (Banu et al., 2008) has been 
shown to significantly increase bone marrow adiposity and bone mass, respectively. The 
addition of CLA to a diet containing 1% calcium increased bone ash, a surrogate marker 
for bone mass, compared with mice supplemented calcium only (Park et al., 2011). This 
effect was only shown for t10,c12 and not c9,t11.  
 
Cross sectional data from postmenopausal women have shown higher than median 
intakes of CLA to be associated with increased BMD in the forearm (Brownbill et al., 
2005). Intervention studies have shown no effect of either 3 g/d or 5 g/d CLA (50:50 
mix) for up to 8 weeks on markers of bone formation or resorption in healthy 
participants (Doyle et al., 2005, Pinkoski et al., 2006). In contrast, another study 
demonstrated a positive association between red blood cell c9,t11 content, a marker of 
long-term CLA intake (~4 months), and BMD in men after 16 weeks of 
supplementation with 3 g/day c9,t11 (Deguire et al., 2012). CLA may be beneficial in 
increasing osteoblastogenesis, reducing bone marrow adiposity and increasing bone 
mineral density, but at present we await evidence from human studies to support the in 




1.3.4.5 Body weight  
The anti-obesity effect of CLA remains an active area of research over a decade since it 
was first demonstrated in mice (Park et al., 1997). Human CLA supplementation has 
been shown to reduce BMI (Gaullier et al., 2005), WC (Riserus et al., 2001) and body 
fat mass and increase lean muscle mass (Gaullier et al., 2007). A recent systematic 
review and meta-analysis showed a significant difference in fat loss and BMI favouring 
the CLA group, but no effect on WC. However, as a result, the authors concluded that 
CLA had no clinically relevant effect on body composition (Onakpoya et al., 2012). It 
has been suggested that the unresolved effects of CLA isomers may relate to their 
antagonistic effects- t10,c12 decreases, while c9,t11 increases adipogenesis (Brown et 
al., 2003). When the isomers are provided together, the combined effect may counteract 
the individual effects of each isomer resulting in no significant overall change in 
adiposity.  
 
A number of studies have investigated the effects of CLA supplementation on body 
composition. A mix of CLA isomers has been shown to decrease sagittal abdominal 
diameter (Riserus et al., 2001), waist size (Gaullier et al., 2007) and WHR (Chen et al 
2012), while other studies demonstrated no effect on waist size (Gaullier et al., 2007, 
Carvalho et al., 2012) or body weight (Tricon et al., 2006). Supplementation with a pure 
t10,c12 isomer was also found to decrease waist girth (Risérus et al., 2002). Skimmed 
milk (200 ml/d) fortified with 3 g/d mixed CLA isomers was recently shown to decrease 
body weight and total fat mass in healthy, overweight subjects after 24 weeks (Lopez-
Plaza et al., 2013). Another study supplemented healthy subjects with yoghurt-like 
products enriched with 3.76 g/d mixed CLA isomers for 14 weeks and found no effect 
on body weight, fat mass or fat free mass, but energy expenditure and PPAR-γ 
expression were both increased in adipose tissue (Nazare et al., 2007).  
 
The mechanisms underlying the anti-obesity effects of CLA have been investigated 
extensively and include anti-adipogenic effects, apoptosis and lipolysis and altered fatty 
acid oxidation and energy expenditure, which are discussed below in more detail.  
 
Anti-adipogenic effects  
Reducing TG storage and adipocyte size may be one of the main mechanisms 
underlying the anti-obesity effects of CLA. t10,c12 has been shown to decrease 
adipocyte size in rats (DeClercq et al., 2010) and TG accumulation in 3T3-L1 
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adipocytes (Brown et al., 2001, Evans et al., 2001, Granlund et al., 2003, Miller et al., 
2008, den Hartigh et al., 2013). De novo lipogenesis was also inhibited by t10,c12 in 
SGBS adipocytes (Obsen et al., 2012).  Contrary to the t10,c12 isomer, c9,t11 has been 
shown to be less potent in reducing TG accumulation (Fischer-Posovszky et al., 2007) 
and has been shown to increase adipocyte size in rats (Lopes et al., 2008).  
 
These anti-adipogenic effects of CLA have been suggested to occur as a result of down 
regulation of PPAR-γ (Kang et al., 2003). A number of studies demonstrated reductions 
in PPAR-γ, which were associated with reduced lipid accumulation (Brown et al., 2003, 
Granlund et al., 2003). Brown et al (2003) showed that chronic treatment with t10,c12 
until day 9 significantly reduced the expression of several adipocyte-specific genes 
including PPAR-γ, aP2, Plin1 and leptin. In contrast, c9,t11 significantly increased 
PPAR-γ gene expression in other studies (Brodie et al., 1999, Brown et al., 2004). CLA 
has also been shown to increase PPAR-γ phosphorylation in an adenosine 
monophosphate-activated protein kinase (AMP)-dependent manner and to increase the 
amount of PPAR-γ bound to sirtuin-1, a histone/protein deacetylase that affects energy 
homeostasis, and is capable of inhibiting PPAR-γ activity (Jiang et al., 2012). Miller et 
al (2008) suggest that t10,c12 may affect the ability of ligands to interact with PPAR-γ, 
which may explain why in some studies, t10,c12 has been shown not to interact directly 
with PPAR-γ. 
 
The anti-adipogenic effect of CLA may also occur as a result of alterations in PPAR-γ 
target genes. Plin1 is a PPAR-γ target gene responsible for protecting the adipocyte 
from the lipolytic action of cellular lipases. CLA may induce delipidation of adipocytes 
through down-regulation of Plin1 (Cai et al., 2012). Furthermore, supplementation with 
1% t10,12 in mice was shown to significantly decrease Plin1 expression (House et al., 
2005). Similar results have been demonstrated in stromal vascular cells from human 
adipose tissue (Brown et al., 2004) and in primary human adipocytes (Kennedy et al., 
2008). In contrast, t10,c12 was also found to increase Plin1 expression, which preceded 
an increase in lipolysis in primary human adipocytes from abdominal adipose tissue 
(Chung et al., 2005). Interestingly, c9,t11, a potential PPAR-γ agonist, has been shown 
to increase Plin1 expression in 3T3-L1 adipocytes (Brown et al., 2003, Zhai et al., 
2010). The role of leptin in the anti-adipogenic effects of CLA is unclear; in vitro 
studies show increased leptin secretion in response to CLA (Kim et al., 2013b), while 
animal studies have shown that a diet containing 1% or 2% CLA significantly reduced 
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serum leptin in mice (Shelton et al., 2012) and adipose tissue of rats (Gudbrandsen et 
al., 2009), respectively.  However, some studies failed to find an effect of CLA on 
leptin in animals (Lopes et al., 2008), middle-aged men with PPAR-γ Pro12Ala 
polymorphism  (Rubin et al., 2012) and overweight type 2 diabetics (Shadman et al., 
2013).   
 
Apoptosis and lipolysis  
In vitro, CLA isomers have been shown to induce apoptosis in human SGBS adipocytes 
treated with t10,c12 (Fischer-Posovszky et al., 2007). CLA isomers have been 
suggested to induce lipolysis via alteration of LPL, an enzyme responsible for the 
hydrolysis of stored TG, but results to support this are inconsistent. In 3T3-L1 
adipocytes, t10,c12 has been shown to significantly decrease LPL protein levels (Brown 
et al., 2003), which occurs via a PPAR-γ-dependent mechanism (Kennedy et al., 2008). 
In mice fed 1% CLA, adipose LPL mRNA levels decreased (Castellanos-Tapia et al., 
2009), while mice fed a high fat diet plus 3% CLA were found to have increased 
epididymal adipose tissue LPL (Andreoli et al., 2009). Studies in humans do little to 
clarify these inconsistencies, with some demonstrating reduced LPL mRNA expression 
in adipose tissue after 16 weeks of supplementation (Raff et al., 2009), while others 
have shown an increase in plasma LPL in young men prescribed 3 g/d CLA and 
exercise three times per week (Bulut et al., 2013). Further research is required in the 
area to determine the exact effects of CLA on LPL-mediated lipolysis. Down-regulation 
of Plin1 as discussed in the previous paragraph, may also contribute to the lipolytic 
effects of CLA.  
 
Altered fat oxidation and energy expenditure  
Free fatty acid transportation across the outer mitochondrial membrane is a crucial 
initial step in fatty acid oxidation. Once inside the cell, fatty acids are acylated into fatty 
acyl-CoA with the help of carnitine palmitoyl transferase 1 (CPT1) (den Hartigh et al., 
2013). A recent study in 3T3-L1 adipocytes showed that t10,c12 increased CPT1 and 
fatty acid oxidation (den Hartigh et al., 2013). Another study in 3T3-L1 adipocytes 
showed that t10,c12 stimulated fatty acid oxidation and energy expenditure, while 
c9,t11 had no effect on fatty acid oxidation (Zhai et al., 2010). Similarly, a recent study 
in mice fed 0.5% of either c9,t11 or t10,c12 showed that t10,c12, but not c9,t11, 
promoted fatty acid oxidation and thereby improved exercise capacity (Kim et al., 
2012). A study in rats fed a 1% mixed CLA diet for 8 weeks showed significant 
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alterations in proteins involved in fatty acid oxidation and energy dissipation, including 
PPAR-α, acyl-CoA oxidase and uncoupling protein (Choi et al., 2007). One study in 
humans has shown that 6 months of supplementation with 4 g/d mixed isomers 
increased fat oxidation and reduced protein oxidation (Close et al., 2007).  
   
In summary, CLA isomers appear to have differential effects on adipogenesis and fatty 
acid oxidation; t10,c12 has the most potent anti-obesity effects, while c9,t11 has the 
opposite effect and may promote adipogenesis by increasing PPAR-γ.  
 
 
1.3.5 Safety  
In some studies, CLA supplementation has been shown to have a negative effect on 
glycaemic parameters (Moloney et al., 2004) and as a result, concerns have been raised 
about the safety of CLA supplements given their widespread availability as a weight 
loss supplement. However, in 2008 the United States Department of Agriculture 
recognised CLA (Clarinol
®
) as generally recognised as safe for use in certain food types 
and a European Food Safety Authority assessment in 2010 concluded that consumption 
of up to 3.75 g/d Clarinol
®
 (80% CLA; c9,t11:t10,c12 (1:1)) for up to 6 months had no 
significant adverse effects on liver function, insulin sensitivity or blood glucose control 
(EFSA, 2010). In line with these reports, a recent review concluded that 
supplementation with high quality (80-90%) CLA in the range of 0.5 g - 7 g/day did not 
cause adverse effects in humans (Dilzer and Park, 2012).  Furthermore, a study in 
patients with T2DM found no effect of CLA on fasting and postprandial glycaemic 
indicators after 8 weeks (Shadman et al., 2013), and a study in overweight and obese 
subjects found no effect on glucose metabolism or insulin sensitivity after 6 months 
with 3.4 g/d CLA (Syvertsen et al., 2007). Interestingly, a recent cross-sectional study 
found an inverse association between c9,t11 in adipose tissue and risk of diabetes 





As outlined in the introductory paragraph, the aim of the research described in this 
thesis was to investigate the contribution of ARVs to adipocyte dysfunction and the role 
of CLA isomers in mitigating this dysfunction in vitro. This research also aimed to 
explore the prevalence of lipodystrophy in a London-based HIV population, the factors 
associated with it and the role of CLA supplementation in improving aspects of 
lipodystrophy in vivo. It was hypothesised that CLA isomers would prevent 
antiretroviral drug-induced adipocyte dysfunction in vitro and improve dysregulated 




















Chapter 2  
 
Methods 




2.1 In vitro experiments  
 
2.1.1 General study design 
Two sets of in vitro experiments were conducted in order to test the hypothesis 
proposed in this thesis. The first investigated the effect of five different ARVs at 
physiological concentrations on adipocyte function, gene expression and inflammation. 
The second set of experiments investigated the effect of two CLA isomers (c9,t11 and 
t10,c12) on the same markers in adipocytes treated with ARVs. An outline of the study 



























Figure 2.1 In vitro study design. 3T3-L1 adipocytes were treated with (A) near Cmax 
concentrations of ARVs with or without (B) 100 μM c9,t11 or t10,c12 for 5 days. Cell 
viability was confirmed for all treatments prior to experimental work.   
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2.1.2 Resuscitation of frozen cells and seeding  
Cryovials containing 3T3-L1 pre-adipocytes (kind gift of Dr Emilie Stolarczyk, King’s 
College London) were removed from the -80 °C freezer and immediately placed into a 
37°C water bath to thaw rapidly. The vials were then wiped with 70% ethanol and 
transferred to the tissue culture hood. Upon thawing, the entire content of the ampoule 
was pipetted into 5 ml of pre-warmed DMEM-F12 (Invitrogen Life Technologies, 
Paisley, UK) supplemented with 10% foetal bovine serum, 8 μg/ml pantothenate (MP 
Biomedicals Europe, London, UK) and 8 μg/ml biotin, 200 mM L-glutamine, 10,000 
U/mL penicillin and 10 μg/L streptomycin (all Sigma Aldrich, Poole, UK) and 10 mg/L 
MycoKill AB mycoplasma antibiotic (PAA Laboratories Ltd., Yeovil, UK). Cells were 
centrifuged at 1,000 rpm for 5 minutes. The supernatant was quickly aspirated and the 
cells resuspended in a 5 ml volume of the same medium. A haemocytometer (Hawksley, 
Sussex, UK) was used for cell enumeration using a 1:1 mix of the above cell solution 
with trypan blue stain (Invitrogen Invitrogen Life Technologies) according to 
manufacturer’s instructions. Cells were initially seeded at a density of 0.5 x 106 cells 




 tissue culture flask (Thermo Scientific, Rosklide, 
Denmark) to which the same medium was added giving a final volume of 20 ml. 
 
2.1.3 Routine culture and differentiation 
Cells were maintained in an incubator at 37°C with 5% CO2 until they reached 80-90% 
confluence after approximately 5 days. Culture medium was carefully removed and the 
cells were washed twice with pre-warmed 1X phosphate buffered saline (PBS) 
(Invitrogen Invitrogen Life Technologies, Paisley, PA). A 0.05% v/v solution of 
Trypsin/EDTA (Sigma Aldrich, Dorset, UK) in PBS was prepared and added to the 75 
cm
2
 flask ensuring complete coverage of the cell monolayer. The flask was incubated 
until the cells detached after 2 minutes. The trypsin/EDTA solution was quenched by 
the addition of 20 ml of fresh pre-warmed medium. The cell solution was centrifuged at 
1,000 rpm for 5 minutes. The supernatant was removed and the cells were resuspended 
in 5 ml of medium. Cells were counted as described previously and seeded in 6-, 24- or 
96- well plates for experimental work as shown in Table 2.1. 
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Table 2.1 3T3-L1 seeding densities 
Plate/flask type Total volume of 
medium per well 
Seeding density per 
well 
Total seeding 
density per plate 
75 cm
2 
flask 20 ml 0.5 x 10
6
 0.5 x 10
6
 
6-well plate 3 ml 4 x 10
4
 2.4 x 10
5 
24-well plate 500 μl 2.5 x 103 0.6 x 105 
96-well plate 100 μl 1.56 x 102 0.15 x 105 
 
 
2.1.4 Adipocyte differentiation 
Cells were incubated for a further 48 hours to initiate growth arrest.  On day 7, pre-
adipocyte medium was replaced with medium supplemented with 0.5 mM 3-isobutyl-1-
methylxanthine (IBMX) (Cayman chemical, Cambridge Biosciences, Cambridge, UK), 
0.25 μM dexamethasone (Sigma Aldrich, Dorset, UK) and 1 μg/ml insulin (Sigma 
Aldrich, Dorset, UK) (Differentiation medium). Table 2.2 illustrates the different media 
used for maintenance, differentiation and treatment of 3T3-L1 adipocytes in this study.   
 




Differentiation medium  Treatment medium 
500 ml DMEM-F12 Pre-adipocyte medium in 
necessary volume 
Pre-adipocyte medium in 
necessary volume 
10% foetal calf serum 1 μg/ml insulin  1 μg/ml insulin 
200mM L-glutamine 
penicillin / streptomycin 
0.25 μM dexamethasone  ZDV (1 μM)  / d4T (10 μM) / 
RTV (20 μM) / IDV (10 μM) 
/ TDF (1 μM) 




100 μM c9,t11  / t10,c12  
8 μg/ml biotin    
8 μg/ml pantothenate    
DMEM-F12, Dulbecco's Modified Eagle Medium: Nutrient Mixture F-12. ZDV, 




2.1.5 Adipocyte treatment  
After two days (day 9), medium was removed and cells were washed with pre-warmed 
PBS. Medium was replaced with treatment medium (Table 2.2) containing ZDV, d4T, 
RTV, IDV or TDF at concentrations comparable to their Cmax in patients’ serum, and 
100 μM CLA isomers (c9,t11 or t10,c12). The vehicle for ARVs was ethanol (filter 
sterilised; VWR, Leicestershire, UK) and for CLA it was DMSO. In all experiments, all 
treated cells received one or both vehicles consisting of 0.1% ethanol and/or 0.1% 
DMSO as appropriate. Medium was changed every 2 days until cells were fully 
differentiated at day 14. Cells were exposed to the respective treatments for a total of 
five days.  
 
2.1.6 Preparation of antiretroviral drugs 
Ethanol was used as the vehicle for the ARVs used in these in vitro experiments. ARV 
stock solutions (1000X) were prepared, aliquoted and stored at -20 °C prior to use. 
ARVs were diluted in differentiation medium to near Cmax concentrations (the maximum 
drug concentration observed in patients’serum) as outlined in Table 2.3.  
 
 
Table 2.3 Preparation of antiretroviral drugs 
Drug Drug class Supplier Mw Stock conc. Cmax conc. 
ZDV NRTI Sigma Aldrich 267.24 1 mM 1 μM 
d4T NRTI Sigma Aldrich  224.21 10 mM 10 μM 
RTV PI Santa Cruz 
Biotechnology Inc. 
720.94 20 mM 20 μM 
IDV PI Santa Cruz 
Biotechnology Inc. 
711.87 10 mM 10 μM 
TDF  NtRTI Santa Cruz 
Biotechnology Inc. 
287.21 1 mM 1 μM 
Mw, molecular weight. ZDV, zidovudine NRTI, nucleoside reverse transcriptase 
inhibitor. d4T, stavudine. RTV, ritonavir. PI, protease inhibitor. IDV, indinavir. TDF, 




2.1.7 Preparation of CLA isomers 
DMSO was used as the vehicle for CLA isomers in these experiments. Stocks solutions 
of 100 μM of each CLA isomer were prepared as shown in Table 2.4 and 20 μl aliquots 
stored at -80 °C prior to use. Each CLA isomer was prepared to a working concentration 
of 100 μM in cell culture medium. The working concentration of c9,t11 added to cells is 
four-fold greater than that observed in plasma of healthy subjects, while that of t10,c12 
is 28-fold greater than in vivo concentrations (Shafer, 2006).  
 
Table 2.4 Preparation of fatty acid stock solutions  





trans-10, cis-12 VWR 
International 
280.5 28.05 mg/ml 
 
28.05 mg/L 
cis-9, trans-11 VWR 
International 
280.5 28.05 mg/ml 28.05 mg/L 
Mw, molecular weight.  
 
2.1.8 Cell viability  
A colorimetric cell viability assay was used in determining the number of viable cells in 
culture. The CellTiter 96
®
 AQueous One Solution Reagent (Promega, Southampton, UK) 
contains 3-(4,5-dimethylthiazol-2-yl)-5-(3-carboxymethoxyphenyl)-2-(4-sulfophenyl)-
2H-tetrazolium, inner salt (MTS) and an electron coupling reagent (phenazine 
ethosulfate; PES). Prior to conducting the MTS assay, cells were washed with pre-
warmed medium three times. 100 μl of medium was then added to each well followed 
by 20 μl of MTS assay solution. Cells were incubated for 1 h at 37 °C with 5% CO2. 
The quantity of formazan produced by cellular reduction of MTS is directly 
proportional to the number of living cells in culture and was measured at 490 nm in a 
96-well plate reader (Synergy HT-1, Biotek, Bedfordshire, UK).  
 
2.1.9 Oil Red O staining  
Oil Red O (ORO) stain is a lysochrome fat soluble diazo dye used to stain neutral lipids 
(Sigma Aldrich, 2014a). The stain was used to indicate the degree of adipogenesis in 
differentiated adipocyte cultures. ORO stock solution was prepared as follows: 0.7g of 
ORO powder (Sigma Aldrich, Dorset, UK) was dissolved in 200 ml of propan-2-ol 
(VWR International, Leicestershire, UK). This mixture was stirred overnight using a 
magnetic stirrer, filtered through a 0.22 μm membrane filter (Nalgene® Thermo 
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Scientific, Fischer Scientific Ltd. Leicestershire, UK) and stored at 4°C until use. To 
make the ORO working solution six parts of ORO stock solution were added to 4 parts 
distilled water. This solution was mixed, allowed to sit at room temperature for 20 
minutes and then filtered through a 0.22 μm membrane filter. Induction medium was 
removed from the plate and cells were washed once with PBS. 500 μl of 10% formalin 
(Sigma Aldrich, Dorset, UK) was added to each well and cells were incubated at room 
temperature for 5 minutes. The formalin was discarded and the same volume of fresh 
formalin added. Parafilm and aluminium foil were placed around the plate to prevent it 
drying out and the plate was incubated at room temperature for 1 hour. After this time, 
the formalin was removed and cells in each well were washed with 500 μl of 60% 
propan-2-ol then allowed to dry completely. 200 μl of ORO working solution was added 
to each well, taking care not to touch the walls of the wells, and cells were incubated for 
10 minutes at room temperature. All of the ORO was removed and distilled water was 
added immediately. Cells were washed four times with distilled water. The distilled 
water was then removed and cells were allowed to air dry completely. Photographs of 
cell morphology were taken with a DXM 1200 Digital Camera (Nikon, Kingston Upon 
Thames, UK) and a Lucia G Image-Processing System (version 4.61; Nikon). The ORO 
was eluted by adding 750 μl of 100% propan-2-ol to each well and cells were then 
incubated at room temperature for 10 minutes. The ORO and propan-2-ol were pipetted 
up and down several times to ensure that all of the ORO was in solution. 250 μl of this 
solution was then transferred to wells of a 96-well plate and the optical density of the 
solution was measured at 540 nm in a spectrophotometer (Synergy HT).  
 
2.1.10 RNA extraction 
Total RNA was extracted from adipocytes on day 14 using the RNeasy Mini Kit 
(Qiagen, Manchester, UK). Cells were lysed directly in each well by adding 350 μl 
proprietary Buffer RLT, a highly denaturing guanidine-thiocyanate–containing buffer 
which inactivates RNases to ensure purification and supports the binding of the RNA to 
the silica membrane. Lysate was collected using a pipette and pipetted into a 
microcentrifuge tube. Lysate was vortexed or mixed to ensure no cell clumps were 
visible. 350 μl of 70% ethanol was added to the homogenised lysate to provide 
appropriate binding conditions, and mixed well by pipetting. Up to 700 μl of the sample 
was transferred, including any precipitate that may have formed, to an RNeasy spin 
column placed in a 2 ml collection tube. The lid was closed gently, and the tube 
centrifuged for 15 seconds at 10,000 rpm. Total RNA bound to the membrane and 
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contaminants were washed away as the flow-through was discarded. 700 μl buffer RW1 
was added to the RNeasy spin column. Buffer RW1 is a washing buffer containing a 
guanidine salt, as well as ethanol, used for the removal of biomolecules such as 
carbohydrates that are non-specifically bound to the membrane. The lid was closed 
gently, and the tube centrifuged for 15 seconds at 10,000 rpm to wash the spin column 
membrane. The flow-through was discarded. 500 μl Buffer RPE was added to the 
RNeasy spin column. Buffer RPE is a mild washing buffer containing ethanol, which 
removed traces of salts associated with use of previous buffers. The lid was closed 
gently, and the tube centrifuged for 15 seconds at 10,000 rpm to wash the spin column 
membrane. The flow-through was discarded. 500 μl Buffer RPE was added to the 
RNeasy spin column. The lid was closed gently, and the tube centrifuged for 2 min at 
10,000 rpm to wash the spin column membrane. The long centrifugation dried the spin 
column membrane, ensuring that no ethanol was carried over during RNA elution. 
Residual ethanol interferes with downstream reactions. The RNeasy spin column was 
placed in a new 1.5 ml collection tube. 30 μl RNase-free water was added directly to the 
spin column membrane. The lid was closed gently, and the tube centrifuged for 1 min at 
10,000 rpm to elute the RNA.  
 
2.1.11 RNA quantification 
The quality of the RNA was assessed using the NanoDrop
®
 1000 3.7.1 
spectrophotometer (Thermo Scientific, USA). The NanoDrop
®
 accurately measures 
RNA quantity and integrity up to 3,700 ng/μl without dilution. It automatically detects 
the high concentration and utilises the 0.2 mm path length to calculate absorbance and 
determine RNA concentration in ng/μl as shown in Table 2.5. For NanoDrop® 
spectrophotometry, 1.0 μl of sample was used to quantify RNA concentration. A blank 
of nuclease-free water was used to optimise the NanoDrop
®
. Sample pedestals were first 
cleaned with nuclease-free water and ethanol prior to use.  
 











The ratio of absorbance at 260 and 280 nm (260/280) was used to assess the integrity of 
the RNA. A ratio of ~2.0 is generally accepted as pure for RNA. A lower ratio may 
indicate the presence of contaminants such as protein or phenol that absorb strongly at 
or near 280 nm. After quantifying the RNA and assessing the integrity, samples were 
aliquoted and frozen at -80°C. Samples were defrosted as required for analysis.  
 
2.1.12 Reverse transcription 
During reverse transcription, a DNA polymerase enzyme (reverse transcriptase) 
incorporates deoxynucleotides sequentially along a single-stranded RNA template 
strand and catalyses the formation of phosphodiester bonds between these nucleotides to 
generate a complementary DNA (cDNA) strand.   In vitro, DNA polymerase generates 
complementary strands using a 3’ hydroxyl group provided by an oligonucleotide 
primer (Avison, 2007). The result is a labelled cDNA strand complementary to the 
target RNA species of interest. The number of cDNA target molecules equals the 
number of RNA molecules copied and provided the RT reaction goes to completion, all 
reagents are in excess and each RNA molecule is copied only once, the RNA molecule 
of interest can be quantified (Avison, 2007).   
 
cDNA fragments were generated by reverse transcription using the High Capacity 
RNA-to-cDNA kit (Invitrogen Life Technologies). Up to 2 μg of total RNA was used 
per 20 μl reaction. Kit components were thawed on ice.  Up to 9μl of each RNA sample 
was added to a microcentrifuge tube (Starlab, Milton Keynes, UK). To this, 10 μl 
reverse transcriptase buffer was added along with 1 μl reverse transcriptase enzyme mix 
(Invitrogen Life Technologies). This volume was made up to 20μl with nuclease-free 
water. Microcentrifuge tubes were sealed, mixed gently and centrifuged (Jencons, 
Bedfordshire, UK) to spin down the contents and eliminate air bubbles. Tubes were 
placed in a thermal cycler (Thermo Electron Corporation, Thermo Scientific) set at 
conditions optimised for use with the High Capacity RNA-to-cDNA kit as shown in 
Table 2.6.  
 
Table 2.6 Reverse transcription conditions 
 Step 1 Step 2 Step 3 
Temperature (°C) 37 95 4 




2.1.13 Real-time reverse transcriptase polymerase chain reaction 
Real-time reverse transcriptase polymerase chain reaction (RT-PCR) is a well 
established, mainstream technology for the detection and quantification of RNA targets 
(Bustin and Mueller, 2005). The discovery of Taq polymerase in the early 1980s 
eliminated the need for the addition of a new enzyme previously destroyed during 
thermocycling (Avison, 2007). The Taq polymerase has a 5′–3′ exonuclease activity, as 
well as dual-labelled fluorogenic oligonucleotide probes. The probes emit a fluorescent 
signal only upon cleavage.
 
In this system, a probe (TaqMan
®
) is designed to anneal to 
the target sequence between the classical forward and reverse primers (Figure 2.2). The 
probe is labelled with both a reporter fluorochrome (e.g., 6-carboxyfluorescein, or 
FAM) at one end and a quencher dye (e.g., 6-carboxy-tetramethyl-rhodamine, or 
TAMRA) at the 3′ end. In its intact form, the fluorescence emission of the reporter dye 
will be absorbed by the quencher dye. The melting point of the probe is 10°C higher 
than that of the primers in order to anneal to the amplicon during the extension phase of 
the PCR process (performed at 60°C). The probe is then degraded during the extension 
phase by the 5′–3′ exonuclease activity of the Taq polymerase. The reporter and 
quencher are separated, which results in an increase in the fluorescence emission of the 
reporter. Fluorescence released is directly proportional to the amount of product 
generated in each PCR cycle and thus can be applied as a quantitative measure of the 













cDNA (1 μg) was used in real-time RT-PCR to measure PPAR-γ, adiponectin, leptin, 
resistin, IL-6, perilipin and Cidea gene expression, and 1 μg of cDNA was used in the 
hypoxanthine-guanine phosphoribosyltransferase (Hprt) control RT-PCR. Reactions 
were prepared in a MicroAmp™ Optical 96-well reaction plate (Invitrogen Life 
Technologies) to give a total volume of 25 μl. PCR reaction mix components and 
volumes are detailed in Table 2.7. cDNA template was added to each well followed by 
TaqMan
®
 gene expression assays (20X) specific for each target gene. TaqMan
®
 gene 







 dye label on the 5’ end and minor groove binder (MGB) and 
non-fluorescent quencher (NFQ) on the 3’ end. TaqMan® Gene Expression Master Mix 
(2X) was also added, which consists of AmpliTaq Gold
®
 DNA polymerase, a passive 
internal reference based on proprietary ROX
™
 dye and AmpErase
®
 Uracil N-
Glycosylase. Diethylpyrocarbonate (DEPC)-treated water was added to make up a total 
volume of 25 μl in each well. Each plate also contained a no template control (NTC) 
containing all reaction components except the cDNA template. A no-reverse 
transcriptase (RT) control containing all reaction components except the TaqMan
®
 
reverse transcriptase was also added to each plate. DEPC-treated water was used to 
replace the cDNA template and reverse transcriptase in the NTC and no-RT controls, 
respectively. The PCR plate was covered with a MicroAmp
™
 Optical Film and 
centrifuged briefly in a PCR Plate Spinner (Labnet International, Edison, USA) to spin 
down the contents and eliminate air bubbles. A MicroAmp
™
 Optical Film Compression 
Pad was applied to the top of the plate and the plate placed in the ABI Prism 7000 
Sequence Detection System (Invitrogen Life Technologies). Thermal cycling conditions 
were set to default PCR thermal cycling conditions as shown in Table 2.8.    
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Table 2.7 RT-PCR reagents and volumes 
Sample  Reaction mix component Volume per 25 μl 
reaction 
No template control TaqMan
®
 Gene Expression 




 Gene Expression 
Assay 
1.25 
 DEPC-treated water 11.25 
No-RT control TaqMan
®
 Gene Expression 
Master Mix 
12.5 
 cDNA template 2.00 
 DEPC-treated water  10.5 
Samples TaqMan
®





 Gene Expression 
Assay 
1.25 
 cDNA template 2.00 
 DEPC-treated water 9.25 




Table 2.8 RT- PCR conditions 
Step Time Temperature 
UDG Incubation HOLD 2 min 50 °C 
Taq Enzyme 
activation 





Denature 15 sec 95 °C 
Anneal/ extend 1 min 60 °C 
UDG, uracil DNA glycosylase   
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2.1.14 Global gene expression studies  
 
2.1.14.1 RNA amplification and labelling 
Previously quantified RNA samples extracted using the RNeasy Mini Kit (Qiagen) were 
pooled and 500 ng of each pooled sample in 5 μl nuclease-free water was used in the 
reactions. The MessageAmp
™
 Premier RNA Amplification kit (Invitrogen, UK) was 
used for cDNA synthesis using ArrayScript
™
 reverse transcriptase. cDNA was then 
used in an in-vitro transcription (IVT) reaction to synthesise biotin-modified amplified 
RNA (aRNA) according to manufacturer’s protocol. The kit employs the reverse 
transcription T7 in vitro transcription (RT-IVT) method, considered the gold standard 
for sample preparation in micro-array profiling. After synthesis, the biotin-modified 
aRNA was purified to remove enzymes, salts and unincorporated nucleotides using the 
same kit. The concentration of aRNA was determined using the NanoDrop
® 
spectrophotometer (Thermo Scientific). Biotinylated aRNA was fragmented prior to 
hybridisation using the 5X Array Fragmentation Buffer supplied with the 
MessageAmp
™
 Kit.  
 
2.1.14.2 aRNA fragmentation and hybridisation 
The sample was then evaluated using the Agilent
®
2100 Bioanalyser instrument (Agilent 
Technologies Inc., Santa Clara, USA) and RNA 6000 Nano Kit loaded with 300 ng of 
aRNA per well. The fragmented aRNA had a distribution of 35-200 nucleotides with a 
peak at approximately 100-200 nucleotides. Figure 2.3 shows typical bioanalyser 
electropherograms of unfragmented and fragmented aRNAs. 11 μg of aRNA were 
hybridised onto the Affymetrix Mouse Genome 430 2.0 Array Kit (Affymetrix, High 
Wycombe, UK), which covers over 39,000 transcripts on a single array of the mouse 
genome. The arrays were subsequently washed, stained and scanned on the Fluidics 
Station 400 and the GeneArray Scanner (Agilent Technologies, Inc.) according to the 




















2.1.14.3 Microarray data analysis 
The Robust Multi-array Average approach was used to analyse the data using quantile 
normalisation and the average change in expression was determined for each gene using 
the formula =IF(‘ratio value’<1, -1/’ratio value’, ‘ratio value’) where the ratio value is 
ratio of treatment/control. A two-fold change relative to control (signal log ratio ≥ 1.0 or 
≤ -1.0) was selected as the threshold to define differentially expressed genes. Altered 
gene lists were imported into MetaCore
™
 pathway analysis software (GeneGo, 
Thomson Reuters, New York) where differentially expressed genes were classified into 
functionally-related gene clusters and signalling and metabolic pathway maps were 
generated.  
 
2.1.15 Enzyme-linked immunosorbent assay  
Enzyme-linked Immunosorbent Assay (ELISA) is a fundamental technique in cell 
biology used to detect and colorimetrically quantitate the presence of antigen (AbD 
Serotec, 2014). Commercially available ELISA kits employ a quantitative sandwich 
enzyme immunoassay technique, which allows for the measurement of antigen in cell 
culture supernatants. A primary (capture) antibody is immobilised to a 96-well 
microplate and the sample and standards are sandwiched to this antibody. The 
secondary (detection) antibody is conjugated with the enzyme horseradish peroxidise 
(HRP), which acts upon a substrate tetramethylbenzidine (TMB), to produce a blue 
colour directly proportional to the amount of antigen present. An acidic solution such as 











2.1.15.1 Mouse Adiponectin ELISA 
The commercially available DuoSet ELISA Development kit (R&D Systems, 
Abingdon, Oxfordshire, UK) was used for the capture of antigen in samples of cell 
supernatants. This kit included primary (capture) antibody, secondary (detection) 
antibody, standard and streptavidin-HRP, and was stored at 4°C. Capture antibody, 
detection antibody and standards were supplied as lysophilised powders and were 
reconstituted and stored at -20 °C until use. Prior to performing the assay of the 
complete sample set, a preparatory ELISA was performed to establish optimal dilution 
factors for the supernatants, to ensure they fit within the sensitivity of the kit. Typical 
adipokine concentrations published from the 3T3-L1 cell line were reviewed. 
Supernatant samples were diluted according to expected adipokine yield and the 
sensitivity of the kit. Capture antibody was diluted to a working concentration, as per 
the manufacturer’s instruction, with PBS and coated onto a microtitre plate (StarLab). 
The plate was sealed and incubated overnight at room temperature. The plate was then 
washed by submerging in 0.05% v/v Tween 20
®
 (Sigma Aldrich) in PBS, gently 









3. Secondary Ab 
immobilised to 
plate 
4. HRP added 
5. Oxidation of 






then tapped against paper towel to dry. Wells were blocked with reagent diluent (1% 
w/v bovine serum albumin (BSA; Sigma Aldrich) in PBS) for 1 hour. Standards were 
reconstituted to working concentrations using serial 1:2 dilutions in reagent diluent. 
Samples were diluted to optimal concentrations as determined in the optimisation step 
in reagent diluent. After blocking with BSA, wells were washed as before and loaded 
with standards, samples and blank wells consisting of reagent diluent alone. Plates were 
sealed and incubated at room temperature for 2 hours. Wells were washed as before and 
loaded with detection antibody for 2 hours. The plate was washed three times and the 
strepavidin-HRP enzyme was added and allowed to sit at room temperature and away 
from direct light for 20 minutes. Plates were washed again. TMB substrate solution 
(Sigma Aldrich) was added to each well and the plate incubated at room temperature for 
20 minutes to oxidise the TMB. Stop solution (2N H2SO4) was added, which stopped 
the reaction, causing a colour change from blue to yellow. Absorbance was read in a 
microplate reader (Synergy HT) at 450 nm with wavelength correction at 570 nm. A 
standard curve was constructed by plotting the mean absorbance values (optical density) 
from the standard solutions versus the known adipokine concentrations. Sample 
concentrations were calculated using the equation of the standard curve.  
 
2.1.16 Multiplex ELISA 
A MILLIPLEX™ MAP Mouse Adipocyte Panel (Merck Millipore, Watford, UK) was 
used for the simultaneous quantification of leptin, resistin and IL-6 in cell culture 
supernatant samples. The MILLIPLEX
™





 technology, which internally colour-codes microspheres with two fluorescent 
dyes. Through precise concentrations of these dyes, 100 distinctly coloured specific 
capture antibody-immobilised bead sets are created. After an analyte from a test sample 
is captured by the bead, a biotinylated detection antibody is introduced. The reaction 
mixture is then incubated with Streptavidin-PE conjugate (PE), the reporter molecule, to 
complete the reaction on the surface of each microsphere. The microspheres pass 
rapidly through a laser, which excites the internal dyes marking the microsphere set. A 
second laser excites PE, the fluorescent dye on the reporter molecule. Finally, high-
speed digital-signal processors identify each individual microsphere and quantify the 
result of its bioassay based on fluorescent reporter signals. Cell supernatants from 
treated adipocytes were collected on day 14, centrifuged to remove debris, aliquoted and 
stored at -20°C. Prior to the assay, all reagents were warmed to room temperature. The 
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assay was performed in duplicate.  Standards were prepared from serial dilutions of the 
50,000 pg/ml highest standard as shown in Table 2.9.  
 
Table 2.9 Preparation of working standards for multiplex ELISA 
Standard concentration 
(pg/ml) 
Volume of assay buffer 
 (μl) 
Volume of standard 
(μl) 
50,000 ------- ------- 
12,500 150 50 μl of 50,000 
3,125 150 50 μl of 12,500 
781.3 150 50 μl of 3,125 
195.3 150 50 μl of 781.3 
48.8 150 50 μl of 195.3 
12.2 150 50 μl of 48.8 
3.2 150 50 μl of 12.2 
 
The Microtiter Filter Plate was set on a plate holder so that the bottom of the plate did 
not touch any surface. The filter plate was pre-wet by pipetting 200 µl of the proprietary 
assay buffer into each well of the plate. The plate was sealed and mixed on a plate 
shaker for 10 minutes at room temperature (20-25°C). A plate vacuum was used to 
remove the assay buffer taking care not to invert the plate. Excess buffer was removed 
by blotting the bottom of the plate with a paper towel. 10 μl of each standard or control 
was added to appropriate wells. Assay buffer was used as the background for the 0 
pg/ml standard. 10 μl assay buffer was added to each sample well followed by 10 µl of 
appropriate adipokine-free medium to the background, standards, and control wells and 
10 µl of sample into the appropriate wells. The mixing bottle containing the antibody-
immobilised beads was vortexed and 25 μl of the mixed beads was added to each well. 
The plate was sealed and covered with a lid. A rubber band was wrapped around the 
plate holder, plate and lid and incubated with agitation (500-800 rpm) on a plate shaker 
over night at 4°C. After the overnight incubation, the fluid was gently removed by 
vacuum, taking care not to invert the plate. The plate was then washed 3 times with 200 
µl/well of wash buffer, removing wash buffer by vacuum filtration between each wash. 
Excess buffer was removed by blotting the bottom of the plate with a paper towel. 50 µl 
detection antibodies were added to each well. The plate was sealed, covered with a lid 
and incubated with agitation on a plate shaker for 30 minutes at room temperature. After 
the incubation period, 50 µl PE was added to each well containing the detection 
antibodies. The plate was sealed again, covered with a lid and incubated with agitation 
on a plate shaker for 30 minutes at room temperature. After the incubation, the contents 
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of each well were removed gently by vacuum taking care not to invert the plate. The 
plate was washed 3 times with 200 µl/well wash buffer. Wash buffer was removed by 
vacuum filtration between each wash. Excess buffer was removed by blotting the 
bottom of the plate with a paper towel. 100 µl of sheath fluid was added to all wells and 
the beads resuspended on a plate shaker for 5 minutes. The Luminex 100
™
 IS (Merck 
Millpore, Watford, UK) was set up according to assay protocol as shown in Table 2.10. 
Data for the Median Fluorescent Intensity (MFI) using a weighted 5-parameter logistic 
was used to calculate analyte concentrations of standards and samples.  
 
Table 2.10 Luminex 100™ IS settings 
Events 50 per bead 
Sample size 50 μl 
Gate settings  8,000 to 15,000 
Reporter Gain Default (low PMT) 
Time Out  60 seconds 
Bead Set           Beads Luminex Bead Region 
 Leptin 16 
 IL-6 58 
 Resistin  78 
IL-6, interleukin-6. PMT, photo multiplying tubes.  
 
2.1.17 Nuclear protein extraction 
The Active Motif Nuclear Extract kit (Active Motif, Rixensart, Belgium) was used for 
the extraction of nuclear proteins from adipocytes on day 14 as per manufacturer’s 
protocol. Briefly, cells were washed with ice-cold PBS/phosphatase inhibitors. This 
solution was aspirated out and cells removed from the plate by gently scraping with a 
plastic Pasteur pipette. Cells were centrifuged at 500 rpm for 5 minutes, the supernatant 
discarded and pellet gently resuspended in 500 μl of proprietary hypotonic buffer. The 
suspension was incubated for 15 minutes on ice. Detergent (10% NP-40) was added and 
the suspension was vortexed for 10 seconds. The suspension was then centrifuged for 
30 seconds at 13,000 rpm and the supernatant (cytoplasmic fraction) transferred into a 
pre-chilled microcentrifuge tube (Starlab), aliquoted and stored at -80°C. The pellet was 
then resuspended in complete lysis buffer and incubated on ice for 30 minutes on a 
rocking platform (Bibby Scientific, Stone, UK). The pellet was vortexed and then 
centrifuged for 10 minutes at 13,000 rpm. The supernatant (nuclear fraction) was then 
transferred into pre-chilled microcentrifuge tubes, aliquoted and stored at -80°C.  
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2.1.17.1 Protein quantification 
The Bradford protein assay is one method used to determine total protein concentration 
in a sample. Proteins present in solution form a complex with the Bradford Reagent dye 
(containing Brilliant Blue G; Sigma Aldrich) and the resulting protein-dye complex 
shifts the absorption maximum of the dye from 465 nm to 595 nm. The amount of 
absorption is proportional to the protein present in solution. The Bradford regent is 
compatible with low concentrations of detergents present in buffers frequently used to 
stabilise proteins in solution. For nuclear extracts, samples were diluted 1:2 in PBS 
giving a total volume of 5 μl per well. Standards were prepared from a stock solution of 
2 mg/ml BSA (Sigma Aldrich) providing a linear standard concentration range of 
between 0-2 mg/ml in PBS for nuclear fractions. 5 μl of each standard and sample was 
incubated with 250 μl of Bradford Reagent (Sigma Aldrich) in a 96-well plate. Samples 
were shaken for 30 seconds on a plate shaker (IKA, Staufen, Germany) followed by 
incubation for 30 minutes at room temperature. Absorbance was measured at 595 nm 
using a spectrophotometer (Synergy HT). The concentration of protein in the samples 
was calculated by comparing the net absorbance values against the standard curve.  
 
2.1.18 PPAR-γ DNA binding ELISA 
PPREs consist of an extended 5′-half-site, a core DR1, and adenine as the spacing 
nucleotide between the two hexamers, giving the consensus sequence: 5′-AACT 
AGGTCA A AGGTCA-3′. PPAR interacts with the upstream extended core hexamer of 
the DR1, while retinoid-X-receptor (RXR) binds to the 3’half site. PPARs are unable to 
bind DNA as monomers and require the carboxy-terminal extension region in 





















Figure 2.5 PPAR:RXR heterodimer on DR1 (Adapted from (Chandra et al., 2013). 
LBD, ligand binding domain. DBD, DNA binding domain.  
 
 
Transcription factor activation (PPAR-γ binding to PPRE) was measured using a 
TransAM
®
 DNA-binding ELISA (Active Motif). The TransAM kit consists of a 96-well 
plate to which oligonucleotides containing PPRE are immobilised. PPAR-γ present in 
nuclear extracts binds to the immobilised PPRE on the plate and is detected using an 
antibody directed against PPAR-γ. The addition of a secondary (detection) antibody, 
conjugated to HRP, produces a colorimetric readout directly proportional to the amount 
of PPAR-γ bound to PPRE.  
 
Complete binding buffer (40 μl) was added to each well of a 96-well plate. 10 μg 
nuclear extract diluted in complete lysis buffer was added to each sample well. To blank 
wells 10 μl complete lysis buffer was added. The plate was sealed with an adhesive 
cover and incubated at room temperature for 1 hour at 100 rpm with mild agitation on a 
rocking platform. Following incubation, wells were washed three times with wash 
buffer and wells were emptied by flicking the plate over the sink, then gently inverting 
the plate three times on a paper towel. PPAR-γ antibody was diluted in antibody binding 
buffer and 100 μl was added to all wells being used. The plate was covered and 
incubated for 1 hour at room temperature without agitation. After incubation the plate 
was washed three times as described previously. Anti-mouse HRP-conjugated antibody 
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diluted in antibody binding buffer was added to all wells. The plate was covered and 
incubated for 1 hour at room temperature without agitation. After incubation the plate 
was washed four times as described previously. 100 μl developing solution was added 
to each well and the plate was incubated for 5-10 minutes at room temperature protected 
from the light. The plate was observed until a medium to dark blue colour developed. 
100 μl stop solution was added immediately, which stopped the reaction, causing a 
colour change from blue to yellow. Absorbance was read in a microplate reader 
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2.2 Human study 
 
2.2.1 Equipment 
Table 2.11 List of equipment 
Item Supplier 
Jouan CR 412 centrifuge for blood 
handling 
Thermo Scientific, Loughborough, UK 
TBF 300MA bioelectrical impedance 
analyser 
Tanita UK Ltd, Middlesex, UK 
Weighing scale Seca, Canterbury, UK 
Stadiometer Seca, Canterbury, UK 
Skinfold calliper  Holtain, Crymych, UK 
Tape measure Seca, Canterbury, UK 
 
2.2.2 Consumables  
Table 2.12 Venous blood collection tubes 
Vacutainer tubes Supplier 
5 ml gold tubes with clot activator and 
gel for serum separation 
Becton Dickinson; cat no. 367954 
4 ml EDTA lavender tubes Becton Dickinson; cat no. 367839 
2 ml fluoride/oxalate grey tubes Becton Dickinson; cat no. 368920 
 
2.2.3 Supplements  
Table 2.13 CLA and placebo supplements 
Item Supplier 
1 g CLA-rich soft gel capsules (Clarinol
®
 A80) Stepan Lipid Nutrition, Koog aan de 
Zaan, Netherlands. 1 g HOSF soft gel capsules 
CLA, conjugated linoleic acid. HOSF, high oleic sunflower oil 
 
 
2.2.4 Anthropometry  
Weight and height were measured using a digital column scale and stadiometer (Seca, 
Birmingham, UK) to the nearest 0.1 kg and 0.1 cm, respectively. WC was measured to 
the nearest 0.1 cm and in the standing position with arms placed on opposite shoulders, 
and weight evenly distributed on each leg. The measurement was taken as the midpoint 
between the lowest rib and the right ilium at the midaxillary line (World Health 
Organisation, 2008). Where possible, WC measurements were taken with patient’s 
waist uncovered or without heavy outer garments where this was not possible. Readings 
were taken at the end of a normal exhalation. Skinfolds were measured in triplicate to 
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the nearest 0.1 mm using a Holtain calliper (Crymych, UK) with the patient in standing 
position with arms hanging loosely by the side and weight evenly distributed on both 
legs. Skinfolds consisted of a double thickness of skin measured at four sites: triceps, 
biceps, suprailiac and subscapular. The triceps skinfold was measured on the right upper 
arm mid-point mark on the posterior surface.  Skinfolds at the subscapular site were 
measured at the inferior angle of the right scapula. Suprailiac skinfolds were measured 
at the high point of the right iliac crest on the midaxillary line. The average of each 
skinfold was calculated and as the values obtained with the calliper are not normally 
distributed it was necessary to log-transform the data. The total combined skinfold 
thickness was calculated and the resulting values used in body density equations 
(Appendix 10) to estimate percentage body fat (Durnin and Womersley, 1974). Body 
fat was also assessed using the Tanita TBF 300MA according to the manufacturer’s 
instructions with 0.5 kg allowance for clothing.   
 
2.2.5 Dietary assessment  
The EPIC-Norfolk food frequency questionnaire (FFQ) (Appendix 11) was used in this 
study to assess participants’ habitual food intake. Participants were asked to complete 
the FFQ at baseline and week 12 to establish baseline intake and to determine whether 
this changed after the 12 week intervention. The FFQ is a 9-page document consisting 
of two parts: the first and main part asks the participant to indicate their usual 
consumption of 130 foods from categories ranging from "never or less than 
once/month" to "6 times per day”. Part two consists of an additional set of questions to 
gather supplementary information on cooking methods and breakfast cereals, and to 
gain more information about milk, total fat and fatty acid intake. Data obtained from 
each FFQ were analysed using programs created in Microsoft Access and Excel for use 
in previous studies carried out at King’s College London. These programs were 
originally set up to determine dietary intake per day for each participant for the 
macronutrients. Average portion sizes were derived based on those used originally in 
the EPIC questionnaire, values in “Food Portion Sizes” (Mills and Sejal, 2005) and “A 
Photographic Atlas of Food Portion Sizes” (Nelson et al., 1997).  
 
Retrospective assessment of dietary intake was carried out by the researcher using the 
triple pass 24-hour recall method (Nelson et al., 2008); Appendix 12) at baseline and 
week 12 to assess participants’ food intake during the previous 24 hours. The 24-hour 
recall was undertaken in chronological order of consumption, following a pattern of a 
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free and uninterrupted recall of intake, followed by detailed and specific questions about 
intake and quantities consumed. The recall concluded with a review of the information 
previously recalled, allowing for the addition of any items not remembered up to that 
point. Data obtained from each 24-hour recall were analysed using Microdiet™ 
software (Downlee Systems Ltd, High Peak, UK).  
 
2.2.6 Physical activity  
A self-administered, short version of the International Physical Activity Questionnaire 
(International Physical Activity Questionnaire, 2001); Appendix 13) was used to obtain 
an estimate of participants’ physical activity levels (PALs) over the previous 7 days. 
Scores for physical activity ranging from low to moderate and high were determined for 
each participant based on number of days and duration of vigorous and moderate 
activity, and walking and are reported as metabolic equivalent (MET) minutes per week 
(International Physical Activity Questionnaire, 2005).  
 
2.2.7 Blood analytic methods  
Unless patient results were available within the previous 3 months, venous blood 
samples for the analysis of FG, TG, TC, HDL-C, LDL-C, liver function, CD4 count, 
HIV viral load, oxidative stress, CLA and adipocytokines were collected in evacuated 
tubes with the minimal compression necessary to display the vein. All blood samples 
were drawn after a minimum 12-hour overnight fast. Blood for glucose was collected 
into 4 ml fluoride oxalate vacutainers. Blood for TG, lipids and liver function was 
collected into 5 ml serum tubes containing a clot activator and gel for separation. Blood 
for CD4 count, HIV viral load, oxidative stress, CLA and adipocytokines was collected 
into 4 ml EDTA tubes. Blood samples used for the analysis of glucose, lipids, liver 
function, CD4 count and HIV viral load were sent immediately after draw to the Blood 
Sciences and Virology Laboratories at St Thomas’ Hospital and blood for the 
measurement of adipocytokines was sent to the Department of Clinical Biochemistry, 
King’s College Hospital. The author was not involved in analysing these variables. One 
vacutainer to be used for the analysis of CLA and oxidative stress was retained by the 
investigator, centrifuged at 2,000 rpm for 10 minutes at 4 °C and the plasma removed 




2.2.8 Determination of biochemical parameters 
Determination of plasma TG, TC, HDL-C, LDL-C, glucose and liver function was 
conducted by the Blood Sciences Laboratory and CD4 count and HIV viral load 
conducted at the Virology Laboratory at St Thomas’ Hospital. Analysis of plasma 
adipocytokines concentrations were conducted by the Department of Clinical 
Biochemistry at King’s College Hospital. For detailed methodology refer to 
Appendices 14-22.  
 
2.2.8.1 Lipids 
TC was determined using an automated enzymatic method on the Roche c8000 cobas c 
system. Briefly, cholesterol esters were cleaved by the action of cholesterol esterase to 
yield free cholesterol and fatty acids. The free cholesterol was oxidised to cholesten-3-
one and hydrogen peroxide by cholesterol oxidase. Peroxidase catalysed the reaction of 
hydrogen peroxide with 4-aminoantipyrine and phenol to produce a red coloured 
quinoneimine product. Colour intensity was directly proportional to concentration of 
cholesterol and was measured spectrophotometrically at 520 nm.  
 
HDL-C was measured using an automated enzymatic colorimetric assay in which 
polyethylene glycol was used to modify cholesterol esterase and cholesterol oxidase 
enzymes. Cholesterol esters were broken down quantitatively into free cholesterol and 
fatty acids by cholesterol esterase. In the presence of oxygen cholesterol was oxidised 
by cholesterol oxidase to cholestenone and hydrogen peroxide. In the presence of 
peroxidase, hydrogen peroxide reacted with 4-amino-antipyrine to form a purple-blue 
dye. Colour intensity, which was directly proportional to concentration of HDL-C, was 
measured at 600 nm.  
 
TG was measured using an automated enzymatic colorimetric assay. TG was 
hydrolyzed to glycerol and free fatty acids by lipase. Three enzymatic steps using 
glycerol kinase, glycerophosphate oxidase, and horseradish peroxidase caused oxidative 
coupling of 3,5-dichloro-2-hydroxybenzenesulfonic acid with 4-aminoantipyrine to 
form a red quinoneimine dye. The change in absorbance (520 nm) was directly 
proportional to the concentration of TG in the sample. LDL-C was calculated using the 
Friedwald formula if fasting plasma TG concentrations were < 4.49 mmol/l. The 




2.2.8.2 Glucose  
Glucose was determined using the enzymatic hexokinase/ glucose-6-phosphate 
dehydrogenase method. Glucose was oxidised by glucose oxidase to gluconolactone in 
the presence of atmospheric oxygen. Hydrogen peroxide produced as a result, oxidised 
4-aminophenazone and phenol to 4-benzoquinone-monoimino phenazone in the 
presence of peroxidase. The colour intensity of the red dye, which is directly 
proportional to the glucose concentration, was measured spectrophotometrically at 340 
nm.  
 
2.2.8.3 Liver function 
Albumin was determined by binding with bromcresol green (BCG) at a pH of 4.1 to 
form an albumin-BCG complex. The colour intensity of the blue-green colour was 
directly proportional to the albumin concentration and was measured 
spectrophotometrically at 570 nm. ALT catalyses the transamination of L-alanine and 2-
oxoglutarate to pyruvate and L-glutamate. Pyruvate is then reduced to lactate in the 
presence of lactate dehydrogenase with the concurrent oxidation of NADH to NAD. 
The rate of the NAD oxidation is directly proportional to the catalytic ALT activity, 
which was determined by measuring the decrease in absorbance at 340 nm. For ALP, 
p‑nitrophenyl phosphate is cleaved by phosphatases into phosphate and p‑nitrophenol 
in the presence of magnesium and zinc ions. The p‑nitrophenol released is directly 
proportional to the catalytic ALP activity and was determined by measuring the increase 
in absorbance at 480 nm. Total bilirubin in the presence of caffeine, benzoate, and 
acetate is coupled with a diazonium ion in a strongly acidic medium. The intensity of 
the colour of the azobilirubin produced is proportional to the total bilirubin 
concentration and was measured spectrophotometrically at 520 nm.  
 
 
2.2.8.4 CD4 count and HIV viral load  
Samples were prepared on the automated FP1000 system (Beckman Coulter, High 
Wycombe, UK) and CD4 T cell count was subsequently measured by flow cytometry 
using the Cytomics FC 500 (Beckman Coulter). Absolute CD4 count was determined 
based on the CD4 cell percentage and the total white blood cell count. HIV viral load 
was defined as the number of copies of HIV-1 RNA per ml of plasma and was 






 HIV-1 Test 
v2.0 (Roche Diagnostics, Mannheim, Germany).  
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2.2.8.5 Adipocytokines  
Total plasma adiponectin was determined using a Quantikine Adiponectin ELISA kit (R 
& D Systems). This sandwich ELISA technique consisted of a monoclonal antibody 
specific for adiponectin pre-coated onto a microplate. Samples were added to the wells 
and any adiponectin present in the sample bound to the monoclonal antibody. The 
addition of a substrate solution induced a colour change proportional to the amount of 
bound adiponectin. The colour change was measured spectrophotometrically.  
 
Plasma cytokine concentrations (IL-2, IL-4, IL-6, IL-8, IL-10, vascular endothelial 
growth factor (VEGF), IFN-γ, TNF-α, IL-1α, IL-1β, monocyte chemoattractant protein-
1 (MCP-1), epidermal growth factor (EGF)) were determined using the Evidence 
Investigator cytokine and growth factor array cytokine chip array kit (Randox 
Laboratories, Crumlin, UK), which performed simultaneous quantitative detection of 
adipocytokines. The Randox Biochip consisted of a biochip containing an array of 
discrete test regions of immobilised antibodies specific to the cytokines of interest and 
employed a sandwich chemiluminescent immunoassay for the cytokine array. The 
antibody labelled with HRP bound to the sample according to the concentration of 
cytokine in the sample and thus an increase in cytokine concentration led to an increase 





The following tests were performed by the investigator. Determination of plasma CLA 
levels was conducted by the author at the Diabetes and Nutritional Sciences Division, 
King’s College London under the guidance of Mr Robert Grey.  
 
2.2.8.6 Determination of plasma CLA  
Gas liquid chromatography (GLC) was used to quantitatively analyse fatty acid methyl 
esters (FAMEs) derived from fatty acids in plasma samples. The basic processes 










Figure 2.6 GLC analysis of fatty acid methyl esters (Adapted from (Yung, 2013).  
 
 
GLC is used for separating components of volatile compounds based on their boiling 
points, as well as differences in their partition coefficients in a gaseous moving phase 
and a liquid stationary phase. An inert solid material acts as a support onto which the 
liquid stationary phase is adsorbed. The initial step in GLC analysis involves the 
esterification of fatty acids to FAMEs. Fatty acids are bound to glycerol and circulate in 
the blood as TG. Therefore, these TG must be broken down to release the FFA, which 
are then esterified to volatile methyl esters. Analysing fatty acids as FAMEs reduces 
their polarity making them easier to analyse (Sigma Aldrich, 2014b). Secondly, 
neutralising the polar carboxyl functional groups allows for the detection of small 
differences exhibited by unsaturated fatty acids based on their boiling points and cis and 






R = hydrocarbon chain  
GC analysis  















Esterification involves condensation of the carboxyl group of the fatty acid and the 
hydroxyl group of the alcohol. The addition of a catalyst allows for protonation of an 
oxygen atom of the carboxyl group. This makes the acid more reactive and the resulting 
combination with alcohol produces an ester. Use of methanol at this stage results in the 
formation of methyl esters (Sigma Aldrich, 2014b). The GLC output consists of a series 
of peaks. The first peak is the solvent peak and after this, the FAMEs appear in order of 
chain length i.e. C10:0 before C12:0 before C14:0, etc. For a given chain length, 
saturated fatty acid methyl esters appear before monounsaturated before 
polyunsaturated.   
 
Lipid extracts from the same subjects were treated at the same time. FAMEs were 
created by transesterification as previously described (Lepage and Roy, 1986). 100 μl 
plasma was pipetted into a Teflon lined screw cap tube. 10 ml acetyl chloride was added 
drop-wise into 100 ml internal standard mixture containing 20 ml Toluene and 80 ml 
methanol with C15:0 at 1 mg/ml. 2.2 ml of this acidic methanol solution was added to 
the tube. The tube was sealed and incubated overnight at 40 °C to effect 
transesterification. Samples were cooled and 5 ml of 6% potassium/sodium carbonate 
was added to neutralise excess acid. The upper organic phase of the sample was 
collected and transferred using a Pasteur pipette to a GLC vial. 1 μl of each sample was 
injected into Agilent Technologies 6890 gas chromatograph (Agilent Technologies UK 
Limited) fitted with a 25 m length x 0.22 mm i.d. x 0.25 µm film thickness Supelco 
SAC-5 capillary column (Sigma Aldrich) and equipped with a flame ionisation detector 
set at 250°C. The injection was performed in split mode (50:1) with the inlet maintained 
at 240°C. Temperature programming was employed to optimise the separation. This 
was achieved by holding the initial column temperature at 160°C for 4 min, followed by 
ramping at 10°C/ min to 200°C and holding at this temperature for 10 min to ensure 
complete elution. The identities of the separated fatty acids were established by 
matching their retention times with those present in authentic reference standards run 
under identical conditions. Proportions of fatty acids as weight % were quantified by 
expressing the areas under the chromatographic peaks as a % of the total integrated 
area. CLA isomers were identified by reference to CLA analytical standards (Sigma 
Aldrich).   
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2.2.8.7 Oxidative stress  
Free-radicals are produced under conditions of oxidative stress, which induce 
peroxidation of PUFA in the phospholipid bilayer leading to the formation of bioactive 
aldehydes (Catalá, 2013). Malondialdehyde (MDA) is an example of one of these 
aldehydes and is an end-product of PUFA peroxidation. MDA reacts with thiobarbituric 
acid reactive substances (TBARS) under high temperature and acidic conditions to form 
MDA-TBARS adducts, which can be measured colorimetrically as a marker of lipid 
peroxidation (Pizzimenti et al., 2013). Measurement of TBARS formation has been 
used previously to determine oxidative stress in HIV-positive individuals in response to 
acute exercise regimes (Deresz et al., 2010). Lipid peroxidation was measured in the 
current study as a marker of safety, as studies have shown that CLA supplementation 
can cause an increase in markers of oxidative stress (Turpeinen et al., 2008).  
 
Frozen samples were thawed on ice for 30 minutes. 100 μl of each sample was used in a 
TBARS assay kit (Cayman Chemicals, Cambridge Bioscience, Cambridge, UK) to 
determine lipid peroxidation as an indicator of oxidative stress. Standards were prepared 
from a stock solution of 125 μM MDA by serial dilution in the range 0- 50 μM. 100 μl 
sample or standard was added to a labelled vial, to which 100 μl SDS solution was 
added. 4 ml of a colour reagent consisting of thiobarbituric acid (TBA) acetic acid 
solution and TBA sodium hydroxide was then added to the vial which was boiled for 1 
hour. Vials were removed immediately and placed in ice water for 10 minutes. Vials 
were centrifuged at 2,750 rpm for 4 minutes. 150 μl of each sample was then loaded 
onto a colorimetric plate in duplicate and the absorbance of the solution read at 540 nm 
in a spectrophotometer (Synergy HT). A standard curve was constructed by plotting the 
mean absorbance values (optical density) from the standard solutions versus the known 
MDA concentrations. Sample concentrations were calculated using the equation of the 


























Chapter 3  
 




Abnormalities of body fat distribution are a characteristic feature of HALS (Galescu et 
al., 2013). The extent to which different ARVs induce these abnormalities varies greatly 
between and within the drug classes. Although Carr et al (1998a) originally attributed 
the abnormalities observed in HALS to PIs, other researchers showed that these 
abnormalities also occurred in those not receiving PIs (Lo et al., 1998). PIs are known 
to cause central fat accumulation and IR (Carr et al., 1998a), while NRTI have been 
associated with the development of LA of the face and extremities (Nolan, 2003).  In 
contrast, NtRTI-based regimens have been shown to be beneficial in improving LA 
(Ribera et al., 2013), highlighting the fact that not all ARVs are equal in their effects on 
adipose tissue.  
 
During the process of adipogenesis, fibroblast-like mesenchymal precursor cells 
proliferate and commit to differentiation along an adipocyte lineage. Under hormonal 
stimulation, the resulting preadipocytes undergo mitotic clonal expansion and numerous 
rounds of cell division. The expression and activity of the transcription factors CEBP-β 
and CEBP-δ induces PPAR-γ and CEBP-α expression in the terminal stages of 
differentiation, which activate the transcription of numerous lipid metabolism genes 
including adipocyte lipid binding protein, glucose metabolism genes such as GLUT4 
and secreted factors such as adiponectin, leptin and resistin (Ahmadian et al., 2013). 
PPAR-γ, CEBP-α and CEBP-β maintain the expression of lipid and glucose metabolism 
genes (Lefterova and Lazar, 2009). Lipid droplets occupy the majority of a mature 
adipocyte and their size is maintained by a fine balance between lipid droplet proteins 
such as perilipin and members of the Cide family, and lipolytic enzymes such as HSL 
and adipose triglyceride lipase (Suzuki et al., 2011).  
 
Disruption of this adipogenic process has been shown to play a key role in the 
pathogenesis of HALS (Caron et al., 2009). ARVs have been shown to induce adipocyte 
dysfunction by inhibiting adipocyte differentiation and adipogenesis (Grigem et al., 
2005), increasing lipolysis (Adler-Wailes et al., 2005) and increasing pro-inflammatory 
cytokine secretion (Johnson et al., 2004). The group of Caron et al (2009) suggest that 
ARV-induced down-regulation of PPAR-γ contributes to adipocyte dysfunction in 
HALS. Data on the effect of ARVs on PPAR-γ are inconsistent; some studies have 
shown ARVs to down-regulate PPAR-γ in vitro (Vernochet et al., 2005, Caso et al., 
2010) and in adipose tissue biopsy samples from HALS patients (Gallego-Escuredo et 
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al., 2013), while other in vitro studies show no effect (Grigem et al., 2005, Kim, 2006, 
Adler-Wailes et al., 2008). PPAR-γ target genes such as adiponectin are also down-
regulated by ARVs (Lagathu, 2007). The use of synthetic PPAR-γ ligand rosiglitazone 
has been shown to enhance PPAR-γ and target gene expression in adipose tissue of 
HALS patients (Sutinen et al., 2004) and to improve LA (Raboud et al., 2010), which 
provides further support for the role of PPAR-γ in HALS.  
 
To date, no studies have collectively examined the effect of ARVs on PPAR-γ and its 
target genes involved in adipocyte differentiation, function, and inflammation. 
Furthermore, although it is plausible to suggest that down-regulation of PPAR-γ may be 
responsible for ARV-induced adipocyte dysfunction, little is known about the effects of 




ARVs dysregulate adipocyte function, differentiation and inflammatory profile. 
    
3.3 Aims 
The specific aims of this study were to investigate the effects of PI (RTV and IDV), 
NRTI (d4T and ZDV) and NtRTI (TDF) on: 
 adipocyte function (TG storage) 
 expression of markers of adipocyte differentiation (PPAR-γ, adiponectin, 
perilipin, Cidea) 
 expression of markers of inflammation (IL-6, leptin, resistin) 
 global gene expression  






3.4.1 Experimental model 
The 3T3-L1 murine adipocyte cell line was maintained as outlined in Section 2.1.3 
Cells were enumerated by Trypan Blue staining and seeded at a density of 5 x 10
5
 cells 
in 75 ml tissue culture flasks. Once confluent, cells were sub-cultured, enumerated and 
re-seeded at a density of 2.4 x 10
5 
cells in 6-well plates and 0.6 x 10
5 
cells in 24-well 
plates. Cells were grown to 80%-90% confluence in induction medium (day 1-5) and 
incubated for a further 48 hours to initiate growth arrest. On day 7, the medium was 
removed and replaced with adipogenic medium consisting of induction medium plus 
IBMX, dexamethasone and insulin. After two days, (day 9) this medium was removed 
and replaced with new medium containing insulin only in addition to the ARVs. 
Thereafter, the medium was changed every 2 days until cells were fully differentiated at 
day 14. Cells were exposed to the respective treatments for a total of five days. All 
experiments were conducted on mature adipocytes at day 14.  
 
3.4.2 Antiretroviral drug treatments 
Differentiated adipocytes were treated with near Cmax concentrations of ZDV (1 μM), 
d4T (10 μM), RTV (20 μM), IDV (10 μM) and TDF (1 μM) for 5 days in 6- or 24-well 
plates as described in Section 2.1.6. Near Cmax concentrations were obtained from 
published literature (Caron et al., 2004, Viengchareun et al., 2007, Minami et al., 2011) 
and were deemed non-toxic by MTS cell viability assays. The vehicle for the ARVs was 
0.1 % ethanol, which was received by all treated cells.  
 
3.4.3 Oil Red O staining  
Once adipocytes reached maturity (day 14), induction medium was removed and cells 
were washed once with PBS. Cells were formalin fixed for 1 hour. Formalin was 
removed, allowed to dry and the cells were washed with 60% isopropanol. Isopropanol 
was removed and cells were incubated in ORO working solution for 10 minutes. The 
ORO was removed and the cells were washed four times with distilled water. The ORO 
was then eluted by incubating in 100% isopropanol for 10 minutes. A volume of this 
solution was then transferred to a 96-well plate and the optical density of the solution 
was measured as described in Section 2.1.9.  
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3.4.4 Real time RT-PCR 
At day 14, total RNA was extracted from adipocytes using the RNeasy Mini Kit as 
described in Section 2.1.10. Briefly, cells were lysed and homogenized in the presence 
of a highly denaturing guanidine-thiocyanate–containing buffer to inactivate RNases 
and ensure purification of intact RNA. Ethanol was added to provide appropriate 
binding conditions, and the sample was then applied to an RNeasy Mini spin column, 
where total RNA binds to the membrane and contaminants were efficiently washed 
away. High-quality RNA was then eluted in RNAse-free water. RNA was quantified 
using the NanoDrop
®
 spectrophotometer. cDNA fragments were generated by reverse 
transcription using the High Capacity RNA-to-cDNA kit as described in Section 2.1.12. 
TaqMan
®
 RT-PCR was performed for PPAR-γ, adiponectin, perilipin, Cidea, leptin, 
resistin, IL-6 and Hprt (endogenous housekeeping control) using pre-developed assay 
kits and the ABI Prism 7000 sequence detection system (see Section 2.1.13).  
 
3.4.5 Sandwich and multiplex ELISA 
On day 14, culture medium was removed and centrifuged at 5,000 rpm for 10 minutes. 
Supernatants were removed from the resulting adipocyte pellets and stored at -80 °C. 
Secretion of adiponectin into supernatant was quantified by DuoSet ELISA (Section 
2.1.15.1) and secretion of leptin, resistin and IL-6 were quantified by Multiplex ELISA 
(Section 2.1.16).  
 
3.4.6 PPAR-γ consensus site binding    
Nuclear activation of PPAR-γ (binding to PPRE) was investigated using a DNA binding 
ELISA TransAM™ PPAR-γ Transcription Factor Assay Kit (Active Motif Europe, 
Rixensart, Belgium) (Section 2.1.18). Briefly, complete binding buffer was added to 
each well of a 96-well microplate to which the PPRE consensus sequence (5’-
AACTAGGNCAAAGGTCA-3’) was immobilised. 10 μg nuclear extract from ARV 
and ethanol treated cells was diluted in lysis buffer and added to each well. The plate 
was incubated for one hour at room temperature with gentle agitation. Primary antibody 
was directed against PPAR-γ and a secondary anti-mouse IgG antibody conjugated with 
HRP were added to each well.  Absorbance was read in a spectrophotometer at 450 nm 




3.4.7 Global gene expression assay  
Microarray analysis was carried out on RNA extracted from adipocytes treated with 
control, RTV and TDF to provide support for the RT-PCR data and to identify any 
additional and novel pathways which might be affected by the drugs. On day 14, total 
RNA was extracted from adipocytes using the RNeasy Mini Kit as described in Section 
2.1.10. RNA samples were prepared for microarray analysis using MessageAmp™ 
Premier RNA Amplification Kit as described in Section 2.1.14. RNA samples were 
pooled and 500 ng of each pooled sample in 5 µl was used in the reactions. The 
concentration of the resulting RNA was determined using the NanoDrop
®
 
spectrophotometer. Biotinylated amplified RNA (aRNA) was fragmented prior to 
hybridisation using the 5X Array Fragmentation Buffer supplied with the 
MessageAmp
™
 Kit. The sample was then evaluated using the Agilent
®
2100 Bioanalyser 
instrument and RNA 6000 Nano Kit loaded with 300 ng of aRNA per well. 11 μg  of 
aRNA was hybridised onto the Affymetrix Mouse Genome 430 2.0 Array Kit 
(Affymetrix, UK) and was subsequently washed, stained and scanned on the Fluidics 
Station 400 and the GeneArray Scanner (Affymetrix, UK) according to the 
manufacturer’s protocol.  Data were analysed using the RMA algorithm and the average 
change in expression (ratio of treatment/ control) determined for each gene. Metacore
™
 
pathway analysis software (GeneGo, Thomson Reuters) was used for functional 
analysis of differentially expressed genes and pathway analysis. 
 
3.4.8 Statistical analysis 
Statistical analyses were performed using SPSS software (version 20; IBM Corp, 
Armonk, New York). Data were analysed using one-way analysis of variance 
(ANOVA), with post-hoc analysis using Dunnett’s test after demonstration of 
significant differences by ANOVA. Differences were considered significant if P < 0.05. 
Data are expressed as the mean ± standard error of the mean (SEM) of four parallel 
observations unless otherwise stated. For microarray analysis, a two-fold change 
relative to control (signal log ratio ≥ 1.0 or ≤ -1.0) was selected as the threshold to 






3.5.1 Cell viability  
The effect of near Cmax concentrations of ARVs, obtained from published literature 
(Caron et al., 2004, Viengchareun et al., 2007, Minami et al., 2011), was investigated 
prior to all experimental work. At these concentrations, viability of cells treated with 
ARVs was not significantly different from vehicle control cells (Figure 3.1). Therefore, 





Figure 3.1 Effect of ARVs on cell viability. Adipocytes were treated with vehicle 
control or near Cmax concentrations of ZDV, d4T, RTV, IDV or TDF. An MTS assay 
was carried out at day 14 to determine cell viability, which was measured 
spectrophotometrically at 490 nm. Results represent mean ± SEM of 4 parallel cell 









































3.5.2 Triglyceride accumulation 
To investigate the effects of each ARV on adipocyte function, TG accumulation was 
measured in 3T3-L1 adipocytes treated with ARVs or vehicle control (ethanol). RTV 
was the only ARV that significantly decreased TG accumulation (29 %) in 
differentiated adipocytes (P < 0.001; Figure 3.2). ORO stained images show reduced 
TG accumulation in RTV-treated adipocytes compared with vehicle control and other 




Figure 3.2 Effect of ARVs on TG accumulation. Adipocytes were treated with vehicle 
control or near Cmax concentrations of ZDV, d4T, RTV, IDV or TDF and stained at day 
14 with ORO to quantify lipid content, which was measured spectrophotometrically at 
540 nm. Results represent mean ± SEM of 4 parallel cell culture experiments. 


































   
 
Figure 3.3 Oil Red O stained adipocytes treated with ARVs. Adipocytes were treated 
with vehicle control or near Cmax concentrations of ZDV, d4T, RTV, IDV or TDF and 
stained at day 14 with ORO to visualise lipid content. Black arrows indicate cells with 
lipid droplets and lipid vesicles (magnification is at 40x).   
50 μm 50 μm 
50 μm 




3.5.3 Lipid droplet protein transcription 
The effect of ARVs on the expression of genes for lipid droplet-associated proteins 
perilipin and Cidea was investigated in 3T3-L1 adipocytes. RTV caused a significant 
decrease in perilipin gene expression (P = 0.003; Figure 3.4). Both RTV and IDV 
significantly decreased Cidea gene expression compared with control (P < 0.001 and P 





Figure 3.4 Effect of ARVs on perilipin transcription. Adipocytes were treated with 
vehicle control or near Cmax concentrations of ZDV, d4T, RTV, IDV or TDF and 
expression of perilipin mRNA was measured on day 14 relative to Hprt housekeeping 
gene by RT-PCR. Results represent mean ± SEM of 4 parallel cell culture experiments. 














































Figure 3.5 Effect of ARVs on Cidea transcription. Adipocytes were treated with vehicle 
control or near Cmax concentrations of ZDV, d4T, RTV, IDV or TDF and expression of 
Cidea mRNA was measured on day 14 relative to Hprt housekeeping gene by RT-PCR. 
Results represent mean ± SEM of 4 parallel cell culture experiments. *Significantly 









































3.5.4 PPAR-γ gene expression and nuclear activation 
There was a significant reduction in PPAR-γ gene expression in RTV-treated adipocytes 
compared with control (P = 0.014; Figure 3.6). Nuclear PPAR-γ binding to the 
immobilised consensus site was also significantly reduced in cells exposed to RTV 
during differentiation (P = 0.03; Figure 3.7), whereas IDV and TDF significantly 
increased nuclear PPAR-γ binding to its consensus site (P = 0.035 and P = 0.037, 




Figure 3.6 Effect of ARVs on PPAR-γ transcription. Adipocytes were treated with 
vehicle control or near Cmax concentrations of ZDV, d4T, RTV, IDV or TDF and 
expression of PPAR-γ mRNA was measured on day 14 relative to Hprt housekeeping 
gene by RT-PCR. Results represent mean ± SEM of 4 parallel cell culture experiments. 


























































Figure 3.7 Effect of ARVs on nuclear PPAR-γ binding to PPRE. Nuclear proteins were 
extracted on day 14 from adipocytes treated with vehicle control or near Cmax 
concentrations of ZDV, d4T, RTV, IDV or TDF and nuclear PPAR-γ consensus site 
binding was measured. Results represent mean ± SEM of 4 parallel cell culture 
experiments. *Significantly different (P = 0.03, 0.035 and 0.037, respectively) from 




































3.5.5 Adiponectin gene expression and secretion 
Adiponectin mRNA expression was lower by 72 % in the presence of RTV; however, 
this was far from significance (P = 0.982; Figure 3.8). d4T caused a significant increase 
in adiponectin gene expression (P = 0.014; Figure 3.8). Adiponectin protein secretion 
was significantly decreased by RTV, IDV and TDF (P < 0.001, P = 0.004 and P < 





Figure 3.8 Effect of ARVs on adiponectin transcription. Adipocytes were treated with 
vehicle control or near Cmax concentrations of ZDV, d4T, RTV, IDV or TDF and 
expression of adiponectin mRNA was measured on day 14 relative to Hprt 
housekeeping gene by RT-PCR. Results represent mean ± SEM of 4 parallel cell culture 












































Figure 3.9 Effect of ARVs on adiponectin protein secretion. Adipocytes were treated 
with vehicle control or near Cmax concentrations of ZDV, d4T, RTV, IDV or TDF. 
Supernatants were collected from adipocytes on day 14 and used to quantify 
adiponectin secretion. Results represent mean ± SEM of 4 parallel cell culture 
experiments. *Significantly different (P < 0.001, 0.004 and < 0.001, respectively) from 











































3.5.6 Leptin, resistin and interleukin-6 transcription and secretion 
Expression of leptin was significantly increased in the presence of ZDV and TDF (P = 
0.021 and P < 0.001, respectively; Figure 3.10). Leptin protein secretion was 
undetectable by multiplex ELISA (data not shown). TDF caused a significant increase 
in resistin mRNA expression (P = 0.003; Figure 3.11), while RTV significantly 
decreased resistin protein secretion (P < 0.001; Figure 3.12). Both IDV and TDF 
significantly increased IL-6 mRNA expression (P = 0.022 and P < 0.001, respectively; 




Figure 3.10 Effect of ARVs on leptin transcription. Adipocytes were treated with 
vehicle control or near Cmax concentrations of ZDV, d4T, RTV, IDV or TDF and 
expression of leptin mRNA was measured on day 14 relative to Hprt housekeeping gene 
by RT-PCR. Results represent mean ± SEM of 4 parallel cell culture experiments. 









































Figure 3.11 Effect of ARVs on resistin transcription. Adipocytes were treated with 
vehicle control or near Cmax concentrations of ZDV, d4T, RTV, IDV or TDF and 
expression of resistin mRNA was measured on day 14 relative to Hprt housekeeping 
gene by RT-PCR. Results represent mean ± SEM of 4 parallel cell culture experiments. 




Figure 3.12 Effect of ARVs on resistin protein secretion.  Adipocytes were treated with 
vehicle control or near Cmax concentrations of ZDV, d4T, RTV, IDV or TDF and 
resistin protein secretion was measured on day 14 using a multiplex ELISA. Results 
represent mean ± SEM of 8 parallel cell culture experiments. *Significantly different (P 
















































































Figure 3.13 Effect of ARVs on IL-6 transcription. Adipocytes were treated with vehicle 
control or near Cmax concentrations of ZDV, d4T, RTV, IDV or TDF and expression of 
IL-6 mRNA was measured on day 14 relative to Hprt housekeeping gene by RT-PCR. 
Results represent mean ± SEM of 4 parallel cell culture experiments. *Significantly 











































3.5.7 Global gene expression  
Given the potent effect of RTV on PPAR-γ and target genes, it was decided that 
microarray analysis be carried out on RNA samples from RTV-treated cells. To provide 
a comparison, TDF, which also significantly affected a number of genes and is a newer 
class of ARV, was also chosen for analysis using microarray.  
 
3.5.7.1 RTV 
The expression of 1,657 genes was up-regulated greater than 2-fold and 1,379 down-
regulated greater than 2-fold in RTV-treated cells compared with control. A list of key 
adipogenic genes of interest which were altered by RTV are shown in Table 3.1. 
Altered gene lists were imported into MetaCore
™
 pathway analysis software (GeneGo), 
which generated a list of top canonical pathway maps representing a set of signalling 
and metabolic maps of genes affected by RTV (Table 3.2). RTV had a profound effect 
on cell cycle pathways, with 5 of the top ten pathway maps representing changes in 
genes involved in cell cycle regulation. Other pathways included immune response, 
insulin-like growth factor (IGF) signalling and adipocyte differentiation pathways. 
Figure 3.14 illustrates the pathway map for ‘Differentiation of white adipocytes’, in 
which 16 out of 53 genes were altered (P = 0.007; false discovery rate (FDR) = 0.046).  
Similarly, 16 out of 53 genes were altered in the ‘Insulin, IGF-1 and TNF-α in brown 
adipocyte differentiation’ pathway (P = 0.007; FDR = 0.046; Figure 3.15). The genes 
up- or down-regulated within each of these adipogenic pathways are listed in more 
detail in Table 3.3.  
 
Table 3.1 Key genes of interest affected by RTV 
Gene Change in mRNA expression 
PPAR-γ 6-fold   ↓ 
Adiponectin 24-fold ↓ 
Leptin 5-fold   ↓ 
Resistin 95-fold ↓ 







Table 3.1 Top 10 canonical pathways affected by RTV 




1 Chromosome condensation in 
prometaphase 
< 0.001 < 0.001 14/21 
2 The metaphase checkpoint < 0.001 < 0.001 18/36 
3 Spindle assembly and chromosome 
separation 
< 0.001 < 0.001 17/33 
4 Role of APC in cell cycle regulation < 0.001 0.001 16/32 
5 Initiation of mitosis < 0.001 0.001 14/25 
6 Histamine H1 receptor signalling in 
immune response 
0.001 0.005 18/48 
7 IGF family signalling in colorectal 
cancer 
0.001 0.011 19/60 
8 Insulin, IGF-1 and TNF-α in brown 
adipocyte differentiation 
0.007 0.046 16/53 
9 Differentiation of white adipocytes 0.007 0.046 16/53 
10 Role of Nek in cell cycle regulation 0.009 0.057 12/32 
P value is based on the number of interactions of the gene in the pathway. FDR is 
calculated taking into account the P value for each map and the rank of the map, given 
the total number of maps in the whole Pathway Maps ontology. * Ratio of genes altered 






Figure 3.14 White adipocyte differentiation (GeneGo).Histograms located next to each 
gene indicate the direction (blue = down-regulated; red = up-regulated) and the degree 





Figure 3.15 Insulin, IGF-1 and TNF-α in brown adipocyte differentiation 
(GeneGo).Histograms located next to each gene indicate the direction (blue = down-
regulated; red = up-regulated) and the degree of change in expression of each gene. Full 




Table 3.2 Adipogenic pathways and genes altered by RTV 
Pathway 8: Insulin, IGF-1 and TNF-α in brown adipocyte differentiation 
Gene name Symbol Description Fold change* 
Down-regulated    
Adipsin Cfd Stimulates glucose transport for TG 




Adiponectin Adipoq Adipokine involved in fat 




Lips Hydrolyses stored TG  20 
Stearoyl-CoA 
desaturase-1 





Glut4 Insulin-dependent glucose 
transporter induced by PPAR-γ 
13.4 
CCAAT/enhancer 
binding protein  α 
Cebpα Induces adipogenesis through 
PPAR-γ 
11.3 
Fatty acid binding 
protein 4 
Fabp4 Carrier protein for fatty acids and 










Irs2 Up-regulates CEBPα, PPAR-γ and 
adipocyte differentiation 
4.9 
Beta 3 adrenergic 
receptor  





Insig1 Regulates cholesterol synthesis by 
blocking SREBP processing 
3 
Fatty acid synthase Fasn Catalyses fatty acid synthesis  2.8 
Insulin-like growth 
factor 1  
Igf1 Involved in adipocyte differentiation 
and glucose metabolism  
2 
Pathway 9: Differentiation of white adipocytes 
Gene name Symbol Description Fold change* 
Down-regulated    
Adipsin Cfd Stimulates glucose transport for TG 
accumulation in adipocytes and 
inhibits lipolysis 
238 
Resistin Retn Involved in IR in obesity 95 
Cell death-inducing 
DFFA-like effector c 
Cidec Lipid droplet protein. Inhibits 
lipolysis in favour of lipid storage  
74 
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Gene name Symbol Description Fold change* 
CCAAT/enhancer 
binding protein  α 
Cebpa Induces adipogenesis through 
PPAR-γ activation 
11 
Fatty acid binding 
protein 4 
Fabp4 Carrier protein for fatty acids and 
other lipophilic compounds 
7.5 




Ppar-γ Key regulator of adipocyte 
differentiation 
6 
Leptin  Lep Energy homeostasis and regulation 
of TG storage in adipose tissue 
4.8 
Ribosomal s6 kinase Rps6kb1 Cell proliferation, survival and 
differentiation 
3 
Insulin-induced gene 1 Insig1 Regulates cholesterol synthesis by 
blocking SREBP processing 
3 
Nuclear receptor 
interacting protein 140 
Nrip1 Blocks the expression of genes 





Rbl1 Regulator of cell division 2.1 
Up-regulated 




Smad1 Regulates adipocyte differentiation 
through PPAR-γ activation 
3.2 
Extracellular signal-
regulated kinase 1/2 
Erk 1 / 2 Phosphorylates nuclear receptors 





Ppargc1 Regulates energy metabolism genes 
through interaction with PPAR-γ 
2.1 







Unlike RTV, no relevant genes were up- or down-regulated greater than 1.5- or 2-fold 
compared with control in TDF-treated cells and so altered gene lists could not be 
explored further using MetaCore
™







In this study, ARVs had a significant effect on adipocyte function, differentiation and 
inflammatory cytokines. We have demonstrated the detrimental effects of a number of 
ARVs, RTV in particular, on TG accumulation, lipid droplet-associated proteins, 
PPAR-γ, adiponectin, leptin, resistin and IL-6. Furthermore, microarray analysis has 
identified novel effects of RTV on a number of adipogenic genes, as well as upstream 
regulators of PPAR-γ, which has not previously been reported.    
 
3.6.1 Effect of ARVs on triglyceride accumulation 
RTV significantly decreased TG accumulation, while the other ARVs had no significant 
effect. Moreover, adipocytes treated with RTV appear less well differentiated in Oil Red 
O stained images. This finding is in agreement with results from previous studies using 
the well-characterised 3T3-L1 cell line (Minami et al., 2011). A number of studies have 
demonstrated a detrimental effect of RTV on lipid accumulation in other cells types 
including human SGBS adipocytes (Kim, 2006), C3H10T1/2 stem cells (Lenhard et al., 
2000) and adipocytes isolated from human subcutaneous (Lagathu, 2007) and omental 
adipose tissue (Jones et al., 2008). Interestingly, at concentrations of just 10 μM, RTV 
induced a 50% reduction in insulin-stimulated lipogenesis in SGBS adipocytes (Grigem 
et al., 2005). These findings, as well as our own, exemplify the lipoatrophic effect of 
RTV.  
 
3.6.2 Effect of ARVs on lipid droplet-associated proteins  
An analysis of lipid droplet-associated proteins was undertaken in an attempt to 
investigate their role in the observed effects on TG accumulation. Consistent with the 
finding of reduced TG accumulation in RTV-treated cells, expression of perilipin was 
also reduced by RTV and Cidea expression by RTV and IDV. In contrast, microarray 
analysis did not find any significant alteration in perilipin or Cidea mRNA expression in 
response to RTV treatment. However, Cidec, another member of the Cide family, was 
down-regulated 74-fold by RTV in microarray analysis. Cidec regulates lipid droplet 
size by binding to lipid droplets and restricting lipolysis, thereby enhancing TG storage. 
This has been suggested to occur via interaction of Cidec with perilipin (Puri et al., 
2007). Only one study has previously investigated the effect of ARV on Cidec 
expression and found that saquinavir significantly decreased its expression (Bociaga-
Jasik et al., 2013). Our findings for perilipin and Cidea substantiate those of Adler-
Wailes et al (2005) and (2008). Lipid droplet-associated proteins, perilipin and Cidea 
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act as a barrier, protecting stored TG from the lipolytic action of cellular lipases (Puri et 
al., 2008). RTV and other drugs from the PI family have previously been shown to 
decrease perilipin expression in 3T3-L1 adipocytes, which was associated with an 
increase in glycerol and FFA release (Adler-Wailes et al., 2005, Kovsan et al., 2007). 
Although lipolysis was not measured in our study, the observed reduction in TG 
accumulation may be due to the decreased perilipin expression as a result of RTV 
treatment. Furthermore, both perilipin and Cidea are PPAR-γ target genes (Dalen et al., 
2004, Puri et al., 2008); therefore, down regulation of PPAR-γ in this study may have 
mediated the reduction in lipid droplet proteins observed in RTV-treated adipocytes.  
 
3.6.3 Effect of ARVs on PPAR-γ 
PPAR-γ plays a central role in regulating adipogenesis and lipid metabolism in mature 
adipocytes (Desvergne and Wahli, 1999). Binding of lipophilic ligands to PPAR-γ leads 
to the transcription of adipocyte genes including perilipin (Dalen et al., 2004), Cidea 
(Puri et al., 2008) and adiponectin (Iwaki et al., 2003). Both IDV and TDF significantly 
increased PPAR-γ binding to PPRE. In contrast, previous studies report decreased 
PPAR-γ expression in response to IDV (Caron et al., 2001, Viengchareun et al., 2007), 
while the effect of TDF on PPAR-γ expression has not previously been investigated in 
vitro. RTV significantly decreased PPAR-γ gene expression and binding to its PPRE. 
Microarray analysis confirmed these findings and showed a 6-fold decrease in PPAR-γ 
expression compared with control. Our results substantiate previous reports for PPAR-γ 
gene and protein expression in vitro (Dowell et al., 2000, Vernochet et al., 2005, Caso et 
al., 2010). However, it is worth noting that a number of studies have failed to find an 
effect of ARVs on PPAR-γ using near Cmax concentrations (Grigem et al., 2005, Kim, 
2006, Adler-Wailes et al., 2008). The group of Caron et al. (2009) highlight a central 
role for PPAR-γ down-regulation in the aetiology of adipocyte dysfunction in HALS. 
Down-regulation of PPAR-γ has been correlated with decreased expression of 
adiponectin and increased expression of IL-6 (Bastard et al., 2002b, Kannisto et al., 
2003, Vigouroux et al., 2003, Jan et al., 2004). PPAR-γ is essential for adipogenesis 
(Tontonoz and Spiegelman, 2008). Therefore, it is plausible to suggest that down-
regulation of PPAR-γ leading to reduced adipogenesis may be responsible for the 




3.6.4 Effect of ARVs on adiponectin 
Adiponectin is an insulin-sensitising adipokine induced during adipocyte differentiation 
(Scherer et al., 1995). In the current study, d4T caused an unexpected increase in 
adiponectin gene expression. However, data from microarray analysis show a 24-fold 
decrease in adiponectin mRNA expression in RTV-treated cells compared with control. 
When protein secretion was investigated, it was found that RTV, IDV and TDF 
significantly decreased adiponectin protein secretion. In contrast to RT-PCR data, 
previous studies have shown a reduction in adiponectin in response to d4T (Jones et al., 
2005, Stankov et al., 2007). This, together with the fact that microarray and protein 
secretion data do not confirm this effect, may indicate that the observed effect of d4T on 
adiponectin expression is an anomaly. A number of other studies have demonstrated 
effects for PIs (RTV, amprenavir, atazanavir and abacavir) on adiponectin mRNA 
expression (Grigem et al., 2005, Kim, 2006, Lagathu, 2007, Adler-Wailes et al., 2008). 
Consistent with our findings for adiponectin protein secretion, two other research 
groups demonstrated a significant reduction in adiponectin gene expression in SGBS 
adipocytes in response to 20 μM RTV (Grigem et al., 2005, Kim, 2006). In adipocytes 
derived from adult stem cells, RTV induced a significant decrease in the expression of 
PPAR-γ and adiponectin (Vernochet et al., 2005). A study of human adipocytes cultured 
in the presence of RTV has shown reduced expression, secretion and release of 
adiponectin (Lagathu, 2007). Furthermore, hypoadiponectinaemia is a common finding 
in individuals with HALS (Mynarcik et al., 2002, Addy et al., 2003, Sutinen et al., 
2003, Vigouroux et al., 2003, Johnson et al., 2004, Bezante et al., 2009, Minami et al., 
2009). Adiponectin plays a role in insulin sensitisation and down-regulation may 
contribute to IR in HIV (Kim, 2006). The precise mechanism underlying the inhibition 
of adiponectin is not yet clear. PPAR-γ has been suggested to play a role in the 
transcriptional activation of the adiponectin gene via a PPRE in the adiponectin 
promoter (Iwaki et al., 2003). Thus, down-regulation of adiponectin secretion in RTV-
treated adipocytes in this study may be mediated by down-regulation of PPAR-γ.  
 
3.6.5 Effect of ARVs on leptin 
Leptin circulates proportional to levels of body fat and is thought to play a role in the 
regulation of energy intake and expenditure (Mantzoros, 2012). Leptin has been shown 
to be related to adiposity in HALS and to increase in response to WC (de Luis et al., 
2012). In this study, the effect of ARVs on leptin was investigated using RT-PCR and 
microarray analysis. It was found that leptin mRNA expression was significantly 
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increased by ZDV and TDF. In contrast, microarray analysis showed a significant 
down-regulation of leptin mRNA expression in RTV-treated cells (5-fold).  Decreased 
leptin expression in RTV-treated cells may suggest a conversion of adipocytes from 
cells that store TG to fatty acid oxidising cells and may be one mechanism underlying 
RTV-induced LA. In contrast to our RT-PCR data, Lagathu et al (2007) showed 
reduced leptin secretion in human primary adipocytes treated with ZDV. The effect of 
TDF on leptin mRNA has not previously been shown. Similar to our microarray data, 
reduced leptin secretion has also been identified in human adipocytes treated with 
lopinavir boosted RTV (Gallego-Escuredo et al., 2010). Hypoleptinaemia is observed in 
patients with HALS and leptin replacement therapy is being explored as a potential 
therapeutic strategy to decrease central fat mass in HALS (Mantzoros, 2012).  
 
3.6.6 Effect of ARVs on resistin  
RTV showed no effect on resistin mRNA expression in RT-PCR, but in subsequent 
microarray analysis, resistin expression was decreased 95-fold compared with control. 
For the first time, we have shown a significant increase in resistin gene expression in 
adipocytes treated with TDF, although no effect was observed for TDF at the protein 
level. In contrast to microarray data, RTV significantly decreased resistin protein 
secretion. Rajala et al (Rajala et al., 2004) also found differences in resistin mRNA and 
protein levels in ob/ob mice and suggest a negative feedback loop may exist whereby 
low circulating resistin may enhance gene expression. It is also important to note that 
only four replicates were performed giving a lack of power which may account for the 
differences observed.  Resistin is an adipokine originally thought to be the link between 
diabetes and obesity (Steppan et al., 2001). The role of resistin in HALS is not fully 
understood. Ranade et al (2008) found a SNP in the resistin gene associated with 
elevated lipids, IR and body composition changes among HIV-infected individuals 
taking HAART. Another study found significantly greater plasma resistin levels in 
HALS patients compared with uninfected controls (Escote et al., 2011). However, 
others have found no association between serum resistin and fat redistribution, IR or 
metabolic profile in HIV-infected patients (Barb et al., 2005, Arama et al., 2013).  
 
3.6.7 Effect of ARVs on IL-6 
IL-6 gene expression was significantly increased by IDV and TDF in the current study. 
Additionally, microarray data demonstrated a 10-fold increase in IL-6 mRNA 
expression in response to RTV treatment. IDV has previously been shown to increase 
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IL-6 release from human adipocytes (Lagathu, 2007), but the effect of TDF on IL-6 
expression has not been shown previously. RTV has been shown to significantly 
increase IL-6 expression in 3T3-F442A adipocytes (Lagathu et al., 2004) and a number 
of studies in SGBS (Grigem et al., 2005, Kim, 2006) and human adipocytes (Lagathu, 
2007). IL-6 has been suggested to play a role in IR by blocking insulin signalling in 
adipocytes (Lagathu et al., 2005). Increased IL-6 has been demonstrated in SCAT from 
patients with HALS (Kannisto et al., 2003) and may mediate IR in these patients.  
 
3.6.8 Global gene expression analysis 
In addition to supporting RT-PCR results, pathway analysis carried out on microarray 
data allowed for the investigation of potential mechanisms underlying the effects of 
RTV on PPAR-γ and target genes. In our experiment, extracellular-signal-regulated 
kinase 1/2 (ERK1/2) expression was up-regulated by RTV. ERK1/2 phosphorylation of 
PPAR-γ results in decreased transcription and protein expression of the transcription 
factor, as well as a reduction in its ability to promote adipogenesis (Hu et al., 1996). 
Previously, PI (IDV and nelfinavir) have been shown to decrease phosphorylation of 
ERK1/2 in 3T3-L1 adipocytes and myocytes, which altered the activation of insulin 
signalling (Ben-Romano et al., 2004, Hong-Brown et al., 2004). However, the effect of 
ARVs on ERK1/2 in relation to PPAR-γ has not been investigated. It could be 
suggested that RTV-induced up-regulation of ERK1/2 in our experiment had a direct 
effect on PPAR-γ phosphorylation, expression and adipogenesis.  
 
The negative effect of RTV on liver-X-receptor alpha (LXR-α) has not previously been 
shown and is a novel finding of this study. During adipocyte differentiation, insulin 
induces the expression of LXR-α, which enhances the expression of SREBP1, resulting 
in transcriptional activation of PPAR-γ (Seo et al., 2004). Down-regulation of LXR-α in 
this experiment may provide another possible mechanism for the observed down-
regulation of PPAR-γ by RTV in our experiment.   
 
Nuclear receptor interacting protein 140 (NRIP1) and retinoblastoma-like 1 (RBL1) 
have been shown to suppress PPAR-γ transcriptional activity (Fajas et al., 2002). In this 
study, both genes were down-regulated by RTV and it is therefore unlikely that they are 
involved in suppressing PPAR-γ. NRIP1 and RBL1 are involved in the conversion of 
WAT to a brown-fat-like phenotype and up-regulate BAT gene uncoupling protein-1 
(UCP1) (Scime et al., 2005, Fritah et al., 2010). As such, these genes may be worth 
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investigating in future studies to determine the effects of ARVs on the conversion of 
WAT to BAT.  
 
Mothers against decapentaplegic homolog 1 (SMAD1) was one of three genes in the 
adipocyte differentiation pathway up-regulated by RTV, a finding which has not been 
previously reported. SMAD1 is activated by bone morphogenic proteins and is 
responsible for activating PPAR-γ transcription (Jin et al., 2006). SMAD1 expression 
was up-regulated in our experiment, while PPAR-γ transcription was down-regulated, 
indicating that SMAD1 is unlikely to be involved in RTV-mediated PPAR-γ down-
regulation. Similarly, PPAR-γ coactivator 1 alpha (PPARGC1) was up-regulated by 
RTV in our experiment, yet expression of PPAR-γ was down-regulated. PPARGC1 
expression has been shown to be lower in SCAT biopsy samples from HALS patients 
compared with patients without HALS (Kannisto et al., 2003).  
 
Additional genes altered in the ‘Insulin, IGF-1 and TNF-α in brown adipocyte 
differentiation’ pathway included adiponectin, insulin-like growth factor (IGF)-1, 
insulin receptor substrate (IRS)-2, beta 3 adrenergic receptor (ADRB3), GLUT4 and 
FASN. GLUT4 and FASN are well known to be down-regulated in response to RTV 
(Grigem et al., 2005) and explain in part the mechanisms underlying RTV-induced 
disturbances in adipocyte lipid and glucose metabolism. The in vitro effect of ARVs on 
IGF-1 has not yet been investigated, but serum IGF-1 was found to be higher in patients 
treated with PI compared with those treated with NNRTI and healthy subjects 
(Parfieniuk-Kowerda et al., 2013). Similarly, the in vitro effect of ARVs on the 
expression of ADRB3 has not previously been shown. Acute activation of ADRB3 is 
suggested to result in HSL-mediated release of FFA from adipocytes resulting in an 
inflammatory process which leads to down-regulation of PPAR-γ and CEBP-α (Mottillo 
et al., 2010). Moreover, Vonkeman (2000) showed that patients with a polymorphism in 
the ADRB3 gene were more likely to develop LD when taking ARVs compared with 
those who do not have the polymorphism. We have shown down-regulation of ADRB3 
in response to RTV, which might be expected to result in increased PPAR-γ expression. 
However, as PPAR-γ was down-regulated by RTV in our experiment, it excludes the 




3.6.9 Limitations and conclusion 
Limitations of our study include the fact that no combinations of ARV were tried in the 
experiments, as the focus was to elucidate the effects of each drug individually. As each 
drug was investigated separately, our experimental set-up does not represent the fixed 
drug combinations currently used in vivo. In the current study, we investigated the 
effects of RTV at near Cmax concentrations only. In vivo, levels of circulating ARVs are 
not sustained i.e. levels peak and trough. Furthermore, protein binding, blood flow and 
drug transporters may also play a key role in drug distribution, which will affect 
circulating ARV concentrations. RTV, which is routinely used as a boosting agent to 
increase the plasma concentrations of other PI (Hsu et al., 1998), appears to have a 
profound effect on adipocyte function and differentiation. Microarray analysis 
confirmed some of the RT-PCR data and identified additional genes modulated by 
RTV. We hypothesise that modulation of ERK1/2 signalling and LXR-α expression 
could represent key events leading to down-regulation of PPAR-γ and adipogenic genes, 
and inhibition of adipocyte differentiation and TG storage as observed in RTV treated 
cells. PPAR-γ is a nutrient sensor and master adipogenic transcription factor, and may 
therefore represent a suitable target for nutrient interventions to combat ARV-induced 



























Chapter 4  
The effects of conjugated linoleic acid on 3T3-L1 adipocytes pre-





CLA isomers are positional and stereo-isomers of linoleic acid formed by bacterial 
biohydrogenation of linoleic acid in the rumen (Bauman et al., 1999). The c9,t11 and 
t10,c12 isomers appear to be the most biologically active (Kennedy et al., 2010). c9,t11 
constitutes 90% of total dietary CLA and is found largely in beef and dairy products 
(Reynolds and Roche, 2010), while commercial CLA supplements typically contain 
large quantities of the t10,c12 isomer (Wang and Jones, 2004). CLA isomers may have 
beneficial effects with respect to obesity (Onakpoya et al., 2012), inflammation (Sofi et 
al., 2010), cancer (Mohammadzadeh et al., 2013), bone health (Deguire et al., 2012) and 
regression of atherosclerosis (Mitchell et al., 2012).  
 
PPAR-γ is a master adipogenic transcription factor (Desvergne and Wahli, 1999) and its 
down-regulation has been suggested to be central to the development of HALS  (Caron 
et al., 2009). Down-regulation of PPAR-γ has been demonstrated in numerous in vitro 
studies in response to ARVs (Caron et al., 2001, Bastard et al., 2002a, Caron et al., 
2004, Grigem et al., 2005, Pacenti et al., 2006, Díaz-Delfín et al., 2011), as well as in 
mice (Goetzman et al., 2003). Furthermore, adipose tissue biopsies from HALS patients 
have shown reduced expression of PPAR-γ compared with non-lipodystrophic patients 
(Gallego-Escuredo et al., 2013). A study in healthy volunteers receiving NRTI for 2 
weeks showed decreased adipose tissue expression of PPAR-γ (Mallon et al., 2005), 
while a 6-month interruption of HAART has been shown to improve adipose tissue 
expression of PPAR-γ (Kim et al., 2007c) indicating that changes in PPAR-γ, although 
quick to occur, may be reversible.   
 
Binding of lipophilic ligands to PPAR-γ leads to the association of the transcription 
factor with co-activators and heterodimerisation with RXR. The heterodimer then 
targets the co-activator complex to PPRE on the target gene promoter, which initiates 
target gene transcription (Desvergne and Wahli, 1999). TZDs are synthetic PPAR-γ 
ligands, which are licensed for the treatment of T2DM and have been investigated for 
their role in mitigating aspects of HALS (Raboud et al., 2010). Pioglitazone was found 
to be effective at increasing limb fat in HIV-infected individuals compared with placebo 
(Raboud et al., 2010). Another study in patients with LA found that after only 2 weeks 
of rosiglitazone treatment, PPAR-γ expression in SCAT was significantly increased 
(Mallon et al., 2008). Current European AIDS Clinical Society guidelines for the 
management of diabetes in HIV question the use of TZDs and recommend metformin as 
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the first choice (European AIDS Clinical Society, 2014). These findings suggest that 
PPAR-γ ligands may be potentially beneficial in the management of aspects of HALS, 
but due to questions regarding the safety of TZDs, natural ligands should be explored.  
 
CLA isomers are natural PPAR-γ ligands (Belury et al., 2002, Brown et al., 2003) and 
have been shown to differentially affect adipocyte lipid accumulation (Granlund et al., 
2003), adiponectin secretion (Ahn et al., 2006) and expression and secretion of perilipin 
(Chung et al., 2005). As far as could be ascertained, no studies have investigated the 
effects of CLA isomers on PPAR-γ and target genes in adipocytes exposed to ARVs.  
 
4.2 Hypothesis 
CLA isomers, as PPAR-γ ligands, will mitigate adipocyte dysfunction, PPAR-γ down-
regulation and modulate the inflammatory profile in 3T3-L1 adipocytes exposed to 
ARVs.   
 
4.3 Aims 
The specific aims of this study were to investigate the effects of two CLA isomers 
(c9,11 and t10,c12) on: 
 adipocyte function (TG accumulation) 
 expression of markers of adipocyte differentiation (PPAR-γ, adiponectin, 
perilipin, Cidea) 
 expression of markers of inflammation (IL-6, leptin, resistin) 
 global gene expression  





4.4.1 Experimental model 
The 3T3-L1 murine adipocyte cell line was maintained as outlined in Section 2.1.3. 
Cells were enumerated by Trypan Blue staining and seeded at a density of 5 x 10
5
 cells 
in 75 ml tissue culture flasks. Once confluent, cells were sub-cultured, enumerated and 









plates. Cells were grown to 80-90% confluence in induction medium (day 1-5) and 
incubated for a further 48 hours to initiate growth arrest.  On day 7, the medium was 
removed and replaced with adipogenic medium consisting of induction medium plus 
IBMX, dexamethasone and insulin. After two days, (day 9) this medium was removed 
and replaced with new medium containing insulin only, ARVs which showed 
significant effects in Chapter 3, as well as CLA isomers. Differentiated adipocytes were 
treated with near Cmax concentrations of RTV (20 μM), IDV (10 μM) or TDF (1 μM), in 
addition to 100 μM c9,t11 or t10,c12 for 5 days in 6- or 24-well plates, as previously 
described. CLA isomers, c9,t11 and t10,c12, were dissolved in vehicle control DMSO. 
All treated cells received one or both vehicles consisting of 0.1% ethanol and/or 0.1% 
DMSO as appropriate. Thereafter, the medium was changed every 2 days until cells 
were fully differentiated at day 14. Cells were exposed to the respective treatments for a 
total of five days. All experiments were conducted on mature adipocytes at day 14.  
 
4.4.2 Oil Red O staining  
Once adipocytes reached maturity (day 14), induction medium was removed and cells 
were washed once with PBS. Cells were formalin fixed for 1 hour. Formalin was 
removed, allowed to dry and the cells were washed with 60% isopropanol. Isopropanol 
was removed and cells were incubated in ORO working solution for 10 minutes. The 
ORO was removed and the cells were washed four times with distilled water. The ORO 
was then eluted by incubating in 100% isopropanol for 10 minutes. A volume of this 
solution was then transferred to a 96-well plate and the optical density of the solution 





4.4.3 Real time RT-PCR 
At day 14, total RNA was extracted from adipocytes using the RNeasy Mini Kit as 
described in Section 2.1.10. Briefly, cells were lysed and homogenised in the presence 
of a highly denaturing guanidine-thiocyanate–containing buffer to inactivate RNases 
and ensure purification of intact RNA. Ethanol was added to provide appropriate 
binding conditions, and the sample was then applied to an RNeasy Mini spin column, 
where total RNA binds to the membrane and contaminants were efficiently washed 
away. High-quality RNA was then eluted in RNAse-free water. RNA was quantified 
using the NanoDrop
®
 spectrophotometer. cDNA fragments were generated by reverse 
transcription using the High Capacity RNA-to-cDNA kit as described in Section 2.1.12. 
TaqMan
®
 RT-PCR was performed for PPAR-γ, adiponectin, perilipin, Cidea, leptin, 
resistin, IL-6 and Hprt (endogenous housekeeping control) using pre-developed assay 
kits and the ABI Prism 7000 sequence detection system (see Section 2.1.13).  
 
4.4.4 Sandwich ELISA 
On day 14, culture medium was removed and centrifuged at 5,000 rpm for 10 minutes. 
Supernatants were removed from the resulting adipocyte pellets and stored at -80 °C. 
Secretion of adiponectin into supernatant was quantified by DuoSet ELISA as outlined 
in Section 2.1.15.1.  
 
4.4.5 PPAR-γ consensus site binding    
Nuclear activation of PPAR-γ (binding to PPRE) was investigated using a DNA binding 
ELISA TransAM™ PPAR-γ Transcription Factor Assay Kit (Active Motif) (Section 
2.1.18). Briefly, complete binding buffer was added to each well of a 96-well 
microplate to which the PPRE consensus sequence (5’-AACTAGGNCAAAGGTCA-
3’) was immobilised. 10 μg nuclear extract from ARV and ethanol treated cells was 
diluted in lysis buffer and added to each well. The plate was incubated for one hour at 
room temperature with gentle agitation. Primary antibody was directed against PPAR-γ 
and a secondary anti-mouse IgG antibody conjugated with HRP were added to each 
well. Absorbance was read in a spectrophotometer at 450 nm with a reference 




4.4.6 Global gene expression assay 
Microarray analysis was carried out on RTV-treated adipocytes, as RTV emerged as the 
most potent ARV from Chapter 3. RNA extracted from adipocytes treated with control 
(RTV + DMSO), RTV + c9,t11 or RTV + t10,c12 were analysed to provide support for 
the RT-PCR data and to identify any additional genes and pathways which might be 
affected by the addition of CLA to RTV treated cells. On day 14, total RNA was 
extracted from adipocytes using the RNeasy Mini Kit as described in Section 2.1.10. 
RNA samples were prepared for microarray analysis using MessageAmp™ Premier 
RNA Amplification Kit as described in Section 2.1.14. RNA samples were pooled and 
500 ng of each pooled sample in 5 µl was used in the reactions. The concentration of the 
resulting RNA was determined using the NanoDrop
®
 spectrophotometer. Biotinylated 
aRNA was fragmented prior to hybridisation using the 5X Array Fragmentation Buffer 
supplied with the MessageAmp
™
 Kit. The sample was then evaluated using the 
Agilent
®
2100 Bioanalyser instrument and RNA 6000 Nano Kit loaded with 300 ng of 
aRNA per well. 11 μg  of aRNA were hybridised onto the Affymetrix Mouse Genome 
430 2.0 Array Kit (Affymetrix, UK) and were subsequently washed, stained and 
scanned on the Fluidics Station 400 and the GeneArray Scanner (Affymetrix, UK) 
according to the manufacturer’s protocol.  Data were analysed using the RMA 
algorithm and the average change in expression (ratio of treatment/ control) determined 
for each gene. Metacore
™
 pathway analysis software (GeneGo, Thomson Reuters) was 
used for functional analysis of differentially expressed genes and pathway analysis. 
 
4.4.7 Statistical analysis 
Statistical analyses were performed using SPSS software (version 20; IBM Corp). Data 
were analysed using one way analysis of variance (ANOVA), with post-hoc analysis 
using Dunnett’s test after demonstration of significant differences by ANOVA. 
Differences were considered significant if P ≤ 0.05. Data are expressed as the mean ± 
SEM of four independent observations unless otherwise stated. For microarray analysis, 
a 1.5-fold (signal log ratio ≥ 0.5 or ≤ -0.5) and 2-fold (signal log ratio ≥ 1.0 or ≤ -1.0) 
change relative to control was selected as the threshold to define differentially expressed 
genes in c9,t11 and t10,c12 treated cells, respectively.    
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4.5  Results 
 
4.5.1 Cell viability 
Adipocyte viability was assessed at day 14 using an MTS assay. Increasing 
concentrations of CLA isomers (25 μM, 50 μM and 100 μM) were tried and compared 
with vehicle control (DMSO). There was no significant difference in cell viability 
between any concentration of c9,t11 (Figure 4.1 A) or t10,c12 (Figure 4.1 B). As a 
result, it was decided that a concentration of 100 μM would be used for all experiments, 
as this concentration of c9,t11 and t10,c12 was used previously in 3T3-L1 adipocytes 
(Ahn et al., 2006). We then investigated cell viability in adipocytes treated with ARVs 
found to have significant effects in Chapter 3, RTV, IDV and TDF, and CLA isomers, 
and found no significant difference in cell viability between cells treated with control 
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Figure 4.1 Effect of ARVs and CLA on cell viability. Adipocytes were treated with (A) 
vehicle control (DMSO) or c9,t11 and (B) vehicle control (DMSO) or t10,c12. 100 μM 
c9,t11 or t10,c12 were then added to cells treated with near Cmax concentrations of (C) 
RTV, (D) IDV or (E) TDF and compared with ARV + vehicle control. An MTS assay 
was carried out at day 14 to determine cell viability, which was measured 
spectrophotometrically at 490 nm. Results represent mean ± SEM of 4 parallel cell 
culture experiments. P for ANOVA = 0.880, 0.966, 0.331, 0.389 and 0.133, 
respectively.  
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4.5.2 Triglyceride accumulation 
RTV was the only ARV to significantly alter TG accumulation in previous experiments 
(Section 3.5.2) and as a result, the effect of the two CLA isomers on TG accumulation 
was investigated in adipocytes exposed to RTV. Under RTV exposure, both c9,t11 and 
t10,c12 significantly increased TG accumulation compared to RTV-treated control cells 
(P < 0.001 for both; Figure 4.2). The effect of RTV and CLA isomers on TG 


















Figure 4.2 Effect of RTV and CLA on TG accumulation. Adipocytes were treated with 
control (RTV + DMSO) or near Cmax concentrations of RTV and 100 μM of c9,t11 or 
t10,c12. Adipocytes stained at day 14 with ORO to quantify lipid content, which was 
measured spectrophotometrically at 540 nm. Results represent mean ± SEM of 8 















































































Figure 4.3 Oil Red O stained adipocytes treated with RTV and CLA. Adipocytes were 
treated with control (RTV + DMSO) or near Cmax concentrations of RTV and 100 μM 
of c9,t11 or  t10,c12. Adipocytes were stained at day 14 with ORO to visualise lipid 
content. Black arrows indicate cells with lipid droplets and lipid vesicles (magnification 
is at 40x).  
  
RTV + DMSO 
RTV + c9,t11 






4.5.3 Lipid droplet protein transcription  
RTV was the only ARV which significantly altered perilipin expression in previous 
experiments (Section 3.5.3). The effect of CLA isomers on the expression of genes for 
lipid droplet-associated protein perilipin was then investigated in 3T3-L1 adipocytes 
exposed to RTV. Under RTV exposure, t10,c12 significantly decreased perilipin gene 
expression compared with control (P = 0.004; Figure 4.4). There was no significant 




Figure 4.4 Effect of RTV and CLA on perilipin transcription. Adipocytes were treated 
with control (RTV + DMSO) or near Cmax concentrations of RTV and 100 μM of each 
CLA isomer. Expression of perilipin mRNA was measured on day 14 relative to Hprt 
housekeeping gene by RT-PCR. Results represent mean ± SEM of 4 parallel cell culture 








































RTV, IDV and TDF were the only ARVs to significantly affect Cidea transcription in 
previous experiments (Section 3.5.3) and as a result the effect of CLA isomers on the 
expression of Cidea was tested in adipocytes treated with these three ARVs. CLA 
isomers had no significant effect on Cidea expression in RTV-treated cells (Figure 4.5 
A). In IDV- and TDF-treated cells, t10,c12 significantly decreased Cidea gene 
expression compared with control (P = 0.003 and P = 0.012, respectively; Figure 4.5 B 

























































































Figure 4.5 Effect of ARVs and CLA on Cidea transcription. Adipocytes were treated 
with control or near Cmax concentrations of (A) RTV, (B) IDV or (C) TDF and 100 μM 
of c9,t11 or t10,c12. Expression of Cidea mRNA was measured on day 14 relative to 
Hprt housekeeping gene by RT-PCR. Results represent mean ± SEM of 4 parallel cell 
culture experiments. *Significantly different (P = 0.003 and P = 0.012, respectively) 






































4.5.4 PPAR-γ gene expression and nuclear activation  
The effect of each CLA isomer on PPAR-γ gene expression was tested in RTV-treated 
cells, as RTV was the only ARV to significantly alter PPAR-γ gene expression in 
previous experiments (Section 3.5.4). Neither CLA isomer had a significant effect on 




Figure 4.6 Effect of RTV and CLA on PPAR-γ transcription. Adipocytes were treated 
with near Cmax concentrations of RTV and DMSO or RTV and 100 μM of c9,t11 or 
t10,c12. Expression of PPAR-γ mRNA was measured on day 14 relative to Hprt 




The effect of CLA isomers on nuclear PPAR-γ binding to the immobilised consensus 
site (PPRE) was investigated in adipocytes treated with RTV, IDV and TDF, the ARVs 
shown to significantly affect PPAR-γ nuclear binding in previous experiments (Section 
3.5.4). c9,t11 significantly increased nuclear PPAR-γ binding to the immobilised 
consensus site in both RTV- and TDF-treated cells (P = 0.038 and P = 0.043, 
respectively; Figure 4.7 A and C). t10,c12 significantly decreased nuclear PPAR-γ 
binding to the immobilised consensus site in IDV-treated cells (P = 0.001; Figure 4.7 

















































































































































Figure 4.7 Effect of ARVs and CLA on nuclear PPAR-γ binding to PPRE. Nuclear 
proteins were extracted on day 14 from adipocytes treated with control or near Cmax 
concentrations of (A) RTV, (B) IDV, or (C) TDF and 100 μM of c9,t11 or t10,c12 and 
nuclear PPAR-γ consensus site binding was measured. Results represent mean ± SEM 
of 4 parallel cell culture experiments. *Significantly different (P = 0.038, 0.001 and 




4.5.5 Adiponectin gene expression and secretion 
Although d4T significantly altered adiponectin gene expression in previous 
experiments, it was thought that outliers in the data were obscuring the effect of the 
other drugs. For this reason, we examined adiponectin expression in adipocytes treated 
with CLA isomers and RTV, IDV or TDF only. In RTV-treated cells, c9,t11 had no 
significant effect on adiponectin gene expression, while t10,c12 caused a significant 
reduction in adiponectin expression (P = 0.038; Figure 4.8 A). c9,t11 significantly 
increased adiponectin gene expression in IDV-treated cells (P = 0.005; Figure 4.8 B). 
t10,c12 significantly decreased adiponectin gene expression in TDF-treated cells (P < 





































































































































































Figure 4.8 Effect of ARVs and CLA on adiponectin transcription. Adipocytes were 
treated with control or near Cmax concentrations of (A) RTV, (B) IDV or (C) TDF and 
100 μM CLA isomers, c9,t11 or t10,c12. Expression of adiponectin mRNA was 
measured on day 14 relative to Hprt housekeeping gene by RT-PCR. Results represent 
mean ± SEM of 4 parallel cell culture experiments. *Significantly different (P = 0.038, 





































The effect of the CLA isomers on adiponectin secretion was investigated in adipocytes 
treated with RTV, IDV and TDF, which had significant effects on adiponectin in 
previous experiments (Section 3.5.5). Although c9,t11 did not have a significant effect 
on adiponectin secretion in RTV-treated cells, the t10,c12 isomer significantly 
decreased its secretion (P = 0.003; Figure 4.9 A). Similarly, in IDV-treated cells 
t10,c12 decreased adiponectin secretion (P < 0.001; Figure 4.9 B). In TDF-treated cells, 
both isomers significantly decreased adiponectin protein secretion in (P < 0.001, both; 






























































Figure 4.9 Effect of ARVs and CLA on adiponectin protein secretion. Adipocytes were 
treated with control or near Cmax concentrations of (A) RTV, (B) IDV or (C) TDF and 
100 μM CLA isomers, c9,t11 or t10,c12. Supernatants were collected from adipocytes 
on day 14 and used to quantify adiponectin secretion. Results represent mean ± SEM of 
4 parallel cell culture experiments. *Significantly different (P = 0.003, < 0.001 and < 


































































4.5.6 Leptin, resistin and IL-6 transcription  
The effect of CLA isomers on adipokine expression was investigated in adipocytes 
treated with IDV and TDF, both of which had a significant effect on adipokine 
expression in previous experiments (Section 3.5.6). c9,t11 significantly increased leptin 
expression in IDV- and TDF-treated adipocytes (P = 0.003 and P = 0.016; Figure 4.10).  

















































Figure 4.10 Effect of ARVs and CLA on leptin transcription. Adipocytes were treated 
with control, near Cmax concentrations of (A) IDV or (B) TDF and 100 μM CLA 
isomers, c9,t11 or t10,c12. Expression of leptin mRNA was measured on day 14 relative 
to Hprt housekeeping gene by RT-PCR. Results represent mean ± SEM of 4 parallel cell 
culture experiments. *Significantly different (P = 0.003 and P = 0.016, respectively) 









































The effect of CLA isomers on resistin gene expression was investigated in adipocytes 
treated with TDF, the ARV which had a significant effect on resistin expression in 
previous experiments (Section 3.5.6). The addition of c9,t11 had no significant effect 
on resistin expression in adipocytes treated with TDF, while t10,c12 significantly 





Figure 4.11 Effect of TDF and CLA on resistin transcription. Adipocytes were treated 
with control, near Cmax concentrations of TDF or 100 μM CLA isomers, c9,t11 or 
t10,c12. Expression of resistin mRNA was measured on day 14 relative to Hprt 
housekeeping gene by RT-PCR. Results represent mean ± SEM of 4 parallel cell culture 




The effects of the two CLA isomers on IL-6 gene expression was investigated in 
adipocytes treated with IDV and TDF, the two ARV which significantly increased IL-6 
expression in previous experiments (Section 3.5.6). c9,t11 had no significant effect, but 
t10,c12 significantly increased IL-6 expression in adipocytes treated with both IDV- 














































Figure 4.12 Effect of ARVs and CLA on IL-6 transcription. Adipocytes were treated 
with control, near Cmax concentrations of (A) IDV or (B) TDF and 100 μM CLA 
isomers, c9,t11 or t10,c12. IL-6 gene expression was measured on day 14 relative to 
Hprt housekeeping gene by RT-PCR. Results represent mean ± SEM of 4 parallel cell 
culture experiments. *Significantly different (P = 0.001 and < 0.001, respectively) from 













































































4.5.7 Global gene expression  
 
4.5.7.1 RTV and c9,t11 
Using a threshold cut-off of 2-fold change (signal log ratio ≥ 1.0 or ≤ -1.0), only 
identified 3 differentially expressed genes (phospholipid scramblase 2, SRY-box 
containing gene 4, cDNA sequence AY036118), while detection signals for the majority 
of genes were close to background. Therefore, a 1.5-fold change relative to control 
(signal log ratio ≥ 0.5 or ≤ -0.5), was selected as a threshold to define differentially 
expressed genes for RTV + c9,t11 treated cells. Treatment with c9,t11 up-regulated 111 
genes, while 146 genes were down-regulated compared with control. In relation to RT-
PCR data, no changes ≥ 1.5-fold were observed for PPAR-γ, perilipin, Cidea, 
adiponectin, leptin, resistin or IL-6 compared with control. Altered gene lists were then 
analysed using MetaCore
™
 software (GeneGo, Thomson Reuters), which generated a 
list of top canonical pathway maps representing a set of signalling and metabolic maps 
of genes affected by RTV + c9,t11. The top 10 pathways affected by c9,t11 are listed in 
Table 4.1. No pathways were significantly altered by RTV + c9,t11. ‘Regulation of 
lipid metabolism by niacin and isoprenaline’ was the top pathway affected by RTV + 
c9,t11 in which 3 of 45 genes were altered (P = 0.129; FDR 0.906). Figure 4.13 
illustrates the map for this pathway. The genes up- or down-regulated within this 




Table 4.1 Top 10 canonical pathways affected by RTV and c9,t11 
 Pathway  P value False Discovery 
Rate 
Ratio* 
1 Regulation of lipid metabolism by 
niacin and isoprenaline 
0.13 0.91 3/45 
2 Apoptosis and survival: DNA-damage-
induced apoptosis 
0.18 0.91 2/15 
3 Beta-adrenergic-dependent CFTR 
expression 
0.26 0.91 2/18 
4 O-glycan biosynthesis 0.29 0.91 3/60 
5 O-glycan biosynthesis / Human version 0.32 0.91 3/62 
6 Neurophysiological process: 
Constitutive and regulated NMDA 
receptor trafficking 
0.33 0.91 3/63 
7 Cell cycle: Initiation of mitosis 0.14 0.91 2/25 
8 Apoptosis and survival: Apoptotic 
Activin A signaling 
0.14 0.91 2/25 
9 DNA damage: ATM / ATR regulation 
of G2 / M checkpoint 
0.15 0.91 2/26 
10 Transcription: Role of Akt in hypoxia 
induced HIF1 activation 
0.16 0.91 2/27 
P value is based on the number of interactions of the gene in the pathway. FDR is 
calculated taking into account the P value for each map and the rank of the map, given 
the total number of maps in the whole Pathway Maps ontology. * Ratio of genes altered 







Figure 4.13 Regulation of lipid metabolism by niacin and isoprenaline (GeneGo, 2014). 
Histograms located next to each gene indicate the direction (blue = down-regulated; red 
= up-regulated) and the degree of change in expression of each gene. Full figure legend 




Table 4.2 Genes altered by RTV and c9,t11 
Regulation of lipid metabolism by niacin and isoprenaline 
Gene name Symbol Description Fold change* 
Up-regulated    





Gpr109a Nicotinic acid receptor. 
Mediates increased adiponectin 
secretion and decreased lipolysis 
1.52 
Beta 3 adrenergic 
receptor 
Adrb3 Regulates lipolysis and 
thermogenesis 
1.5 




4.5.7.2 RTV and t10,c12 
Using a threshold cut-off of 2-fold change (signal log ratio ≥ 1.0 or ≤ -1.0) identified 
425 differentially expressed genes in RTV + t10,c12 treated cells. Treatment with 
t10,c12 up-regulated 165 genes, while 260 genes were down-regulated compared with 
control. In relation to RT-PCR data, adiponectin was down-regulated almost 3-fold and 
resistin down-regulated 8-fold compared with control. No change ≥ 2-fold was observed 
for the other genes of interest, PPAR-γ, perilipin, Cidea, leptin or IL-6. Altered gene 
lists were then analysed using MetaCore
™
 software (GeneGo, Thomson Reuters), which 
generated a list of top canonical pathway maps representing a set of signalling and 
metabolic maps of genes affected by RTV + t10,c12.  
 
The top 10 pathways affected by t10,c12 are listed in Table 4.3. The top pathway with 
10 of 52 genes altered by RTV + t10,c12 was the ‘Cell adhesion: extracellular matrix 
(ECM) remodelling’ pathway (P < 0.001; FDR = 0.008). Immune response and 
cholesterol biosynthesis pathways were also significantly affected. Relevant adipose 
tissue genes altered within the ECM remodelling and immune response pathways are 
presented in Table 4.4. Although 10 genes within the cholesterol biosynthesis pathway 
were altered, only two were adipose tissue genes, and as their function is not well 
characterised, they have not been presented here. Relevant adipocyte-specific pathways 
included the ‘Insulin, IGF-1 and TNF-α in brown adipocyte differentiation’ pathway in 
which 8 of 53 genes were altered (Figure 4.14; P = 0.01; FDR = 0.16) and the 
‘Adiponectin in the pathogenesis of type 2 diabetes’ pathway in which 5 of 29 genes 
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were altered (Figure 4.15; P = 0.03; FDR = 0.36). The genes up- or down-regulated 
within these pathways are listed in more detail in Table 4.4.  
 
 
Table 4.3 Top 10 canonical pathways affected by RTV and t10,c12 
 Pathway  P value False Discovery 
Rate 
Ratio* 
1 Cell adhesion: ECM remodelling < 0.001 0.008 10/52 
2 Development: Insulin, IGF-1 and 
TNF-α in brown adipocyte 
differentiation 
0.01 0.16 8/53 
3 Immune response: Alternative 
complement pathway 
0.01 0.16 7/39 
4 Cholesterol biosynthesis 0.01 0.09 10/103 
5 Immune response: Lectin induced 
complement pathway 
0.02 0.12 7/49 
6 Expression targets of Tissue factor 
signalling in cancer 
0.03 0.13 5/22 
7 Immune response: Classical 
complement pathway 
0.03 0.13 7/52 
8 Development: Beta adrenergic 
receptors in brown adipocyte 
differentiation 
0.03 0.14 6/37 
9 Cell adhesion: Chemokines and 
adhesion 
0.05 0.21 9/100 
10 Adiponectin in pathogenesis of type 
2 diabetes 
0.03 0.36 5/29 
P value is based on the number of interactions of the gene in the pathway. FDR is 
calculated taking into account the P value for each map and the rank of the map, given 
the total number of maps in the whole Pathway Maps ontology. * Ratio of genes altered 










Figure 4.14 Insulin, IGF-1 and TNF-α in brown adipocyte differentiation  (GeneGo, 
2014). Histograms located next to each gene indicate the direction (blue = down-
regulated; red = up-regulated) and the degree of change in expression of each gene. Full 





Figure 4.15 Adiponectin in the pathogenesis of type 2 diabetes (GeneGo, 2014). 
Histograms located next to each gene indicate the direction (blue = down-regulated; red 
= up-regulated) and the degree of change in expression of each gene. Full figure legend 
can be found in Appendix 1.    
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Table 4.4 Pathways and genes altered by RTV and t10,c12 
Pathway 1: Cell adhesion: ECM remodelling  
Gene name Symbol Description Fold change* 
Down-regulated    
Insulin-like growth 
factor 1 
Igf1 Involved in adipocyte 
differentiation and glucose 
metabolism 
2.22 
Up-regulated     
Plasminogen activator 
inhibitor-1 
Pai1 Inhibits fibrinolysis 5.74 
Metalloproteinase 
inhibitor 1, 2 and 3 
Timp1, 2 
and 3 





Plat Involved in tissue 
remodelling and degradation  
2.63 
Glia derived nexin Serpine2 Inhibits thrombin. Binds 
heparin 
2.55 





activator surface receptor 




activator surface receptor 
Hbegf Growth factor   2.06 
Pathway 2: Insulin, IGF-1 and TNF-α in brown adipocyte differentiation 
Gene name Symbol Description Fold change* 
Down-regulated    
Adipsin Cfd Stimulates glucose transport 
for TG accumulation in 
adipocytes and inhibits 
lipolysis 
11.21 
Beta 3 adrenergic 
receptor 
Adrb3 Regulates lipolysis and 
thermogenesis 
6.36 
Acyl CoA desaturase Scd Catalyses synthesis of 
unsaturated fatty acids 
4.34 
Glucose transporter type 
4 
Glut4 Insulin-dependent glucose 
transporter induced by 
PPARγ 
3.67 
Adiponectin Adipoq Adipokine involved in fat 





    
Gene name Symbol Description Fold change* 
Insulin-like growth 
factor 1 
Igf1 Involved in adipocyte 
differentiation and glucose 
metabolism 
2.22 
Hormone sensitive lipase Lips Hydrolyses stored TG 2.1 
Fatty acid synthase Fasn Catalyses fatty acid synthesis 2.1 
Pathways 3, 5, 7: Immune response: complement pathways 
Gene name Symbol Description Fold change* 
Down-regulated    
Adipsin Cfd Stimulates glucose transport 
for TG accumulation and 
inhibits lipolysis. 
11.21 
Complement C3 C3 Activates complement 
system 
3.14 




C1qrp Receptor for complement 
component 1q 
3.47 
Pathway 10: Adiponectin in the pathogenesis of type 2 diabetes 
Gene name Symbol Description Fold change* 
Down-regulated    
Stearoyl CoA 
desaturase 
Scd Involved in fatty acid 
biosynthesis, primarily oleic 
acid. 
4.34 
Adiponectin Adipoq Adipokine involved in fat 





Pepck Gluconeogenic enzyme 2.9 
Fatty acid synthase Fasn Catalyses fatty acid 
synthesis 
2.1 
Up-regulated    
Carnitine O 
palmitoyltransferase-1 
Cpt1a Catalyses transfer of acyl 
group of long-chain fatty 
acyl-CoA 
2.19 






For the first time, data presented here demonstrate significant effects of the two main 
CLA isomers on adipocyte function, differentiation and inflammation in adipocytes 
treated with ARVs. We have shown effects for CLA isomers on TG accumulation, 
lipid-droplet protein mRNA expression, PPAR-γ nuclear binding, adiponectin mRNA 
expression and protein secretion, and mRNA expression of IL-6, leptin and resistin.  
Microarray data identified additional genes and pathways including differentiation, lipid 
metabolism and immune response pathways, which were altered by RTV + CLA and 
may be targets for future research.  
 
4.6.1 Effect of CLA isomers on TG accumulation  
We have shown that the addition of both c9,t11 and t10,c12 to adipocytes cultured in 
the presence of RTV resulted in significant increases in TG accumulation compared 
with control. Oil Red O stained images show altered TG distribution and reduced lipid 
droplet size in t10,c12-treated adipocytes. Similar to our results, c9,t11 has previously 
been shown to increase the quantity and size of mature 3T3-L1 adipocytes as 
determined by ORO staining (Sakuma et al., 2010). The increase in TG accumulation 
observed in the presence of t10,c12 in our study contrasts with previous studies in non-
RTV-treated cells where t10,c12 has been shown to decrease TG accumulation (Brown 
et al 2001, Evans 2001, Granlund et al 2003, Miller et al 2008). However, in another 
study, a mixture of the two main CLA isomers promoted lipid filling in 3T3-L1 
preadipocytes (Satory and Smith, 1999). The presence of RTV in our model may have 
reversed the normal adipocyte response to t10,c12. A study in porcine peripheral blood 
mononuclear cells has shown that a combination of LPS and t10,c12 reverses the effects 
of the CLA isomer on NF-κB activity and TNF-α expression (Kim et al., 2011). This 
suggests that t10,c12 may act differently depending on prevalent conditions.  
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4.6.2 Effect of CLA isomers on lipid droplet-associated proteins 
Lipid droplet-associated proteins perilipin and Cidea act as a barrier, protecting TG 
stored within the lipid droplet from the lipolytic action of cellular lipases (Puri et al., 
2008). An analysis of lipid droplet-associated proteins was undertaken in an attempt to 
investigate their role in the observed effects on TG accumulation. t10,c12 significantly 
decreased perilipin gene expression. Two studies have shown similar effects for 
t10,c12, but in non-RTV-treated cells only (Brown et al., 2003, Kennedy et al., 2008). 
Overall, previous studies investigating the effect of t10,c12 on perilipin in non-RTV-
treated cells are inconsistent. In 3T3-L1 adipocytes, treatment for 8 days with 75 μM 
t10,c12 increased perilipin expression 6-fold (Zhai et al., 2010). Another study in 
stromal vascular human adipocytes treated with 30 μM t10,c12 showed that perilipin 
protein signals increased in the first 12 h, decreased at day 4 and the protein signal 
could not be detected at day 8 (Chung et al., 2005). These conflicting results mirror 
those from studies in mice where feeding 0.5% w/w CLA has been shown to increase 
perilipin expression (Ippagunta et al., 2011), while others showed inhibition of perilipin 
expression with 1% (House et al., 2005) and 1.5% mixed CLA isomer supplementation 
(Cai et al., 2012).   
 
t10,c12 also significantly reduced Cidea gene expression in IDV- and TDF-treated cells 
in the present study. In contrast, another study showed that 0.06% w/w CLA isomer mix 
significantly increased Cidea mRNA expression in mice, albeit not treated with ARVs 
(Shen et al., 2013). Our findings for lipid droplet proteins do not corroborate those of 
TG accumulation and mean that an alternative mechanism underlies the increased TG 
accumulation in response to the CLA.  
 
4.6.3 Effect of CLA isomers on PPAR-γ 
PPAR-γ plays a crucial role in regulating adipogenesis and lipid metabolism in mature 
adipocytes (Desvergne and Wahli, 1999). Binding of lipophilic ligands to PPAR-γ leads 
to the transcription of adipocyte genes including perilipin (Dalen et al., 2004), Cidea 
(Puri et al., 2008) and adiponectin (Iwaki et al., 2003). In the current study, we 
investigated the effects of CLA isomers on PPAR-γ expression in cells treated with 
RTV, the only ARV to significantly affect PPAR-γ expression in previous experiments. 
c9,t11 increased PPAR-γ gene expression by 70%, although this did not reach statistical 
significance. Previous studies have shown an increase in PPAR-γ gene expression in the 
presence of c9,t11 in non-ARV-treated adipocytes (Belury et al., 2002, Brown et al., 
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2003, Sakuma et al., 2010). t10,c12 did not significantly affect PPAR-γ gene expression 
in RTV-treated adipocytes. Similarly, a recent study in non-RTV treated adipocytes 
found no effect of DHA (natural PPAR-γ agonist) on PPAR-γ expression even though 
PPAR-γ target genes were reduced (Barber et al., 2013). In contrast to our findings and 
those of Barber et al,  the t10,c12 isomer has previously been shown to decrease PPAR-
γ expression in non-RTV-treated adipocytes (Granlund et al., 2003).  
 
PPAR-γ nuclear binding to the PPRE was significantly increased by c9,t11 in RTV- and 
TDF-treated adipocytes, while t10,c12 significantly decreased PPAR-γ binding in IDV-
treated adipocytes. A recent study in non-ARV-treated human umbilical vein 
endothelial cells found that t10,c12 at concentrations of 5, 10 and 25 μM significantly 
increased PPAR-γ DNA binding activity compared with control, but 100 μM t10,c12 
had no effect (Nakamura and Omaye, 2009). In contrast, the t10,c12 isomer has 
previously been shown to decrease PPAR-γ mass (Miller et al., 2008), activation and 
protein levels (Poirier et al., 2006, Kennedy et al., 2008) in non-RTV-treated cells. At 
present, it appears unlikely that the increase in TG accumulation associated with t10,c12 
in this study is mediated via PPAR-γ or lipid droplet proteins. In order to clarify this, an 
investigation of PPAR-γ target gene expression was required.  
 
4.6.4 Effect of CLA isomers on adiponectin 
Adiponectin is an insulin-sensitising adipokine induced during adipocyte differentiation 
(Scherer et al., 1995). PPAR-γ has been suggested to play a role in the transcriptional 
activation of adiponectin gene via a PPRE in the adiponectin promoter (Iwaki et al., 
2003). In the present study, c9,t11 significantly increased adiponectin expression in 
IDV-treated cells, while t10,c12 significantly decreased its expression in RTV and 
TDF-treated adipocytes. A similar pattern was observed for t10,c12 in RTV- and TDF-
treated cells for PPAR-γ nuclear binding, although this did not reach significance.  
 
We subsequently investigated adiponectin secretion and found that t10,c12 significantly 
decreased secretion in the presence of all three ARVs. This supports RT-PCR data for 
the effect of t10,c12 in RTV- and TDF-treated cells, as well as the trend observed for 
PPAR-γ. Significant decreases in cellular and secreted adiponectin levels in response to 
t10,c12 have previously been shown in 3T3-L1 adipocytes in the absence of ARVs 
(Miller et al., 2008). Studies in mice have shown reduced adiponectin levels in response 
to t10,c12 treatment (Poirier et al., 2006, Miller et al., 2008). Our findings for t10,c12 
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are in agreement with some of those observed for PPAR-γ gene expression and PPRE 
binding, but also mean that the mechanism underlying the effects of t10,c12 on TG 
accumulation remains to be determined.   
 
4.6.5 Effect of CLA isomers on leptin 
Leptin is secreted by adipocytes in proportion to their TG stores and is thought to play a 
role in the regulation of energy intake and expenditure (Mantzoros, 2012). Leptin levels 
have been shown to be significantly reduced in HALS and are associated with insulin 
resistance and LA (Arama et al., 2013). In this study, c9,t11 significantly increased 
leptin gene expression in adipocytes treated with IDV and TDF, which corresponds with 
findings for TG accumulation and may explain the beneficial effect of c9,t11. Results 
from previous studies in non-ARV treated adipocytes are conflicting: some show that 
t10,c12 reduces leptin secretion in adipocytes (Kang and Pariza, 2001, Ahn et al., 2006) 
and serum leptin concentrations in mice (Poirier et al., 2006), while another study found 
no effect of either 75 μM c9,t11 or t10,c12 on leptin mRNA expression (Zhai et al., 
2010).  
 
4.6.6 Effect of CLA isomers on resistin 
In our study, t10,c12 significantly decreased resistin expression in adipocytes treated 
with TDF, thus ameliorating the increase in resistin expression observed in TDF-treated 
cells in the previous experiments (Section 3.5.6). Similarly, Forti and Birk (2007) 
demonstrated reduced resistin expression in 3T3-F442A adipocytes treated with 100 μM 
CLA only; the authors do not specify which isomers were used. Resistin is an adipokine 
originally thought to be the link between IR and obesity (Steppan et al., 2001). Resistin 
expression has been shown to be regulated by PPAR-γ in 3T3-L1 adipocytes (Song et 
al., 2002), where over-expression of the transcription factor markedly decreases resistin 
expression. Some studies in mice fed 1.5% mixed CLA isomers have shown reduced 
resistin mRNA expression (Hernández-Díaz et al., 2010). Contrary to this, Noto et al 
(2006) showed greater resistin mRNA expression in fa/fa rats fed 1.5% mixed CLA 
isomers. In the context of HIV, questions exist regarding the exact role of resistin in 
HALS: some studies have established a link between genetic variations in resistin and 
metabolic complications of HAART, including IR and LD (Ranade et al., 2008, Escote 
et al., 2011) , while other studies failed to find any associations (Barb et al., 2005, 




4.6.7 Effect of CLA isomers on IL-6 
IL-6 has been suggested to play a role in IR by blocking insulin signalling in adipocytes 
(Lagathu et al., 2005). Increased IL-6 has been demonstrated in SCAT from patients 
with HALS (Kannisto et al., 2003) and may mediate IR in these patients. Our results 
show that t10,c12 significantly increases IL-6 expression in adipocytes treated with IDV 
and TDF, the two ARVs which significantly increased its expression in previous 
experiments (Section 3.5.6). In the absence of ARVs, t10,c12 has previously been 
shown to increase IL-6 expression in adipocytes (Ahn et al., 2006, Poirier et al., 2006). 
In contrast, c9,t11 had no effect on IL-6 expression (Ahn et al., 2006). The t10,c12-
induced increase in IL-6 observed in IDV-treated cells could be suggested to contribute 
to the decrease in PPAR-γ binding to consensus site and adiponectin secretion observed 
in IDV-treated cells. Lagathu et al (2004) previously demonstrated that treatment of 
3T3-F442A and 3T3-L1 adipocytes with IL-6 decreases PPAR-γ mRNA. Furthermore, 
PPAR-γ agonist rosiglitazone has been shown to decrease IL-6 (Lagathu et al., 2003). It 
could also be suggested that in the presence of decreased levels of PPAR-γ, IL-6 
expression was no longer inhibited, leading to the expression levels we observe in IDV-
treated adipocytes.   
 
 
4.6.8 Global gene expression  
Microarray analysis was carried out on RNA samples from adipocytes treated with a 
combination of RTV and either c9,t11 or t10,c12 to corroborate RT-PCR data and to 
identify other genes and pathways altered by RTV and CLA. 
 
4.6.8.1 RTV and c9,t11 
Microarray analysis of RNA samples from RTV and c9,t11 treated cells did not identify 
any changes greater than 1.5 fold in our genes of interest investigated previously using 
RT-PCR (PPAR-γ, perilipin, Cidea, adiponectin, leptin, resistin, IL-6). Further analysis 
using MetaCore
™
 software (GeneGo, Thomson Reuters) identified ‘Regulation of lipid 
metabolism by niacin and isoprenaline’ as the top pathway altered by RTV and c9,t11, 
although not significantly. Isoprenaline is a β1- and β2-adrenoreceptor agonist and both 
niacin and isoprenaline bind to G-protein coupled receptor 109A (GPR109A) and affect 
LDL signalling. Microarray analysis revealed that GPR109A and beta 3 adrenergic 
receptor (ADRB3) were both up-regulated compared with control.  
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GPR109A is a niacin receptor, which is regulated by PPAR-γ and inhibits lipolysis by 
reducing cyclic AMP levels (Jeninga et al., 2009). In a previous study, acipimox, a 
niacin derivative and GPR109 agonist, was found to attenuate RTV-induced lipolysis in 
LDL receptor null mice (Guo 2009). In this study, c9,t11 appears to be acting in a 
similar way to niacin and niacin derivatives. Niacin has shown positive results in 
mitigating dyslipidaemia in patients with HALS (Dube 2006), which may occur via 
modulation of GPR109A expression.  
 
Microarray analysis from Chapter 3 revealed up-regulated ADRB3 expression in RTV-
treated cells. Therefore, the addition of c9,t11 had no additional effect on the expression 
of the receptor and implies that RTV has potent lipolytic effects which are not easily 
attenuated by c9,t11. Overall, data show the potential for c9,t11 to attenuate the lipolytic 
effect of  RTV via up-regulation of GPR109A. However, it appears to have little effect 
on lipolysis mediated via up-regulation of the ADRB3.   
   
4.6.8.2 RTV and t10,c12  
Adiponectin was the only gene of interest investigated using RT-PCR which was also 
altered in microarray analysis by RTV and t10,c12 (3-fold down-regulation). The entire 
altered gene list was analysed using MetaCore
™
 software (GeneGo, Thomson Reuters) 
and a list of top 10 pathways affected by RTV and t10,c12 was generated. Similar to 
results from Chapter 3, a number of genes within the ‘Insulin, IGF-1 and TNF-α in 
brown adipocyte differentiation’ pathway were down-regulated compared with control, 
indicating that the addition of t10,c12 to RTV treated cells had no additional effect on 
genes expressed within this pathway.  
 
The addition of t10,c12 to RTV treated cells altered genes within the ‘Cell adhesion: 
ECM remodelling pathway’, which were not previously affected by RTV alone. IGF-1 
was the only gene down-regulated within this pathway and plays an important role in 
adipogenesis (Herrmann 2009). IGF-1 has previously been shown to be down-regulated 
in SCAT biopsy samples after t10,c12 supplementation (Herrmann et al., 2009). This 
suggests that t10,c12 might impair adipogenesis in RTV-treated cells. However, we 
observed an increase in TG in t10,c12 treated cells, which is therefore unlikely to 
involve IGF-1 expression. Plasminogen activator inhibitor-1 (PAI-1) was the top gene 
up-regulated within the ECM remodelling pathway. In addition to its role in ECM 
remodelling, PAI-1 is increasingly being investigated in relation to obesity-associated 
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diseases. In the context of HIV and HAART, PAI-1 was found to be reduced in RTV 
treated adipocytes (Mondal et al., 2001), but increased in plasma of patients with HALS 
(He et al., 2005). A PPRE has been identified in the PAI-1 gene promoter and PPAR-γ 
agonist pioglitazone has been shown to increase PAI-1 expression (Mondal et al., 2001). 
Although t10,c12 decreased PPAR-γ in this study, it increased PAI-1 expression similar 
to PPAR-γ agonists. t10,c12 has previously been shown to decrease PAI-1 expression in 
obese rats (Martins et al., 2010). Further studies using a PPAR-γ inhibitor are needed to 
investigate whether t10,c12 is mediating its effects on PAI-1 via a PPAR-γ independent 
mechanism.  
 
The addition of t10,c12 to RTV treated cells altered gene expression in complement 
pathways involved in the immune response. Complement factor D/ adipsin (Cfd) is 
involved in the initial rate-limiting step of complement activation and is highly 
expressed in adipose tissue (White et al., 1992). CFD was down-regulated in our study. 
A similar finding was observed in mammary tissue of lactating mice treated with 
t10,c12 only (Kadegowda et al., 2013). Complement C3 (C3) was also down-regulated 
by RTV and t10,c12. Acylation stimulating protein (ASP) is a C3 cleavage protein and 
has been shown to stimulate TG storage (Paglialunga et al., 2010). Kotler et al (2003) 
found significantly lower ASP in patients with HALS compared with those without 
HALS and healthy controls. t10,c12 decreased both CFD and C3, and as such these two 
genes are unlikely to be responsible for the increase in TG storage observed in t10,c12 
treated cells. However, t10,c12 may enhance the negative effects of RTV on C3, thus 
affecting adipogenesis. Complement component C1q receptor (C1qR) was the only 
component up-regulated by RTV and t10,c12. C1qR is an essential protein involved in 
adipogenesis and insulin signalling (Kim et al., 2009). Therefore, it could be suggested 
that t10,c12 may mediate some of its effects on adipogenesis via up-regulation of C1qR.  
 
The addition of t10,c12 to RTV treated cells altered gene expression in the ‘Adiponectin 
in the pathogenesis of type 2 diabetes’ pathway. Stearoyl CoA desaturase (SCD), 
adiponectin, phosphoenolpyruvate carboxykinase (PEPCK) and FASN were all down-
regulated by RTV and t10,c12. Microarray data support data from RT-PCR, which also 
showed down-regulation of adiponectin in response to RTV and t10,c12.  
 
SCD plays an important role in de novo lipogenesis and its inhibition has been shown to 
reduce TG content in 3T3-L1 adipocytes, which is associated with down-regulation of 
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genes involved in TG synthesis such as glucokinase, PEPCK and PPARGC1 (Ralston et 
al., 2014). Down-regulation of PEPCK by t10,c12 in our study may, therefore, be 
explained by SCD inhibition. Although inhibition of SCD reduces adipocyte TG 
content, we observed an increase in TG accumulation in t10,c12 treated cells in this 
study, which implies that the effect of t10,c12 on TG accumulation cannot be explained 
by an alteration in SCD expression. FASN was down-regulated in previous experiments 
in Chapter 3 by RTV and suggests that t10,c12 has no additional effect on FASN 
expression in RTV treated cells. Lastly, CPT1 was the only gene up-regulated in this 
pathway in response to RTV + t10,c12. CPT1 plays an important role in β-oxidation of 
fatty acids and in reducing inflammation and FFA-induced IR (Gao et al., 2011). By up-
regulating CPT1, t10,c12 may be said to change adipocytes from cells that store TG to 
fatty acid oxidising cells. However, it also implies that the t10,c12-induced increase in 
TG accumulation in this study was not mediated via CPT1 expression and involves an 
alternative mechanism.   
 
4.6.9 Limitations and conclusion 
Limitations of our study include the fact that no combinations of ARVs were tried. 
Similarly, CLA isomers were also investigated separately, even though other studies 
have used mixed isomers and supplements for human consumption exist mainly in 
mixed form. In this study CLA isomers were dissolved in DMSO, rather than 
conjugated to bovine serum albumin, as is the normal physiological state. This may 
have had an effect on the bioavailability of the fatty acids. However, this study is novel 
and is the first to investigate the effects of CLA isomers in a model of ARV induced-
adipocyte dysfunction. Overall, our results demonstrate that CLA isomers have 
differential effects on a number of markers of adipocyte function and differentiation. 
Microarray analysis identified a number of genes and pathways altered in response to 
RTV and CLA. Both isomers affected lipid metabolism genes and t10,c12 also affected 
genes involved in complement pathways. t10,c12 appears to exacerbate the effects of 
ARVs by down-regulating perilipin, PPAR-γ gene expression and adiponectin 
expression and protein secretion. In contrast, c9,t11 proved beneficial in increasing TG 
accumulation and nuclear activation of PPAR-γ. Although the mechanisms underlying 
the effects of t10,c12 induced TG accumulation remain elusive, c9,t11 may potentially 
mediate its effects through PPAR-γ and may, therefore, be a therapeutic option in 




















Chapter 5  
 
The prevalence of lipodystrophy and factors associated with it in a 
London-based HIV population: data from The CREATE Study  
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5.1 Introduction  
The use of HAART is associated with numerous toxicities including adipose tissue 
disturbances, which manifest as morphological and metabolic abnormalities collectively 
referred to as HALS (Carr et al., 1998a). While major advances have been made in 
elucidating the molecular mechanisms underlying HALS, a clear clinical definition for 
the syndrome has yet to be established. The body composition abnormalities associated 
with HALS are the most stigmatising and may affect quality of life and medication 
adherence (Shenoy et al., 2013). Additionally, metabolic abnormalities including 
dyslipidaemia, IR and inflammation, increase the risk of premature CVD (Galescu et al., 
2013).  
 
Due to different definitions and assessment criteria there is a wide variation in the 
reported prevalence of HALS. Subjective methods, such as patient self-reports and 
physician reports typically report prevalence figures ranging from 17% - 64%, while 
estimates based on objective measurement using DEXA, CT or MRI range from 10% - 
83% (Loonam and Mullen, 2012). Determining its prevalence is further complicated by 
the fact that the terms LD and HALS are used interchangeably to define both the 
metabolic and morphological abnormalities associated with HIV and HAART. The 
distinction between LD, MetS and HALS is illustrated in Figure 5.1. HALS, defined as 
coexistence of morphological and metabolic abnormalities, has been identified by a 
number of groups and may have a plausible biological mechanism related to lipotoxicity 
and FFA uptake in VAT and non-adipose tissues (Caron-Debarle et al., 2010b). Despite 
this, researchers have recently begun to question the existence of HALS, suggesting the 
term “HALS” should be abandoned (Guaraldi and Baraboutis, 2009).  
 
As far as could be ascertained, only one study has previously reported the prevalence of 
LD (defined as abnormalities of body composition only) in a UK HIV population. The 
Cardiovascular Risk Evaluation and Antiretroviral Therapy Effects (CREATE) Study 
was a cross-sectional study of HIV outpatients attending clinics in London and the 
surrounding area. The aim of The CREATE Study was to identify cardiovascular risk 
using the Framingham risk score. The prevalence of MetS in this study was 14% using 
NCEP criteria and 10% using IDF criteria. Median CVD risk was 4% among men and 
1.4% among women as assessed using the Framingham (1991) algorithm (Aboud et al., 
2010). Further analysis was conducted on a subset of the same data to determine 
prevalence of the MetS and factors associated with it (Elgalib et al., 2011). Elgalib et al 
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found that LD was associated with MetS defined using NCEP criteria and was prevalent 
in 24% of patients. As the focus of The CREATE Study was MetS and CV risk, the 
original researchers did not investigate the prevalence of LD in the entire cohort or the 
factors associated with it. Furthermore, the existence and prevalence of HALS 
















To investigate the prevalence of LD, MetS and HALS in a UK-based HIV outpatient 
population using data from The CREATE Study.  
 
5.3 Objectives  
1. Determine the prevalence of LD, characteristics of patients with LD and the factors 
associated with developing LD. 
2. Determine the prevalence of the MetS and the factors associated with it. 
3. Investigate whether HALS, i.e. coexistence of LD and metabolic abnormalities 
associated with HIV / HAART, exists in this population and if so, determine the 





5.4 Methods     
 
5.4.1 The CREATE Study population and design  
The CREATE Study was a cross-sectional study recruiting from among all consecutive 
HIV-infected individuals attending as outpatients a large inner London hospital (n = 
2500) and a medium sized district hospital in the greater London area. Recruitment was 
carried out from June 2005 to September 2006 by trained research nurses and doctors. 
The main data on CV risk and MetS from the study has previously been published in 
two papers by Aboud et al (2010) and Elgalib et al (2011). Data were collected on 
demography, HIV disease and treatment history, current CD4 cell count and HIV viral 
load, as well as information on comorbidities including coinfection with hepatitis. 
Trained, experienced research nurses and doctors collected anthropometric data 
including weight, height, and waist and hip circumference according to standard 
protocol. LD was defined as any self- or doctor-reported change in body fat distribution 
in any region (LA or LH). MetS was defined using either NCEP or IDF criteria. HALS 
was defined as the presence of LD plus any other metabolic abnormality (TG ≥ 1.7 
mmol/L, HDL-C < 1.03 mmol/L for male or 1.29 mmol/L for female, SBP ≥ 130 mm 
Hg, FG ≥ 5.6 mmol/L).  
 
5.4.2 Statistical analysis 
For the present study, statistical analyses using CREATE data were performed with 
SPSS (version 20, IBM Corp). Chi-squared tests for categorical variables or 
Independent Samples t-tests for continuous variables were used to determine differences 
between those with and without LD. Factors thought to be associated with LD, MetS 
and HALS were identified a priori based on previous studies and were entered into a 
multivariable binary logistic regression model. The model for LD contained the 
following variables: age, gender, ethnicity, CD4 count, viral load, years with HIV, first 
line therapy, years on HAART, TG, TC, HDL-C, FG, SBP and WC. The MetS model 
contained the following: age, gender, ethnicity, CD4 count, HIV viral load, duration of 
HIV infection, use of first line regimen, duration of current regimen and BMI. The 
model for HALS contained age, gender, ethnicity, CD4 count, viral load, years with 
HIV, first line therapy, years on HAART and BMI. All data presented in text and tables 
are expressed as means ± SD. Odds ratio (OR) and 95% confidence intervals (CI) are 




5.5 Results  
 
5.5.1 Patient characteristics 
Baseline characteristics of patients are summarised in Table 5.1. The majority of 
patients were Caucasian (51%), homosexual (52%), male (75%) with a mean age of 40 
years. Mean duration of HIV infection was 5 years and ranged from 0–26. The majority 
of patients had well controlled disease as indicated by a CD4 count > 300 cells/mm
3
 
(73%) and a HIV viral load of < 50 copies/ml (62%). Three-quarters of patients were 
taking HAART for an average of 9 years. Of these, almost all (98%) were receiving 
NRTIs, while only 30% were being treated with PI. The mean TG concentration was 1.7 
mmol/L, mean TC was 4.58 mmol/L and mean HDL-C was found to be 1.32 mmol/L. 
Mean SBP and FG were within the normal range at 120 mmHg and 5.1 mmol/L, 
respectively. Mean WC was below the cut-offs used to indicate risk of MetS (≥ 94 cm 
in men). The average BMI was 25 kg/m
2
. When the NCEP criteria were used, 17% of 
patients were classified as having the MetS, which increased to 22% when using the 
IDF criteria. LD, defined as any body fat abnormality either self-diagnosed or diagnosed 
by a doctor, was present in 23% of 945 patients for whom data were available. Only a 
sub-set of patients (n = 555) had complete data for both metabolic parameters and LD. 
Analysis of this sub-set of data revealed that 29 % of patients had a diagnosis of HALS 
(the presence of LD plus any other metabolic abnormality). There was a high degree of 
concordance between doctor and patient diagnoses of LD as indicated by a 0.825 kappa 




Table 5.1 Patient characteristics 
Characteristic   
Demographic  
Male n (%) 762 (75) 
Female n (%) 260 (25) 
Caucasian n (%) 510 (51) 
African n (%) 334 (33) 
Caribbean n (%) 68 (7) 
Asian n (%) 20 (2) 
Age (years) 40 ± 9 
Aged > 45 n (%) 253 (25) 
Men-sex with men n (%) 448 (52) 
Heterosexual n (%) 356 (41) 
Intravenous drug user n (%) 13 (2) 
Smoker n (%) 378 (37) 
HIV disease / drug factors   
Duration HIV infection (yrs)  5 ± 4 
CD4 count, (cells/mm
3
) 442 ± 222 
CD4 >300 n (%) 736 (73) 
HIV <50 copies per ml n (%) 623 (62) 
On HAART n (%) 766 (75) 
Duration of HAART (yrs) 9 ± 2 
First line regimen n (%) 131 (31) 
PI  n (%) 300 (30) 
NRTI n (%)  736 (98) 
Coinfection HBV n (%) 
Coinfection HCV n (%) 
48 (6) 
34 (4) 
Metabolic / morphological   
TG (mmol/L) 1.7 ± 1.3 
TC (mmol/L) 4.58 ± 1.1 
HDL-C (mmol/L) 1.32 ± 0.5 
SBP (mmHg) 121 ± 15 
FG (mmol/L) 5.1 ± 1.3 
WC (cm) 90 ± 11 
Weight (kg) 76 ± 14 
BMI (kg/m
2
) 25 ± 5 
MetS (NCEP) n (%) 96 (17) 
MetS (IDF) n (%) 128 (22) 
LD either diagnosis n (%) 216 (23) 
LD diagnosed by doctor n (%) 178 (19) 
LD diagnosed by patient n (%) 193 (20) 
HALS n (%) 159 (29) 
Values are mean ± SD. Data are presented for all patients 
who participated in the study (n = 1022). Data on LD were 
available for 945 patients, on 581 patients for MetS and on 




Table 5.2 Concordance of doctor and patient reports of LD 
  LD noticed by patient 
Agreement
a
 P value 
  Yes No 
LD noticed 
by doctor  
Yes 155 22 
0.825 < 0.001 
No 29 727 
a 
Kappa test for level of agreement beyond chance between doctor and patient. A score 
of less than 0.2 is considered poor, a score of 0.2-0.4 is fair and a score above 0.4 




5.5.2 Characteristics of patients with LD compared with those without LD 
Table 5.3 shows characteristics of the study sample according to the presence of LD. 
Patients with LD were older (P < 0.001), less likely to be asymptomatic (P = 0.001), 
and tended to be diagnosed with HIV for a greater length of time (P < 0.001) compared 
with those without LD. Patients with LD had higher CD4 cell counts (P < 0.001) and 
the majority had a viral load of less than 50 copies per ml compared with those without 
LD (P < 0.001). A greater proportion of patients with LD were receiving HAART (P < 
0.001), specifically PIs (P < 0.001). Patients with LD were more likely to be taking their 
current HAART regimen for a longer duration compared with those without LD (P = 
0.001). NRTI use was not significantly different between those with LD and those 
without. Coinfection with HCV was more prevalent in those with LD compared with 
those without LD (P = 0.001). Patients with LD had higher TG (P < 0.001), TC (P < 
0.001) and FG (P = 0.011), as well as larger WC (P = 0.003). A greater proportion of 
patients with LD had MetS, defined using NCEP and IDF criteria (P = 0.014 and P = 
0.022, respectively), compared with those without LD.  
 
We further separated ARVs according to LD diagnosis (Table 5.4) and found that 
patients with LD were significantly more likely to be taking PI (P < 0.001), particularly 
RTV (P = 0.047). There was no significant difference between those with LD and those 







Table 5.3 Characteristics of patients with and without LD 
 LD (n = 216) No LD (n = 729) P value 
Demographic    
Age (years) 44 ± 9 39  ± 9 <0.001* 
Gender 
Male n (%) 









Smoker n (%)  77 (36) 273 (38) 0.700 
Ethnicity 
Caucasian n (%) 
African n (%) 
Caribbean n (%) 














Men-sex with men n (%) 
Heterosexual n (%) 












Disease factors    
Disease Stage  
Asymptomatic n (%) 
Symptomatic (pre-AIDS) n (%) 











Duration of HIV (years) 8  ± 5 4  ± 5 <0.001* 
CD4 count (cells/mm
3
) 517 ± 243 422 ± 212 <0.001* 
HIV <50 copies per ml n (%) 171 (85) 375 (53) <0.001* 
Receiving HAART n (%) 205 (95) 496 (68) <0.001* 
First line regimen n (%) 17 (15) 100 (38) <0.001* 
Duration HAART (years) 9 ± 2.2 8 ± 2 0.001* 
PI n (%) 96 (45) 180 (25) <0.001* 
NRTI n (%) 197 (97) 478 (98) 0.363 
Hepatitis B n (%) 







Metabolic parameters    
TG (mmol/L) 2.03 ± 1.5 1.57 ± 1.0 <0.001* 
TC (mmol/L) 4.98 ± 1.1 4.62 ± 1.0  <0.001* 
HDL-C (mmol/L) 1.35 ± 0.5 1.31 ± 0.5  0.209 
SBP (mmHg) 120 ± 14 121 ± 14 0.862 
FG (mmol/L) 5.36 ± 1.7 4.95 ± 0.9 0.011* 
WC (cm) 92 ± 12 89 ± 11 0.003* 
BMI (kg/m
2
) 25.8 ± 5 24.2 ± 5 0.574 
MetS (NCEP) n (%) 35 (16) 74 (10) 0.014* 
MetS (IDF) n (%) 42 (19) 96 (13) 0.022* 
Values are mean ± SD. Difference between groups tested using Chi-square for 
categorical variables and Independent samples t-test for continuous variables. 
Significant difference between groups: *P < 0.05.  
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Table 5.4 Antiretroviral drugs according to LD diagnosis 
 LD (n = 216) No LD (n = 729) P value 
PI  96 (45) 180 (25) <0.001* 
RTV 55 (27) 98 (20) 0.047* 
NRTI  197 (97) 478 (98) 0.363 
d4T 1 (0.5) 7 (1) 0.484 
ZDV 42 (19) 131 (18) 0.623 
NNRTI  108 (53) 281 (58) 0.253 
NtRTI  109 (53.7) 272 (56) 0.566 
Values are n (%). Data are reported for patients for whom data on LD diagnosis were 
available (n = 945). Significances of differences between groups determined using Chi-




5.5.3 Factors associated with LD , MetS and HALS 
Factors associated with LD were investigated using multivariable binary logistic 
regression analysis (Table 5.5). The odds of having LD was 0.32 times lower for male 
patients (P = 0.023) compared with female patients and 0.21 times lower for those 
receiving a first line ART regimen (P < 0.001) compared with those not receiving a first 
line regimen. LD was associated with increasing years of current HAART regimen (OR 
1.29, P = 0.007) and increased FG (OR 1.32, P = 0.043). Other variables included in the 
model, but which showed no effect, included age, ethnicity, CD4 count, HIV viral load, 
duration of HIV infection, BMI, WC, TC, TG, HDL-C and SBP.  
 
MetS was significantly associated with increasing age (OR 1.05, P = 0.015). The odds 
of having MetS were greater for male patients compared with female patients (OR 2.98, 
P = 0.048). Caucasian and Asian ethnicity (OR 2.65, P = 0.034 and OR 7.34, P = 0.030, 
respectively) and increasing BMI (OR 1.22, P < 0.001) were also significantly 
associated with having MetS (Table 5.6). Factors added to the regression model, but 
which showed no effect include gender, CD4 count, HIV viral load, duration of HIV 
infection, receiving a first line regimen and duration of current HAART regimen.  
 
Similar to LD, the odds of having HALS were reduced for those receiving a first line 
ART regimen compared with those not receiving a first line regimen (OR 0.28, P = 
0.003) (Table 5.7). This was the only variable significantly associated with HALS in 
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the regression model. Variables included in the model, but which were not significant 
include age, ethnicity, most recent CD4 count, HIV viral load, duration of HIV infection 
and BMI.  
 
 
Table 5.5 Association of factors with LD 
Data are reported for patients for whom data on all variables were available (n = 264).   
Multivariable binary logistic regression 
Variable [reference] OR 95% CI P  value 
Age, years 1.02 0.98-1.06 0.401 
Gender [Female]                           0.32 0.12-0.86 0.023* 
Ethnicity [African]                           
Caribbean 0.75 0.17-3.42 0.712 
Caucasian 0.87 0.37-2.03 0.747 
Asian 1.04 0.10-10.5 0.977 
Other 0.97 0.29-3.21 0.961 
CD4 count, cells/mm
3
 1.00 1.00-1.00 0.072 
HIV viral load <50 [No]              1.04 0.44-2.44 0.925 
Duration HIV infection, years 1.01 0.94-1.07 0.889 
First line regimen [No]                 0.21 0.10-0.48 <0.001* 
Duration of current HAART 
regimen, years 
1.29 1.07-1.55 0.007* 
BMI, kg/m
2
 0.97 0.85-1.09 0.582 
WC, cm 1.02 0.97-1.08 0.467 
TC, mmol/L 0.81 0.59-1.11 0.181 
TG, mmol/L 1.33 0.99-1.79 0.055 
HDL-C, mmol/L 1.03 0.52-2.02 0.932 
FG, mmol/L 1.32 1.01-1.73 0.043* 
SBP, mm Hg 0.99 0.97-1.02 0.747 
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 Table 5.6 Association of factors with MetS 
MetS was defined using IDF criteria to account for the difference in WC between ethnic 
groups. Data are reported on patients for whom data on all variables were available (n = 
328).  
  
Multivariable binary logistic regression 
Variable [reference]               OR 95% CI  P  value 
Age, years 1.05 1.01-1.09 0.015* 
Gender [Female]                        2.98 1.01-8.75 0.048* 
Ethnicity [African]                        
Caribbean 0.85 0.15-4.71 0.852 
Caucasian 2.65 1.05-6.39 0.038* 
Asian 7.34 1.19-43.2 0.031* 
Other 0.99 0.21-4.71 0.988 
CD4 count, cells/mm
3
 1.00 0.99-1.00 0.962 
HIV viral load <50 [No]            1.29 0.49-3.32 0.601 
Duration HIV infection, years 1.06 0.94-1.08 0.881 
First line regimen [No]              0.79 0.37-1.70 0.553 
Duration of current HAART 
regimen, years 
1.06 0.88-1.28 0.541 
BMI, kg/m
2
 1.22 1.13-1.31 <0.001* 
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Table 5.7 Association of factors with HALS 
Data are reported for patients for whom data on all variables were available (n = 257).  
  
Multivariable binary logistic regression 
Variable [reference] OR 95% CI P  value 
Age, years 1.03 0.99-1.07 0.140 
Gender [Female] 0.82 0.36-2.22 0.898 
Ethnicity [African]    
Caribbean 0.65 0.12-3.54 0.618 
Caucasian 0.97 0.40-2.31 0.940 
Asian 0.46 0.04-5.58 0.542 
Other 0.79 0.23-2.77 0.712 
CD4 count, cells/mm
3
 1.00 1.00-1.00 0.068 
HIV viral load <50 [No] 0.91 0.37-2.19 0.836 
Duration HIV infection, years 1.03 0.97-1.10 0.343 
First line regimen [No] 0.28 0.12-0.65 0.003* 
Duration of current HAART 
regimen, years 
1.18 0.98-1.41 0.089 
BMI, kg/m
2





5.6.1 Prevalence of LD, MetS and HALS 
We identified the prevalence of LD in this study as 23%. This finding is similar to 
(Galli et al., 2002, Puttawong, 2004) or lower than (Saint-Marc et al., 2000) that 
reported in previous studies. In a review of international studies on LD in HIV, we 
found that its prevalence ranged from 9-83% (Loonam and Mullen, 2012) due to the use 
of different definitions to identify the prevalence of LD. Overall, the prevalence of 
MetS was 17% and 22% in these patients, defined using NCEP or IDF criteria, 
respectively. These values are slightly lower than that reported in the general European 
population (24.3%) (Scuteri et al., 2014). Having identified the prevalence of LD and 
MetS, we decided to determine the prevalence of HALS. HALS was defined as a 
coexistence of LD and any other metabolic abnormality and was identified in 29% of 
patients. This is lower than previous cross-sectional studies using similar patient 
numbers (Carr et al., 1998a). Using this definition of HALS allows us to identify 
additional patients with HIV / HAART-associated abnormalities. This is relevant and 
argues against the suggestion that the definition of HALS should be abandoned.   
 
5.6.2 Characteristics of patients with LD compared those without LD 
In this study, patients diagnosed with LD were significantly older than those without 
LD. A greater prevalence of LD among groups of older HIV patients has also been 
observed by others (Bernasconi et al., 2002, Della Justina et al., 2014). Normal aging is 
associated with a significant increase and redistribution of adipose tissue (Zamboni et 
al., 2013). Fat storage in SCAT depots is reduced in aging and is associated with an 
increase in ectopic and VAT lipid deposition (Kuk et al., 2009). SC adipocytes appear 
to lose their ability to store lipid, resulting in an increase in circulating FFA (Findeisen 
et al., 2011). VAT then acts as a buffer for the increased circulating FFA and increases 
in size. This scenario of lipotoxicity also occurs in HIV patients with LD (Caron-
Debarle et al., 2010b). It could therefore be suggested that the natural aging process 
accelerates the development of lipotoxicity and LD in HIV.  
 
Interestingly, patients with LD had CD4 cell counts > 300 cells/mm
3
 and HIV viral 
loads < 50 copies/ ml, both of which indicate well-controlled disease. Similar findings 
have been demonstrated for CD4 count in a study of Rwandan patients with LA (van 
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Griensven et al., 2007). In contrast, another study demonstrated a greater prevalence of 
LA among those with lower CD4 count and higher viral load (Lichtenstein et al., 2003). 
HAART may play a role in the findings we observed as the majority (97.8%) of patients 
with well controlled disease were also receiving HAART (data not shown), which has 
been implicated in the development of LD. When we investigated HAART use in 
patients with LD compared with those without LD we found that patients with LD were 
more likely to be receiving HAART and for a longer period of time. Moreover, patients 
with LD were more likely to be receiving a PI than those without LD. ART has long 
been established as a cause of LD and a number of studies have found an association 
between increased duration of ART and the development of LD (Carr et al., 1999, 
Martínez et al., 2001, Berhane et al., 2012). Data presented here correspond with other 
studies and confirm the long-established role of ARVs in the development of LD (Carr 
et al., 1998a).  
 
Coinfection with HCV is common among HIV-infected individuals (Sherman et al., 
2002). In this study, patients with LD were more likely to be infected with HCV 
compared with those without LD. This finding is supported by data in the literature 
(Galli et al., 2002, Rodriguez-Guardado et al., 2003, Leclercq et al., 2013). In contrast, 
HCV coinfection has been found to be associated with improved lipoprotein profile 
(Wheeler et al., 2014) and a reduced risk of hypercholesterolaemia and 
hypertriglcyeridaemia (Bedimo et al., 2006) and may relate to the effect of the HCV on 
hepatic lipoprotein metabolism and function.  
 
Patients with LD had higher TG, TC and FG, as well as greater WC values, compared 
with those without LD, which is supported by data in the literature (Carr et al., 1998a, 
Dinges et al., 2005, Mutimura et al., 2007, Monnerat et al., 2008, Duro et al., 2013). In a 
recent study, high TG/high WC was found to be associated with a more harmful form of 
LD and increased CV risk compared with those with low TG/low WC (Janiszewski et 
al., 2011). This ratio may be useful in classifying patients at risk of body composition 
abnormalities and CVD. 
 
Patients with LD in this study had a higher prevalence of the MetS defined using any 
criteria compared with those without LD. Coexistence of metabolic and morphologic 
abnormalities in patients with LD has been shown by a number of other studies 
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(Seminari, 2002, Samaras et al., 2007, Jevtovic et al., 2009, Zannou et al., 2009) and 
provides further evidence for the existence of HALS.  
 
5.6.3 Factors associated with LD, MetS and HALS  
This is the first study to report the factors associated with LD among UK HIV-infected 
patients. In this study, male gender was associated with reduced odds of LD. Increased 
duration of current HAART regimen was associated with increased odds of having LD, 
but if this was a first line regimen the odds of having LD decreased by 79%. A previous 
study reported no difference between males and females in terms of LD prevalence, but 
males tended to report peripheral LA more than females, who tended to report more 
central LH (Andany et al., 2011). This finding for LA and male gender has been shown 
by other groups (Leclercq et al., 2013). The apparent protective effect of receiving a 
first line regimen in our data contrasts with previous reports where a first line regimen 
has been associated with body composition abnormalities (Galli et al., 2002, van 
Griensven et al., 2007). However, in these studies, first line regimens typically 
contained d4T, whereas only 1 patient with LD in the CREATE cohort was receiving 
d4T. Newer first line regimens, consisting of drugs with fewer side-effects, may account 
for the lack of a negative association between first line regimen and LD in our study. 
The apparent protective effect of first line regimen in our study may be explained by the 
fact that patients only move to second line regimen if first line fails and they experience 
virological failure. Virological failure is associated with increased risk of MetS 
(Squillace et al., 2008). Patients receiving first line regimen do not have virological 
failure, which may affect their risk of MetS or LD.  
 
We found that age, gender, ethnicity and BMI were significantly associated with MetS. 
Interestingly, no HIV disease or drug factors were significantly associated with MetS, 
which suggests that what we are observing in these patients is the normal MetS, as 
observed in the general population. A recent study from Thailand also found an 
association between increasing age and MetS in ART-experienced patients with HIV 
(Jantarapakde et al., 2014). In contrast to our findings for male gender and MetS, 
Jantarapakde et al found an association with female gender and MetS in ART-
experienced patients with HIV. The association between BMI and MetS is supported by 
previous findings among HIV-infected patients in the literature (Jericó, 2005, Estrada et 
al., 2006, Alvarez et al., 2010, Alencastro et al., 2011), as well as in the general 
population (Scuteri et al., 2014). Similar to our study, white race has previously been 
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shown to be associated with the MetS (Alencastro et al., 2011). The association between 
MetS and Asian ethnicity in this study corresponds with findings in the general 
population where Asian populations typically have an increased risk of MetS, 
necessitating lower MetS cut-offs for early intervention to prevent T2DM and CVD 
(Pandit et al., 2012).  
 
When we investigated the factors associated with HALS, we found that receiving a first 
line ART regimen was significantly associated with reduced odds of having HALS. No 
other HIV disease or drug factors were associated with HALS. Although not found in 
our study, previous studies report an association between HALS and increased duration 
of ART (≥ 1 year), d4T use and low CD4 cell count (Mauss et al., 2002, Feleke et al., 
2012). Use of d4T was limited among the CREATE cohort and the majority of patients 
had high CD4 cell counts, which may explain the lack of associations for these 
parameters in our study.  
 
Overall, the results suggest that this population presents a number of risk factors for LD 
than MetS. Male gender is protective against LD, but not MetS, and increased FG and 
BMI are associated with increased odds of having LD and MetS, respectively. HIV 
disease factors were not associated with any abnormality, but ART, particularly 
receiving a first line regimen, was found to be protective against both LD and HALS.  
 
5.6.4 Limitations and conclusion 
Limitations of this study include the fact that LD was diagnosed using subjective reports 
by the patient or their physician. However, as mentioned previously, this method may 
be the most feasible in a clinical setting where time and resources are limited. LD in this 
study was defined as any body fat abnormality and as a result we do not have specific 
information on whether body fat distribution was predominantly LA, LH or mixed. The 
cross-sectional design of the study does not allow for causality to be determined. 
However, our findings may be used for evaluating and monitoring similar HIV patient 
groups in an outpatient setting. Despite the limitations of the CREATE data, we found 
that a significant proportion of patients (almost a quarter) are affected by LD and 
HALS. Although use of the definition ‘HALS’ has been disputed, focussing on LD or 
MetS in isolation prevents us from seeing the entire clinical picture. Our study 
demonstrates that the term HALS can be used to identify patients at risk of both 
















Chapter 6  
The effect of supplementation with conjugated linoleic acid on waist 





Nutrition plays an important role in the management of HIV and its associated 
complications (American Dietetic Association, 2010). Research investigating the effects 
of nutrition in mitigating aspects of HALS has focused on the traditional 
cardiometabolic risk factors known to be responsive to diet, such as dyslipidaemia and 
IR. Interventions have focused on TG lowering and have found a diet low in fat (Barrios 
et al., 2002), particularly saturated fat (Lazzaretti et al., 2012), with a Mediterranean-
style pattern to be beneficial (Tsiodras et al., 2009, Turčinov et al., 2009). Research has 
demonstrated a clear beneficial effect of n-3 PUFA in lowering TG, with doses ranging 
from 2.9 g to 6 g proven to be effective (Wohl et al., 2005, Baril et al., 2007, De Truchis 
et al., 2007, Gerber et al., 2008, Stradling et al., 2012). To the best of the author’s 
knowledge, no studies have investigated the effects of CLA on any parameter in HIV-
infected individuals.  
 
Excess abdominal fat (abdominal obesity) is the main body fat abnormality observed in 
HIV-infected individuals receiving HAART (Loonam and Mullen, 2012). Recently, 
central obesity in HIV-infected individuals has been shown to be associated with 
neurocognitive impairment (McCutchan et al., 2012) and physical frailty (Shah et al., 
2012). Abdominal obesity in HIV-infected individuals has been shown to be associated 
with a higher risk of heart disease compared with uninfected controls (Lake et al., 
2011). Deficient lipid storage in SCAT has been suggested to result in preferential lipid 
accumulation in VAT, as a result of differences in inflammation, corticosteroid levels 
and mitochondria content between SCAT and VAT, as well as “secondary lipotoxicity”,  
a process whereby fatty acids released as a result of lipolysis in SCAT are taken up by 
VAT, leading to an increase in the size of this depot (Caron-Debarle et al., 2010b).  
Down-regulation of PPAR-γ as a result of ARVs (Caron et al., 2009) leading to 
decreased adipogenesis and increased lipolysis (Lenhard et al., 2000), has been 
suggested to be a driving factor in this process.   
 
In vitro results from Chapter 4 have shown beneficial effects of CLA in mitigating 
some the effects of ARVs on adipocyte metabolism.  Numerous beneficial effects of 
CLA have been demonstrated with respect to modulation of immune and inflammatory 
responses (Mullen et al., 2007), regression of atherosclerosis (Toomey et al., 2006), 
improved lipoprotein profile (Hur et al., 2013), cancer  prevention (Bhattacharya et al., 
2006), bone health (Deguire et al., 2012) and obesity (Gaullier et al., 2007). The anti-
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obesity effects of CLA in particular have been explored extensively. Studies in rodents 
have shown CLA to be beneficial in reducing adipocyte size (DeClercq et al., 2012) and 
inducing body fat loss (Ippagunta et al., 2011). In humans, CLA supplementation has 
been shown to reduce body weight (Berven et al., 2000), body fat (Blankson et al., 
2000, Gaullier et al., 2005) and abdominal obesity (Riserus et al., 2001). At present, no 
studies have investigated the effects of CLA in an HIV population.   
 
 
6.2 Hypothesis   
It was hypothesised that supplementation with CLA would reduce WC, a surrogate 
marker of abdominal obesity and a characteristic of HALS, in HIV-infected men 
receiving HAART.   
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6.3 Study design, participants and recruitment 
 
6.3.1 Study design 
A randomised, double-blind, placebo controlled study was used to investigate the 
potential for CLA supplementation to reduce WC. Participants were randomly allocated 
to receive either CLA (3 g/d; Clarinol
®
 A80) or placebo (3 g/d high oleic sunflower oil 
(HOSF)). The primary outcome variable was a change in WC. Secondary outcomes 
included BMI and percentage body fat. The study protocol was reviewed and approved 
by Queen Square Ethics Committee (Ref 13/LO/1145). The intervention period was 12 
weeks (Figure 6.1) in line with previous research indicating changes in body 
composition were detectable after this duration of supplementation (Berven et al., 2000, 
Blankson et al., 2000, Risérus et al., 2002, Laso et al., 2007). Block randomisation with 
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6.3.2 Experimental capsules  
The experimental oils, 3 g CLA and 3 g HOSF, were supplied by Stepan Lipid Nutrition 
(Koog aan de Zaan, The Netherlands). CLA derived from safflower oil was provided in 
free fatty acid form in soft gel capsules. Each capsule contained 1 g oil, of which 78% 
was CLA as a 50:50 mix of c9,t11 and t10,c12. All subjects were asked to consume 4 
capsules per day to provide a dose of ~3 g/d CLA. Details of the fatty acid composition 
of the capsules and the amount provided by 4 capsules per day can be found in Table 
6.1. Capsules were stored in a dry, dark room at room temperature throughout the study. 
Capsules were packed in securitainers providing a 6-week supply (168 capsules). 
Patients received another 6-week supply when they returned for their mid-point visit. 
Patients were asked to return any remaining capsules at the 6 and 12 week visits. 
Unknown to the participant, 6 extra days capsules were added to each batch of 
supplements, which provided a measure of compliance.  
 
Table 6.1 Fatty acid composition of the capsules and intake per day 
Fatty acid % weight Intake (g/d) 
 Placebo CLA Placebo CLA 
16:0 3.86 5.22 0.15 0.21 
16:1 0.11 0.09 < 0.1 < 0.1 
18:0 3.06 1.84 0.12 0.07 
18:1n-9 84.7 14.0 3.39 0.56 
18:2n-6 7.64 0.84 0.31 0.03 
18:2 cis-9,trans-11 0 39.19 0 1.56 
18:2 cis,12, trans-11 0 38.80 0 1.55 
20:5n-3 0 0 0 0 
22:6n-3 0 0 0 0 
 
 
6.3.3 Participants and recruitment  
The participants were HIV-infected men recruited from the Harrison Wing, HIV 
outpatient clinic at St Thomas’ Hospital, London. The inclusion and exclusion criteria 
are shown in Table 6.2. Patients were approached by the investigator in the clinic 
waiting area. The study was explained to the patient and they were asked if they would 
be interested in taking part. Recruitment posters and leaflets (approved by the Queen 
Square Ethics Committee; Appendix 2-4) were also displayed in the waiting area and in 
clinic rooms. Self-reported WC was used to determine eligibility in the waiting area and 
this was followed up with a screening questionnaire (Appendix 5) to confirm eligibility. 
Once eligibility was confirmed, patients were provided with an information sheet 
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(Appendix 6) and scheduled for a baseline appointment. The investigator consulted 
patient medical notes and electronic patient records to obtain recent blood results, as 
well as disease parameters and details of other relevant comorbidities which the patient 
was unable to provide (e.g. date of diagnosis, duration of HAART and current HAART 
regimen). Recruitment methodology is summarised in Figure 6.2. 
 
 




3. Aged 18 - 55 years 
4. Currently receiving HAART 
5. WC greater than ≥ 94 cm (or ethnic-specific cut-off) and/or BMI > 25kg/m2  
Exclusion criteria 
1. A current AIDS-defining illness 
2. Any acute/chronic condition that might affect the interpretation of the results, or the 
participant's ability to follow protocol correctly 
3. Fasting hypertriglyceridaemia (> 1.7 mmol/L) 
4. Fasting hyperglycaemia (> 7 mmol/L) 
5. Participants receiving testosterone replacement therapy 
6. Use of any medication designed to reduce weight/ body fat 
7. Participants following a diet (self- or practitioner-prescribed) to reduce weight/body 
fat 
8. Use of fat-based supplements (e.g. fish oils) in the previous 3 months 
9. Known hypersensitivity to the investigational products according to the participant 




















Figure 6.2 Recruitment methodology 
  
WC ≥ 94 cm 
Patient assessed for eligibility in the clinic waiting area 
Patient attends baseline appointment and is provided with 
more information. Patient signs the consent form and is 
accepted onto the study. 
 
 
Screening questionnaire completed 
WC < 94 cm 
No further action taken 
Eligible 
Not eligible 
No further action taken 
Patient provided with information sheet and scheduled for a 
baseline appointment. Investigator checks recent 




6.4 Study visits 
Eligible participants were invited to attend the HIV outpatient clinic after a 12 hour 
overnight fast for their first study visit, which lasted approximately 1 hour. Patients 
arrived between 08:30 and 11:00 hours. During this visit, the study was explained in 
detail and participants were given a chance to ask questions before signing a consent 
form (Appendix 7). A copy of the consent form was given to the patient and a copy 
placed in the medical notes along with the information sheet. A fasting blood sample 
was taken by a trained research nurse to assess baseline CLA levels, adipocytokines, 
oxidative stress, liver function, lipids, glucose and disease parameters (CD4 count and 
HIV viral load). In order to minimise burden to the patient, if recent results (within 3 
months) were available, they were obtained from the electronic patient records and were 
not repeated. An anthropometric record sheet (Appendix 8) was completed along with a 
FFQ, a physical activity questionnaire and a 24 hour dietary recall. Patients were 
advised to take four 1 g capsules per day with or after food. At the end of the visit, a 
provisional 6 week appointment was scheduled and participants were provided with a 
monetary sum to buy breakfast before leaving the hospital. A letter was sent to the 




More detailed instructions can be found in Section 2.2.4. Weight and height were 
measured using a digital column scale and stadiometer to the nearest 0.1 kg and 0.1 cm, 
respectively. WC was measured to the nearest 0.1 cm and in the standing position with 
arms placed on opposite shoulders, and weight evenly distributed on each leg. The 
measurement was taken as the midpoint between the lowest rib and the right ilium at the 
midaxillary line (World Health Organisation, 2008). Where possible, WC 
measurements were taken with the patient’s waist uncovered or without heavy outer 
garments where this was not possible. Readings were taken at the end of a normal 
exhalation. Skinfolds were measured in triplicate to the nearest 0.1 mm using a Holtain 
calliper with the patient in standing position with arms hanging loosely by the side and 
weight evenly distributed on both legs. Skinfolds consisted of a double thickness of skin 
measured at four sites: triceps, biceps, suprailiac and subscapular. The triceps skinfold 
was measured on the right upper arm mid-point mark on the posterior surface.  
Skinfolds at the subscapular site were measured at the inferior angle of the right 
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scapula.  Suprailiac skinfolds were measured at the high point of the right iliac crest on 
the midaxillary line. The average of each skinfold was calculated and as the values 
obtained with the calliper are not normally distributed it was necessary to log-transform 
the data. The total combined skinfold thickness was calculated and the resulting values 
used in body density equations (Appendix 10) to estimate percentage body fat (Durnin 
and Womersley, 1974). Body fat was also assessed using the Tanita TBF 300MA 
according to the manufacturer’s instructions.  
 
6.4.2 Dietary assessment and physical activity 
More detailed instructions can be found in Section 2.2.5-2.2.6. The EPIC-Norfolk FFQ 
(Appendix 11) was used in this study to assess participants’ usual food intake over the 
previous year. Participants were asked to complete an FFQ at baseline and week 12. The 
FFQ is a 10-page document consisting of two parts: the first and main part asks the 
participant to indicate their usual consumption of 130 foods from categories ranging 
from "never or less than once/month" to "6 times per day”. Part two consists of an 
additional set of questions, which help to categorise breakfast cereals and gain more 
information about milk, total fat and fatty acid intake.   
 
The triple pass 24-hour recall method (Nelson et al., 2008); Appendix 12) was used by 
the researcher at baseline and week 12 to assess participants’ food intake during the 
previous 24 hours. The 24-hour recall was undertaken in chronological order of 
consumption, following a pattern of free and uninterrupted recall of intake, followed by 
detailed and specific questions about intake and quantities consumed. The recall 
concluded with a review of the information previously recalled, allowing for the 
addition of any items not remembered up to that point (Nelson et al., 2008).  
 
A self-administered, short version of the International Physical Activity Questionnaire 
(International Physical Activity Questionnaire, 2001); Appendix 13) was used to obtain 
an estimate of participants’ PALs during the previous 7 days. Scores for physical 
activity ranging from low to moderate and high were determined for each participant 




6.4.3 Blood sample collection, handling and analysis 
Unless results were available, venous blood samples for the analysis of plasma glucose, 
plasma lipids (TG, TC, HDL-C, LDL-C), liver function (albumin, alanine 
aminotransferase (ALT), alkaline phosphatase (ALP), bilirubin), CD4 count, HIV viral 
load, oxidative stress, adipocytokines and CLA levels were collected in evacuated tubes 
with the minimal compression necessary to display the vein. Blood for glucose was 
collected into 4 ml fluoride oxalate vacutainers. Blood for plasma lipids and liver 
function was collected into 5 ml serum tubes containing a clot activator and gel for 
separation. Blood for CD4 count, viral load, oxidative stress, adipocytokines and CLA 
levels was collected into 4 ml EDTA tubes containing anticoagulant. Tubes were then 
centrifuged at 2,000 rpm for 10 minutes at 4 °C and plasma samples to be used for the 
measurement of oxidative stress, adipocytokines and CLA were stored at -80°C until 
analysis. Blood samples for all other tests were sent to the respective hospital laboratory 
for analysis.  
 
6.5 Determination of biochemical parameters 
Determination of plasma glucose, TG, TC, HDL-C, LDL-C, liver function, CD4 count 
and HIV viral load was carried out by the Blood Sciences and Virology laboratories at 
St Thomas’ Hospital. Plasma adipocytokines were measured at the Department of 
Clinical Biochemistry at King’s College Hospital. For detailed methodology refer to 
Appendix 14-22. Oxidative stress and plasma CLA levels were determined by the 
investigator.   
 
6.5.1 Determination of oxidative stress 
A TBARS assay kit (Cayman Chemicals) was used to determine lipid peroxidation, an 
indicator of oxidative stress, in plasma samples from patients at baseline and week 12. 
Standards were prepared from a stock solution of 125 μM malondialdehyde (MDA) by 
serial dilution in the range 0 - 50 μM. 100 μl sample or standard was added to a labelled 
vial, to which 100 μl SDS solution was added. 4 ml of colour reagent was then added to 
the vial which was boiled for 1 hour. Vials were removed immediately and placed in ice 
water for 10 minutes. Vials were centrifuged at 2,750 rpm for 4 minutes. 150 μl of each 
sample was then loaded onto a colorimetric plate in duplicate and the absorbance of the 
solution read at 530-540 nm in a spectrophotometer (Synergy HT, Biotek). A standard 
curve was constructed by plotting the mean absorbance values (optical density, OD) 
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from the standard solutions versus the known MDA concentrations. Sample 
concentrations were calculated using the equation of the standard curve. 
  
6.5.2 Determination of plasma CLA levels 
The composition of CLA in plasma samples was investigated using GLC. Fatty acid 
methyl esters were created by transesterification as previously described (Lepage and 
Roy, 1986). Briefly, 100 μl plasma was pipetted into a Teflon lined screw cap tube. 10 
ml acetyl chloride was added drop-wise into 100 ml internal standard mixture. 2.2 ml of 
this internal standard was added to the tube. The tube was sealed and incubated 
overnight at 40 °C. Samples were cooled and 5 ml of 6 % potassium/sodium carbonate 
was added. The upper phase of the sample was collected and transferred using a Pasteur 
pipette to a GLC vial. 1 μl of each sample was injected into Agilent Technologies 6890 
gas chromatograph (Agilent Technologies UK Limited) fitted with a 25 m length x 0.22 
mm i.d. x 0.25 µm film thickness, Supelco SAC-5 capillary column (Sigma Aldrich) 
and equipped with a flame ionization detector set at 250°C. The injection was 
performed in split mode (50:1) with the inlet maintained at 240°C. Temperature 
programming was employed to optimize the separation. This was achieved by holding 
the initial column temperature at 160°C for 4 min, followed by ramping at 10°C/ min to 
200°C and holding at this temperature for 10 min to ensure complete elution. The 
identities of the separated fatty acids were established by matching their retention times 
with those present in authentic reference standards run under identical conditions. 
Proportions of fatty acids as weight % were quantified by expressing the areas under the 
chromatographic peaks as a % of the total integrated area. Individual fatty acid contents 
expressed in mg/L of plasma were calculated with reference to the internal standard 
(15:0) peak area and the amount added to each sample. CLA isomers were identified by 





6.6 Statistical analysis  
Power calculations were conducted using WC as the primary endpoint. Using 80% 
power and P < 0.05, a formula to determine sample size was used with the aim of 
detecting a 5 cm difference in WC between treatments based on previous reports of SD 
in WC measurements of 7 cm (Kirkwood and Sterne, 2003). Therefore, the study aimed 
to recruit a total of 60 participants. Due to the small sample size, data were not tested 
for normality. Data were analysed for between subject differences from baseline to 
week 12 using independent samples t-tests. Paired-samples t-test was used to test for 
differences within the treatment groups. Statistical analysis was carried out using SPSS 
version 20 (IBM Corp). Statistical significance was taken at P < 0.05. All data presented 






6.7.1 Subjects  
Recruitment onto the trial commenced in January 2014 and was completed in April 
2014. The investigator assessed eligibility in 478 male patients in the HIV outpatient 
clinic. Of these 431 did not meet the inclusion criteria and 38 were not interested. Nine 
patients were eligible and expressed interest, and were provided with information and 
scheduled for a baseline appointment. Of these, 1 dropped out and 3 suffered adverse 
effects resulting in removal from the study. Details are illustrated in the consort flow 






















Excluded (n = 469) 
- Ineligible (n = 431) 




Excluded (n = 4)   
- Adverse effects of 
supplements (n = 3) 
- Loss to follow-up 
(n = 1) 
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6.7.2 Baseline characteristics of subjects  
A total of 5 patients completed the study. Two patients self-classified as Caucasian, two 
as Caribbean and one as Asian. Baseline characteristics at recruitment are presented 
with respect to treatment allocation in Table 6.3. Duration of HAART use was 
significantly greater among those in the CLA group at baseline (P = 0.011). There were 
no differences between the groups for any other parameter at baseline.  
 
Table 6.3 Characteristics of subjects at baseline 
 Treatment group 
Phenotype Placebo (n = 2) CLA (n = 3) 
Age (years) 42 ± 9.9 43 ± 9.2 
Years diagnosed with HIV 2.5 ± 0.7 7.3 ± 2.5 
CD4 count (cells/ mm
3
)  678 ± 45 623 ± 159 
HIV viral load (copies/ ml)
1
 <50 <50 
Years on current HAART regimen 2.5 ± 0.7 5.7 ± 0.6* 
Receiving PI (n) 0 2 
Receiving NRTI (n)  2 2 
Height (m) 1.8 ± 0.04 1.74 ± 0.04 
Weight (kg) 95.9 ± 2.7 92.7 ± 9.1 
BMI (kg/m
2
) 30.6 ± 2.2 30.7 ± 4.6 
WC (cm)  101.6 ± 3.4 106.6 ± 2.9 
Values are mean ± SD. 
1
 Values for HIV viral load for some patients were reported as 
“undetectable” if < 20, so differences between groups could not be analysed and are 
reported as < 50. Significant differences between the two groups using Independent-




6.7.3 Compliance with taking the supplements 
Compliance with taking the supplements was assessed by capsule counts and by 
measuring changes in the proportions of CLA and oleic acid in plasma. All 5 patients 
returned the capsules and 4 patients consumed greater than 85% of the capsules. Table 
6.4 shows plasma CLA composition (%) at baseline and after 3 g/d CLA or HOSF 
placebo for 12 weeks. Compared with placebo, the CLA group had significantly higher 
plasma 16:0 (palmitic acid; P = 0.002), 20:5 n-3 (eicosapentanoic acid; P = 0.048) and 
22:6 n-3 (docosahexanoic acid; P = 0.013) at week 12. Within the placebo group, 
plasma 22:5 n-3 was lower at week 12 compared with baseline (P = 0.015). Plasma 
CLA (18:2 c9,t11 and 18:2 t10,c12) composition did not change significantly. Similarly, 
there was no significant change in oleic acid (18:1 n-9) after 12 weeks of treatment with 
HOSF capsules. Although capsule counts indicate good compliance, the proportions of 
c9,t11 and t10,c12 in plasma were low and did not increase significantly during 
supplementation as expected.  
 
Table 6.4 Plasma fatty acid composition at baseline and week 12  
 Placebo CLA  
 Baseline Week 12 Baseline Week 12  P value 
14:0 0.70 ± 0.23 0.63 ± 0.01 0.72 ± 0.06 0.94 ± 0.49 0.477 
16:0 20.3 ± 0.98 20.1 ± 0.39 22.5 ± 1.38 23.5 ± 0.37 0.002* 
16:1 1.32 ± 0.15 1.25 ± 0.35 1.16 ± 0.29 1.19 ± 0.35 0.855 
18:0 9.03 ± 0.51 8.86 ± 0.24 9.32 ± 0.53 8.69 ± 0.47 0.692 
18:1n-9 22.9 ± 5.31 24.4 ± 1.42 22.4 ± 1.34 22.0 ± 1.94 0.243 
18:1n-7 1.78 ± 0.13 2.01 ± 0.07 1.52 ± 0.08 1.52 ± 0.21 0.054 
18:2n-6 30.2 ± 6.90 28.62 ± 1.8 25.1 ± 3.11 25.2 ± 1.83 0.131 
18:2c9,t11 0.48 ± 0.30 0.35 ± 0.14 0.41 ± 0.11 0.45 ± 0.21 0.575 
18:2c12,t10 0.18 ± 0.10 0.17 ± 0.15 0.13 ± 0.06 0.18 ± 0.17 0.960 
18:3n-3 0.56 ± 0.20 1.51 ± 0.84 0.77 ± 0.35 0.87 ± 0.53 0.362 
18:3n-6 1.95 ± 0.35 2.11 ± 0.66 1.87 ± 0.18 1.72 ± 0.18 0.554 
18:4n-3 0.56 ± 0.24 0.62 ± 0.34 0.48 ± 0.15 0.47± 0.10 0.653 
20:3n-6 2.08 ± 0.30 1.97 ± 0.59 1.92 ± 0.24 1.72 ± 0.04 0.652 
20:4n-6 4.80 ± 0.77 4.67 ± 1.21 7.89 ± 1.87 7.17 ± 1.70 0.175 
20:5n-3 0.39 ± 0.22 0.48 ± 0.27 0.86 ± 0.08 1.06 ± 0.15 0.048* 
22:4n-6 0.17 ± 0.01 0.13 ± 0.03 0.19 ± 0.06 0.20 ± 0.10 0.455 
22:5n-6 0.16 ± 0.03 0.14 ± 0.00 0.13 ± 0.17 0.12 ± 0.11 0.075 
22:5n-3 0.49 ± 0.07 0.46 ± 0.08† 0.54 ± 0.12 0.54 ± 0.12 0.457 
22:6n-3 1.39 ± 0.17 1.48 ± 0.29 2.10 ± 0.39 2.45 ± 0.12 0.013* 
Values are mean ± SD and expressed as % of total plasma fatty acid composition. 
Significant differences between the two groups using Independent-samples t-tests: *P < 




6.7.4 Dietary intake and physical activity levels  
Dietary intake and physical activity data are presented with respect to treatment 
allocation and compared within and between subjects after treatment for 12 weeks 
(Table 6.5). The total energy intake estimated using the 24 hour recall was significantly 
higher in the CLA group at baseline, which was due to an abnormally high intake 
reported by one subject on one particular day. The percentage of energy from fat was 
significantly higher in the CLA group at week 12 compared with placebo when dietary 
intake was assessed using a 24 hour recall (P = 0.013). Within group analysis revealed a 
significant decrease in energy intake from baseline to week 12 in the placebo group (37 
%; P = 0.002). In the CLA group, the percentage of energy from total fat decreased by 
27 % from baseline to week 12 (P = 0.013). Habitual dietary intake was assessed using 
the EPIC Norfolk FFQ at baseline and week 12. FFQ data revealed that energy intake 
was significantly lower in the CLA group compared with the placebo group at week 12 
(P = 0.028). Within the CLA group, energy intake decreased by 50 % from baseline to 
week 12 (P = 0.028). No significant differences were observed between the groups in 
self-reported PALs at week 12.  
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Table 6.5 Dietary intake and physical activity at baseline and week 12  
 Placebo  CLA  
 Baseline Week 12 Baseline  Week 12 P  
24 hour recall      
Energy (kcal/d) 2623 ± 172 1664 ± 176† 4014 ± 2014 1777 ± 611 0.983 
Protein (% TE) 19.6 ± 2 13 ± 4.6 10.7 ± 1 20 ± 9 0.728 
Fat (% TE) 31.5 ± 2 27 ± 6 50.4 ± 7 37 ± 8† 0.013* 
CHO (% TE) 48 ± 4 60 ± 3 37 ± 6 39 ± 8 0.853 
SFA (% TE) 9.8 ± 2 9.9 ± 6 19 ± 7 14 ± 3 0.281 
MUFA (% TE) 11 ± 1 9.4 ± 3 17.6 ± 4 14 ± 2 0.340 
PUFA (% TE) 7.8 ± 1 4.3 ± 2 6.8 ± 3 6 ± 2 0.782 
FFQ      
Energy (kcal/d) 2046 ± 505 1558 ± 352 2515 ± 920  1261 ± 680† 0.028* 
Protein (% TE) 16.8 ± 5 16 ± 1 16 ± 5 17 ± 5 0.857 
CHO (% TE) 42 ± 2 48 ± 11 47 ± 8 42 ± 4 0.563 
Fat (% TE) 40 ± 6 27.3 ±  6 37 ± 5 36.9 ± 8  1.000 
SFA (% TE) 17 ± 2 13.7 ± 4 14 ± 6 14.4 ± 5 0.871 
MUFA (% TE) 13 ± 1 11.9 ± 5 13.5 ± 2 13 ± 3 0.699 
PUFA (% TE) 6.7 ± 3 5.8 ± 1 6.6 ± 3 6.8 ± 2 0.551 
PAL      
Sitting
 
(hrs/d) 8.5 ± 5 10 ± 3 9 ± 1 8 ± 4 0.591 
Walking 1080 ± 711 1039 ± 0 1721 ± 2132 847 ± 480 0.628 
Moderate  360 ± 509 160 ± 113 1720 ± 2200  320 ± 554 0.554 
Vigorous  600 ± 849 960 ± 339 1707 ± 2956 2800 ± 4849  0.554 
Total PAL 2041 ± 2069 2160 ± 226 5148 ± 4965 3967 ± 4241
 
 0.564 
TE, total energy. PAL, physical activity level. Values are means ± SD. Significant difference between treatment groups assessed using Independent-







6.7.5 Markers of safety 
Liver function, CD4 count, HIV viral load and oxidative stress were measured as 
markers of safety in response to the supplements (Table 6.6). Baseline liver function 
tests were not significantly different between the groups. Albumin concentration was 
significantly higher in the CLA group compared with placebo at week 12 (P = 0.049), 
but was still within the normal range of 35-50 g/L. CD4 cell count and HIV viral load 
were measured as indicators of HIV disease status. CD4 cell counts were > 300 cells/ 
mm
3 
at baseline and did not differ significantly between the groups after 12 weeks of 
treatment. HIV viral load was < 50 copies per ml in all patients at baseline and was not 
affected by treatment with either placebo or CLA for 12 weeks. MDA is a naturally 
occurring product of lipid peroxidation and plasma levels were used as a marker of 
oxidative stress. At week 12, MDA concentration was significantly lower in the CLA 
group compared with the placebo group (P = 0.002).  
 
Table 6.6 Markers of safety at baseline and week 12  





Baseline Week 12 Baseline Week 12 P 
Albumin (g/L) 35-50 49 ± 0 46 ± 1 52 ± 2 50 ± 1 0.049* 
ALP (IU/L) 30-120 71 ± 19 66 ± 12 89 ± 28 88 ± 25 0.344 
ALT (IU/L) 4-59 22 ± 1 20 ± 2 31 ± 11 28 ± 13 0.445 
Bilirubin 
(μmol/L) 








) 500-1500 678 ± 45 531 ± 22 623 ± 160 530 ± 154 0.998 
HIV viral load 
(copies/ ml) 20-107 < 50 < 50 < 50 < 50 - 
Oxidative stress  
MDA (μM) 1.86-3.94 19 ± 8.5 11.5 ± 1.3 8.7 ± 7.4 1.4 ± 1.0 0.002* 
MDA, malondialdehyde. Values are means ± SD. Significant difference between 
treatment groups assessed using Independent-samples t-tests: *P < 0.05. Values for HIV 
viral load for some patients were reported as “undetectable” if < 20, so differences 






Anthropometry was assessed at baseline and week 12 in both groups using weight, WC, 
skinfold measurements and bioelectrical impedance analysis (Table 6.7). At week 12, 
the CLA group had significantly higher subscapular skinfold thickness compared with 
the placebo group (P = 0.008). However, it is unlikely to represent an effect of 
supplementation as baseline values were also significantly different. Within the CLA 
group, suprailiac skinfold thickness increased significantly from baseline to week 12 (P 
= 0.04).  
 
 
Table 6.7 Anthropometry at baseline and week 12  
 Placebo CLA  
 Baseline Week 12 Baseline Week 12 P 
Weight (kg) 95.9 ± 2.7 98.6 ± 5.1 92.7 ± 9.1 91.7 ± 8.2 0.674 
BMI (kg/m
2
) 30.6 ± 2.2 31.5 ± 3.2 30.7 ± 4.6 30.4 ± 4.1 0.975 
WC (cm) 101.6 ± 3.4 104.5 ± 1.6 106.6 ± 2.9 106.7 ± 3.2 0.170 
Tricep (mm) 14.6 ± 2.9 15.6 ± 4.4 20.6 ± 2.4 23.7 ± 3.4 0.085 
Bicep (mm) 10.2 ± 7.2 12.6 ± 12.5 16.1 ± 3.4 15.3 ± 1.4 0.291 
Suprailiac (mm) 24.3 ± 8.4 29.5 ± 3.6 29.6 ± 2.4 34.3 ± 3.8† 0.532 
Subscapular (mm) 13.5 ± 3.7 14.5 ± 8.6 30.1 ± 2.2 28.5 ± 4.1 0.008* 
Body fat- SF (%) 25.9 ± 3.9 19.4 ± 2.8 30.9 ± 3.4 33.9 ± 2.9 0.227 
Body fat- BIA (%) 27.3 ± 0.14 27.4 ± 1.6 30.6 ± 3.9 30.2 ± 2.6 0.334 
SF, skinfold thickness. BIA, bioelectrical impedance analysis. Values are mean ± SD. 
Significant difference between treatment groups assessed using Independent-samples t-
tests: *P < 0.05. Significant difference within the same group assessed using paired t-
test: †P < 0.05.   
217 
 
6.7.7 Plasma glucose and lipid concentrations 
Plasma glucose and lipids were measured at baseline and after 12 weeks of 
supplementation with CLA or placebo (Table 6.8). There were no significant 
differences between the placebo and CLA groups at week 12. No within group 
differences were observed at week 12 for either group.  
 
 
Table 6.8 Plasma glucose and lipid concentrations at baseline and week 12 
 Placebo CLA  
 Baseline Week 12 Baseline Week 12 P 
FG (mmol/L) 5.1 ± 0.4 5.2 ± 0.5 5.1 ± 0.6 5.2 ± 0.6 0.955 
TG (mmol/L) 1.4 ± 0.9 0.5 ± 2.1 1.5 ± 0.8 0.8 ± 1.6 0.564 
TC (mmol/L) 4.1 ± 0.3 4.2 ± 0.8 5.1 ± 1.2 5.4 ± 1.1 0.304 
HDL-C (mmol/L) 1.0 ± 0.1 1.1 ± 0.1 1.4 ± 0.2 1.5 ± 0.4 0.293 
LDL-C (mmol/L) 2.4 ± 0.1 2.6 ± 0.5 2.9 ± 0.9 3.3 ± 0.9 0.439 
TC:HDL-C 3.9 ± 0.6 3.8 ± 0.6 3.7 ± 1.1 3.8 ± 1.4 0.951 




6.7.8 Plasma adipocytokine concentrations   
Plasma adipocytokine concentrations were measured to determine the effect of the 
supplements on markers of insulin sensitivity and inflammation. Table 6.9 shows the 
results at baseline and after 12 weeks of treatment. There were no significant differences 
between the groups at week 12 for any of the adipocytokines investigated.    
 
 
Table 6.9 Plasma adipocytokine concentrations at baseline and week 12  
 Placebo CLA  
 Baseline Week 12 Baseline Week 12 P 
Adiponectin  6.52 ± 1.1 6.15 ± 0.1 4.69 ± 3.3 4.96 ± 3.4 0.669 
IL-2  0.86 ± 0.3 0.79 ± 0.4 0.40 ± 0.4 0.71 ± 0.2 0.819 
IL-4  1.12 ± 0.3 1.15 ± 0.1 1.51 ± 0.3 1.18 ± 0.2 0.554 
IL-6  1.07 ± 0.3 1.13 ± 0.1 0.71 ± 0.2 0.88 ± 0.3 0.367 
IL-8  2.17 ± 0.4 2.23 ± 0.7 2.29 ± 0.3 1.65 ± 0.7 0.436 
IL-10  0.55 ± 0.1 0.42 ± 0.1 0.45 ± 0.1 0.61 ± 0.6 0.564 
VEGF 11.4 ± 2.9 9.38 ± 0.7 13.5 ± 4.6 9.42 ± 4.6 1.000 
IFN-γ  0.25 ± 0.1 0.29 ± 0.6 0.13 ± 0.1 0.25 ± 0.2 0.852 
TNF-α  2.50 ± 0.5 2.30 ± 0.6 1.92 ± 0.2 2.20 ± 0.2 0.851 
IL-1a  0.16 ± 0.1 0.22 ± 0.1 0.15 ± 0.2 0.19 ± 0.1 0.813 
IL-1b  0.81 ± 3.2 0.72 ± 0.3 0.29 ± 0.3 0.75 ± 0.3 0.904 
MCP-1  80.1 ±  13 94.4 ±  48 112 ±  38 86.6 ±  19 0.803 
EGF  6.22 ± 0.8 6.91 ± 8.2 3.03 ±1.8 2.04 ± 1.4 0.564 
Adiponectin concentration expressed as mg/L and all other cytokines as ng/L. Values 





6.7.9 Adverse events  
All patients recruited to the study experienced adverse events, which may have been 
related to supplementation. The majority were gastrointestinal (GI), ranged from mild to 
severe in nature and included acid reflux, flatulence, soft stools, abdominal discomfort 
and increased urinary frequency. Three patients had to be excluded from the study due 
to diarrhoea. Most symptoms appeared to resolve by the 6 week visit or were mild 
enough for the patient to continue with the study. Table 6.10 provides details of the 
adverse events according to treatment allocation. Although there was no significant 
difference in mean CD4 count within the groups at week 12, closer inspection of the 
data revealed that 4 of the 5 patients (2 placebo, 2 CLA) had lower CD4 counts at week 
12 compared with baseline (Table 6.11).  
 











Reflux 2 2 Day 1 6-10 days 5 
Flatulence  1 0 Day 1 2 weeks 6 
Increased bowel 
movements 
0 1 Day 1 Ongoing 3 
“Oiled” stools 2 1 Day 1 Ongoing 2 
Soft stools 2 1 Day 7 4 weeks 3-5 
Diarrhoea 1 3 Day 1 5 days 7-9 
Abdominal 
discomfort 
0 1 Day 7 4 weeks 4 




Table 6.11 Change in absolute and percentage CD4 counts at baseline and week 12  
Patient ID Baseline Week 12 Treatment group 
2 710 (35.53) 515 (36.77) Placebo 
3 775 (41.31) 679 (35.87) CLA 
7 638 (22.33) 372 (18.64) CLA 
8 457 (30.63)  541 (30.22) CLA 
9 646 (38.61) 547 (38.66) Placebo 
Values are CD4 count in cells/mm
3




Of 478 patients assessed for eligibility as part of this study, only 5 were eligible and 
completed the study. Given the small sample size it is difficult to interpret the data or to 
comment on the effect of CLA supplementation. The primary outcome of the study was 
to test whether CLA supplementation would reduce WC. No change in WC was 
observed after 12 weeks of CLA supplementation. The increase in EPA and DHA in the 
CLA group compared with placebo at week 12 may reflect an increase in dietary intake 
of these fatty acids, as the CLA supplements did not contain any detectable EPA or 
DHA. 
  
Overall, compliance with the supplements is difficult to interpret, as plasma CLA and 
oleic acid composition did not increase significantly after 12 weeks of treatment. Noone 
et al (2002) have previously shown almost a two-fold increase in total plasma c9,t11 
composition after 8 weeks of supplementation with 3 g/d mixed CLA isomers (0.33 g to 
0.62 g / 100g total plasma lipids). Similar increases were expected in this study, but 
were not observed, possibly due to variability in the consumption of the supplements as 
a result of the adverse effects experienced by all patients. The adverse effects were 
considered to be probably related to the supplements, with the exception of the 
increased frequency of urination, which was highlighted as a previous issue and also has 
not been reported previously in the literature. As mentioned above, three subjects were 
excluded from the study due to diarrhoea, which ceased once the supplements were 
discontinued. The adverse effects reported in this study have been reported previously 
with CLA (Blankson et al., 2000, Gaullier et al., 2007, Onakpoya et al., 2012) and 
HOSF supplements (Whigham et al., 2004) and may relate to the gelatine capsules 
rather than the oil itself (EFSA, 2010) 
 
Oxidative stress was used as a marker of safety to determine lipid peroxidation 
associated with treatment. MDA levels circulate in plasma at a normal concentration of 
1.86-3.94 μM. In this study, baseline MDA concentrations were above the normal range 
in both groups. MDA has previously been shown to be increased in HIV seropositive 
patients compared with healthy controls and reflects disease progression (Suresh et al., 
2009). There was wide variability in the results from the TBARS assay carried out on 
these samples. This, together with the fact that such large MDA values have not been 
reported previously in HIV may indicate that the high levels of MDA found in this 
221 
 
study may be related to the experimental method. This also limits the interpretation of 
MDA concentrations at week 12.  
 
The decrease in CD4 count observed in 4 of 5 patients was an unexpected finding and 
may be related to the supplements. However, as the effect was not treatment specific 
and the percentage CD4 count did not change more than 5% for any patient, it may also 
reflect physiological variations in this cell population. Subsequent communication with 
the medical team indicated that it is more likely to relate to individual variations in CD4 
count or laboratory variations in its measurement.  
 
Results from our analysis of CREATE Study data (Chapter 4) indicated that 25% of 
men had a large WC (≥ 94 cm or ethnic-specific cut-off). Based on these data, it was 
decided that abdominal obesity as indicated by a large WC was a problem in these 
patients and a measureable target for a CLA intervention study. However, over the 
course of recruitment for the study, it became apparent that large WC (> 94 cm or 
ethnic-specific cut off) was not as prevalent among the current HIV outpatient 
population as in 2005-2006.  
 
It is worth noting that a relatively short timeframe was available in which to assess 
patients for eligibility while they were in the clinic waiting room. As a result, the initial 
assessment of eligibility was based on self-reported WC. It is possible that some 
patients’ WC were greater than that reported. However, a recent study of 1,500 HIV-
infected men showed that the average WC was 87 cm (95% CI 86, 87) (Falutz et al., 
2014). This supports our observation that the majority of patients have a WC below the 
cut-off for MetS. Our findings suggest that body composition may have changed in 
these patients since 2005/2006. The use of newer HAART regimens with fewer 
lipodystrophic side-effects may account for the observed differences, or it may simply 
be due to a greater awareness of HALS among clinicians and patients, which leads to 
more timely and improved management strategies.    
 
Notwithstanding the fact that patients did not meet eligibility criteria, a number of 
patients were not interested in participating. Previous studies have reported problems 
recruiting among this population group; Tien et al (2006) discontinued recruitment at 
two of their sites due to recruitment difficulties. During our study it was also noted that 
certain ethnic groups were less interested in participating in the study, a finding 
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observed by other groups, which has been suggested to relate to the stigma felt by these 
groups regarding their HIV diagnosis (Shacham et al., 2014). In the present study, other 
barriers to participation communicated to the researcher included patients not having the 
time to attend repeat study visits, not wanting to lose weight, not wanting to take extra 
medication and not wanting to have blood taken. Issues with transportation and time 
have previously been cited as barriers to recruitment among HIV-infected men 
(Silvestre et al., 2006). The fact that some patients chose not to participate because they 
did not want to lose weight is an interesting finding. Weight loss was traditionally 
associated with HIV wasting and was a common finding among those infected with 
HIV in the early years prior to HAART (Grinspoon et al., 1996). The patients who cited 
this reason felt that weight loss might somehow lead to disclosure of their HIV-positive 
status, something which they seek to conceal. This highlights the stigma that still exists 
around HIV and is an important consideration for studies recruiting among this patient 
group.  
 
The potential therapeutic role of long chain PUFA in mitigating aspects of HALS is 
worth exploring in future studies. Outlined below are a number of changes which could 
be made in order to increase participant numbers and improve compliance:  
 Using a lower WC cut-off and including other markers of the MetS such as TG, 
FG, HDL-C and BP.   
 Recruiting patients from more than one HIV outpatient clinic in London, as well 
as from smaller hospitals and healthcare centres.  
 The current study recruited for 4 months. Future studies should allocate more 
time for recruitment.  
 During recruitment, it was observed that patients were more comfortable and 
trusting of staff with whom they were familiar and had encountered previously. 
Moreover, patients were more likely to participate if they were referred to the 
investigator by staff members. Researcher integration into the department prior 
to the study may increase awareness of the study and may encourage more 
patient referrals. This may be achieved by attending research team meetings a 
few months in advance of the study.  
 Providing an incentive to encourage referral of patients to the study might be 
another useful strategy. The NIHR Clinical Research Network provides 
infrastructure support, including financial incentives for the Trust, for studies 
which meet certain criteria and are adopted on to their portfolio.  
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 Naturally CLA-enriched dairy products have previously been shown to be 
beneficial in improving lipid profiles, as well as reducing inflammation and 
platelet aggregation in some (Nazare et al., 2007, Pintus et al., 2013) but not all 
(Tricon et al., 2006, Sofi et al., 2010) studies. Future studies could explore the 
use of functional foods such as CLA-enriched dairy products, which may 
minimise the side-effects associated with oil capsules as experienced by all 
patients recruited to the CLAART study. Another strategy may be to use dairy 
products as a vehicle for the CLA, which has previously been shown to reduce 
body weight and total fat mass (Lopez-Plaza et al., 2013).  
 
Overall, this study has provided useful information on HIV patients attending outpatient 
clinics at St Thomas’ Hospital and the difficulties recruiting this group to a nutrition 
intervention study. Patients recruited to the study provided information on the adverse 
effects of supplementation and the overall feasibility of the study, which will be 















Chapter 7  





7.1 Discussion  
The aim of this thesis was to investigate the contribution of ARVs to the development 
of HALS in vitro and the role of CLA in mitigating adipocyte dysfunction. The 
prevalence of HALS and the potential role of CLA isomers in mitigating aspects of 
HALS in HIV-infected individuals were also investigated.  
 
The contribution of ARVs to adipocyte dysfunction, a central mechanism involved in 
the pathogenesis of HALS, was investigated. RTV was found to be the most potent 
ARV and induced a significant decrease in TG accumulation, lipid droplet protein 
expression, PPAR-γ expression and nuclear consensus site binding, as well as 
adiponectin expression and secretion. Similar findings have been demonstrated by other 
groups (Lagathu, 2007, Caso et al., 2010). This is the first study to show an effect of 
RTV on PPAR-γ binding to its PPRE and our results suggest that RTV induces 
adipocyte dysfunction by inhibiting adipocyte differentiation and adipogenesis.  
 
In line with this, microarray analysis revealed that treatment with RTV modulated the 
expression of master adipogenic transcription factors (CEBP-α, PPAR-γ) and adipocyte-
specific markers (adiponectin, leptin, resistin, Fabp4, Cidec). The effect of RTV on 
PPAR-γ expression may involve altered ERK1/2 signalling or LXR-α expression, both 
of which could be explored in future studies using commercially available ERK 
inhibitors and LXR-α knockdown using RNA interference techniques.   
 
Decreased adipocyte differentiation and adipogenesis, possibly mediated via PPAR-γ, 
appear to be central to adipocyte dysfunction in response to RTV treatment. However, it 
is also possible that increased lipolysis may play a role. Microarray analysis shows 
inconsistent results for lipolysis: anti-lipolysis genes such as Cidec were down-
regulated, but lipolytic genes such as HSL were also down-regulated. Zinc alpha-2 
glycoprotein (ZAG) is a lipid mobilising factor shown to decrease TG accumulation and 
increase HSL and adipose tissue TG lipase (Bao et al., 2005). The effect of ARVs on 
ZAG levels has not previously been investigated in vitro. Further investigations of ZAG 






The main limitations of this study are that no combinations of ARVs were tried, PPAR-
γ agonists/ antagonists were not used and lipolysis was not investigated; thus it is 
important to address these points in future studies to mimic current use of fixed dose 
drug combinations among patients, to determine whether adipocyte dysfunction is 
mediated via PPAR-γ and to determine the contribution of lipid mobilising factors and 
lipolysis to the pathogenesis of HALS. 
 
Due to the potent effects of ARVs on PPAR-γ, as well as the beneficial effects of 
PPAR-γ ligands in HALS (Raboud et al., 2010), we chose to investigate the effects of 
CLA isomers, as putative PPAR-γ ligands, in mitigating ARV-induced adipocyte 
dysfunction. Both c9,t11 and t10,c12 significantly increased TG accumulation in RTV 
treated cells. The reason for this increase in TG accumulation in response to t10,c12 is 
uncertain, but may relate to the presence of RTV in the system, which may have 
reversed the normal adipocyte response to t10,c12. Furthermore, the effects of t10,c12 
have been shown to vary depending on the time period of treatment during adipocyte 
differentiation (Evans et al., 2001), which may also explain the observed effect.   
 
The isomers had differential effects on other adipogenic and inflammatory genes. c9,t11 
appears to have a beneficial effect and increased PPAR-γ binding to PPRE. In contrast, 
the addition of t10,c12 appears to enhance the negative effects of the ARVs by 
decreasing perilipin and Cidea expression, PPAR-γ binding to PPRE, adiponectin 
expression and secretion, as well as increasing IL-6 expression. The differential effects 
of CLA isomers has previously been shown (Brown et al., 2003), with t10,c12 
exhibiting a more potent effect on adipocyte metabolism than c9,t11 (Zhai et al., 2010).   
 
Microarray analysis revealed that t10,c12 was the more potent CLA isomer and 
significantly decreased adipogenic genes (Igf1, Cfd, Scd, Adipoq, Pepck, Fasn), which 
provides further evidence for role of t10,c12 in enhancing the anti-adipogenic effects of 
RTV. CPT-1, a key β-oxidation enzyme, was up-regulated by t10,c12 in this study and 
suggests that t10,c12 may increase the fatty acid oxidising capacity of adipocytes, 
thereby preventing TG storage and reducing fat mass. Although this contrasts with the 
observed increase in TG storage in t10,c12 treated cells, it highlights fatty acid 




The main limitation of this study is that no combination of CLA isomers was tried. 
Previous studies have used a combination of the two isomers and commercially 
available supplements tend to consist of an isomeric mixture. This should be addressed 
in future studies. The effects of the isomers could also be investigated in the presence of 
a PPAR-γ inhibitor such as GW9662, to determine whether the effect of t10,c12 on TG 
storage is mediated via a PPAR-γ-dependent mechanism.  
 
This is the first study to report the prevalence of LD and HALS in a UK HIV 
population. Analysis of CREATE data revealed that 23% of patients were diagnosed 
with LD, up to 22% with MetS and 29% with a combination of morphological and 
metabolic abnormalities also known as HALS. This corresponds with previous studies, 
which have been found to report prevalence figures ranging from 9-83% (Loonam and 
Mullen, 2012).  
 
Increased duration of HAART and raised FG levels were associated with increased odds 
of having LD. The associations between LD, HAART and glycaemic parameters are 
shown elsewhere in the literature (Lichtenstein et al., 2001, Freitas et al., 2012). 
Interestingly, Leclercq et al (2013) recently found that after 1-5 years of receiving 
HAART, 28% of their population developed LA; the average duration of HAART use 
among the CREATE cohort was 8 years.  
 
The prevalence of MetS (up to 22%) was slightly lower in this group than in the general 
European population (24.3%) (Scuteri et al., 2014). The fact that no HIV disease or 
drug factors were associated with MetS also implies that what we observe in these 
patients is the normal MetS as seen in the general population.  
 
Receiving a first line HAART regimen was protective against LD in this study, which 
contrasts with previous reports (Galli et al., 2002, van Griensven et al., 2007) and may 
indicate a yet unexplored role for virological failure in the pathogenesis of HALS.  
 
This study is the first to identify the prevalence of LD and HALS and to determine 
factors associated with both in an urban UK HIV population. Findings may be useful for 
evaluating and monitoring similar HIV patient groups in an outpatient setting. 
Additionally, results show that the term HALS is useful in identifying patients with both 
morphological and metabolic abnormalities associated with HIV and HAART.  
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The main limitations of The CREATE Study pertain to data collection; no objective 
measure of LD was used and no details were collected regarding whether the adipose 
tissue alterations were peripheral (LA), central (LH) or mixed. Future studies should 
include objective measures of body fat distribution such as WC and BIA. Due to the 
problems in correctly defining HALS, future studies should also use a definition of 
HALS from the literature, e.g. fat mass ratio, to allow for comparison with existing data.  
 
An intervention study was undertaken to determine the effects of CLA on abdominal 
obesity in HIV-infected men. Interestingly, we observed that the majority of patients 
attending the HIV outpatient clinic did not meet the MetS cut-off for WC. This contrasts 
with findings from The CREATE Study where 25% of patients attending the same 
clinic had a WC ≥ 94 cm. The use of self-reported WC to assess eligibility in this study 
could be said to have underestimated the proportion of patients meeting the eligibility 
criteria. However, self-reported WC has previously been used to assess the prevalence 
of overweight and obesity (Dekkers et al., 2008) and has been found to correlate 
reasonably well with technician-measured WC (Rimm et al., 1990).  
 
For those patients recruited to the study, no statistically significant change in WC was 
observed in the CLA group after 12 weeks of treatment, which may be due to the small 
sample size. However, the proportions of CLA in plasma also did not change over the 
course of the study, which may indicate poor compliance with supplementation. Poor 
compliance may relate to the GI side-effects associated with the supplements, which 
were experienced by patients in both treatment groups and which resulted in drop-out of 
three of the patients. Similar side-effects have been reported in the literature for both 
CLA (Blankson et al., 2000, Gaullier et al., 2007, Onakpoya et al., 2012) and HOSF 
supplements (Whigham et al., 2004). The fact that the side-effects were not treatment 
specific suggests that they may be related to the gelatine capsules, rather than to the oil 
itself, which has been suggested previously (EFSA, 2010).  
 
Difficulty recruiting resulted in a small sample size and limited our ability to interpret 
the data. Despite this, the study provided useful information on recruiting HIV-infected 
men to a nutrition intervention study. Future studies should focus on amending the 
inclusion criteria to increase eligibility, possibly by reducing the WC cut-off or 
including additional MetS criteria such as TG, HDL-C, FG and BP. Another issue 
encountered during recruitment was that patients tended to be more trusting of staff with 
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whom they were familiar and therefore, more likely to engage in research if the study 
was introduced to them by a staff member. Future studies should be carried out over a 
great time period to allow the researcher to better integrate into the department and to 
allow sufficient time to increase awareness of the study among staff in order to 
encourage patient referral to the study. Incentivising recruitment within the department 
may also be beneficial. Future studies could also aim to recruit from more than one site, 
for example from smaller hospitals or through HIV charities such as The Food Chain. 
Less formal, more community-based settings such as these may encourage greater 
participation among this group for whom continuity and familiarity of care appear to be 
important. Lastly, a dietary intervention involving naturally CLA-enriched dairy 
products or dairy products as a vehicle for the CLA may be worth investigating in future 
studies in order to reduce the pill burden and possibly the GI side-effects associated 
with the supplements.   
 
7.2 Concluding remarks and implications for future research 
The strength of this study lies in the novel exploration of the effects of CLA isomers in 
an in vitro model of HALS and the translational potential of the findings among a 
population of HIV patients for whom observational data was available.   
 
ARVs, particularly RTV, induced severe adipocyte dysfunction, characterised by altered 
differentiation and impaired adipogenesis. Future studies using a PPAR-γ inhibitor will 
determine whether this occurs via a PPAR-γ-dependent mechanism, and use of ERK 
inhibitors and LXR knockdown will identify up-stream pathways involved in PPAR-γ 
down-regulation. Microarray analysis identified lipolytic genes affected by RTV and 
suggests that lipid mobilisation may be a promising area for future research.  
 
In preliminary data not shown here, we found that long term non-progressors (patients 
who maintain CD4 count > 500 cells/mm
3
 without ARVs) have lower concentrations of 
markers of adipose tissue mobilisation (ZAG) and insulin sensitivity (adiponectin) 
compared with those acutely infected with HIV. Recent studies have shown that ZAG 
concentrations in HIV positive adults on ARVs are associated with dyslipidaemia and 
are lower than uninfected controls (Ceperuelo Mallafré et al., 2012). Adiponectin 
concentrations have also been shown to be lower in HIV than in uninfected controls and 
are associated with severity of subclinical atherosclerosis (Ketlogetswe et al., 2014). In 
a recent study, higher plasma LPS, a marker of endotoxaemia, was found in patients 
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with HALS compared with those without HALS (Vilades et al., 2014). Future studies 
will investigate the effect of LPS and endotoxaemia on adipose tissue mobilisation 
(ZAG) and insulin sensitivity (adiponectin) as another potential mechanism underlying 
HALS.  
 
CLA isomers demonstrate potential in mitigating ARV-induced adipocyte dysfunction, 
but the isomers have differential effects; c9,t11 may be beneficial, while t10,c12 
appears to enhance the detrimental effects of ARVs. Future work should investigate the 
effect of a combination of CLA isomers and determine the mechanism underlying the 
increase in TG accumulation in response to t10,c12 using a PPAR-γ inhibitor.  
 
A quarter of patients from the CREATE cohort were affected by HALS. As we 
approach ten years since The CREATE Study was conducted, it would appear timely to 
repeat the study to determine the current scenario of HALS in this population. Future 
studies should objectively measure HALS and include a definition of HALS to allow for 
a more robust comparison with existing literature.  
 
The feasibility of a nutrition intervention in HIV-infected men has been explored and 
the barriers to recruitment and participation identified. Future randomised controlled 
trials investigating the effects of long chain PUFA supplementation on body fat in HIV-
infected individuals are warranted, taking into account the lessons learned from the 
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Date  ___________________ 
Name (s) ______________________________________________________  
Address ______________________________________________________ 
Hospital no        
D.O.B.:        Age: _________ 
Contact number/ email: ______________________________________________ 
Receiving HAART   Yes /  No   (circle as appropriate) 
HAART regimen        _____ 
Weight (kg)       or     (stones & lbs)   
Height (m)      or     (feet & inches  
BMI (kg/m
2
)      
Waist circumference (cm)     or (inches)     
Are you suffering from any acute conditions e.g. chest infection?   Yes/ No 
Are you suffering from any chronic conditions e.g. type 2 diabetes?  Yes/ No  
Are you suffering from high cholesterol?      Yes/ No 
Are you suffering from high blood glucose/sugar?     Yes/ No 
Are you currently taking any testosterone replacement therapy?  Yes/ No 
Are you currently taking any medication designed to reduce weight/  Yes/ No 
body fat? 
Are you currently following a diet (self- or practitioner-prescribed)  Yes/ No 
to reduce weight/body fat?  
Are you currently taking or have you taken any fat-based supplements  Yes/ No  
(e.g. fish oils) in the previous 3 months?    
Are you participating in any other studies?     Yes/ No 
Eligible for CLAART study?  Yes/ No 
Baseline appointment scheduled for      ______ 
Year HIV diagnosed:          
When HAART started:         









































































INFORMATION SHEET FOR PARTICIPANTS 
REC Reference Number 13/LO/1145 
YOU WILL BE GIVEN A COPY OF THIS INFORMATION SHEET 
A pilot study to investigate the effects of a novel dairy fat (conjugated linoleic 
acid; CLA) on body fat in men with HIV receiving HAART: the CLAART study 
What is the purpose of this study? 
Excess fat around the abdomen is a side-effect of highly active antiretroviral 
therapy (HAART). Excess fat around the abdomen increases the risk for heart 
disease. Studies have shown that conjugated linoleic acid (CLA), a fatty acid found 
in dairy products, may reduce body fat. CLA is naturally found in meat and dairy 
products. CLA is not produced by the human body and can only be obtained 
through the diet or through supplements. CLA is thought to affect body fat by 
altering levels of a molecule called PPAR gamma, which is known as the ‘master 
regulator’ of fat. HAART has been shown in some laboratory experiments to 
decrease levels of this molecule in fat cells, which may explain the loss of fat in the 
face, arms and legs, and increased fat around the waist sometimes seen when 
HAART is taken. This controlled study will investigate the effect of CLA 
supplements on body fat including waist circumference, with the aim of reducing fat 
around the waist.  
We would like to invite you to participate in this original research project which is 
being carried out as part of the researcher’s PhD project. You should only 
participate if you want to; choosing not to take part will not disadvantage you in any 
way. Before you decide whether you want to take part, it is important for you to 
understand why the research is being done and what your participation will involve. 
Please take time to read the following information carefully and discuss it with 






Are you suitable for this study? 
You have been given this information sheet as you have expressed an interest in 
our research. In order to participate in this study you need to be able to say ‘Yes’ to 
all of the following: 
 I am male 
 I am aged between 18 and 55 years 
 I am receiving HAART 
 I have or think I may have a waist circumference of greater than 94 cm 
(37 inches) or a body mass index (a measure of body fat based on 
your height and weight; BMI) of greater than 25 kg/m
2
 
 I have never had a heart attack, stroke, chest pain, blood clots, heart 
disease, liver or kidney diseases, type 1 or type 2 diabetes, long term 
stomach or intestinal problems, hepatitis C or cancer 
 I do not consume excess alcohol (excess alcohol = greater than 
21units per week) or use illicit drugs 
 I am not taking weight loss medication or following a weight loss diet 
 I am prepared to avoid consumption of fat-based supplements (e.g. 
fish oils) before and during the study 
 
What will happen to you if you take part? 
After completing a screening questionnaire over the telephone, if you are eligible, 
you will be invited to attend the Harrison Wing, St Thomas’ Hospital for a meeting 
that should last about 1 hour. During this first visit, I will explain the study to you in 
detail and I will answer any questions you have.  
If you would like to participate in the study, we will ask you to sign a consent form. 
Following consent, the following measures will be taken: 
 Height using a portable height measure 
 Weight using a weighing scales 
 Waist circumference using a measuring tape 
 Body fat (electronically using a body composition analyser and will be 
confirmed manually by measuring skinfold thickness at three sites: 
tricep, bicep, below the shoulder blade and at the top of the hip bone, 
using a device specially designed for this purpose) 
 
At this stage, if your waist circumference is greater than 94 cm and/or your BMI is 
greater than 25 kg/m
2
: 
 A teaspoon (5 ml) of blood will be taken by a nurse or a trained 
phlebotomist and used to determine levels of fat and glucose in your 
blood, as well as levels of free radicals (free radicals are molecules 
cause damage to cells in the body), liver function, immune function 
(CD4 count and viral load) and CLA levels.   
 You will be asked to complete a food frequency questionnaire to provide 
information on your usual food intake  
 You will be asked to complete a physical activity questionnaire to 
provide information on your activity levels.  
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 I will ask you for information about your food intake in the previous 24 
hours.  
 
I will then organise collection/delivery of supplements to you. These will be either 
CLA or placebo in capsule form.  You will be asked to take four 1g capsules per 
day with or after food (two capsules twice per day) for 12 weeks. These capsules 
are approximately the size of a kidney bean each.  In order for the results to be 
valid, it is very important that you take the correct amount of capsules every day for 
the full 12 weeks. I will obtain details about your HIV diagnosis including years with 
HIV, HAART regimen, years since HAART started, changes in HAART since then, 
any other medications, or other diseases from the dietetic team, if possible, or from 
your medical notes. 
 
I will contact you by telephone on weeks 2 and 4 to answer any questions you may 
have and to check your progress. On week 6 you will be asked to return to the 
Harrison Wing. During this visit, you will have your weight, waist circumference and 
body composition measured as in the first visit.  I will ask you to complete a 
physical activity questionnaire and I will ask you for information about your food 
intake in the previous 24 hours. I will also ask you whether you have had any side-
effects/symptoms as a result of the supplements. A 5 ml blood sample will be taken 
by a nurse or trained phlebotomist to measure the tests mentioned above. This visit 
should last 1 hour. I will also contact you at weeks 8 and 10 by telephone to answer 
any questions and to check your progress.   
 
After 12 weeks, you will be asked to return for a third visit lasting approximately 1 
hour. During this visit your weight, waist circumference and body fat composition 
will be measured as in previous visits and I will ask you to complete a physical 
activity questionnaire. I will ask you for information about your food intake in the 
previous 24 hours and ask you whether you have had any side-effects/symptoms 
as a result of the supplements. A 5 ml blood sample will be taken by a nurse or 
trained phlebotomist to measure all the tests as previously indicated. The overall 


































Screening  Visit 3 
Week 0 Week 6 Week 12 
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What are the possible side-effects of the supplements? 
According to the European Food Safety Authority, the supplements are safe when 
given at a dose of 4 capsules per day for 12 weeks. However, there may be a small 
risk of diarrhoea, soft stools and stomach pain. In rare cases certain blood 
measures of liver function may increase. In rare cases, levels of free radicals in the 
body may increase; free radicals may cause damage to cells. 
If you choose to take part in the study, we will monitor your progress closely and if 
you have any side-effects we will inform your doctor at Harrison Wing who will 
decide whether or not you should continue with the study.   
 
Will your participation be kept confidential? 
Information collected about you during this research will be kept strictly confidential 
and anonymity will be observed throughout the study by using a study ID in place of 
your name. Your name will be linked to this code in a separate file which will be 
kept locked in a secure place. Your name will only ever be linked to your study ID if 
you wish to withdraw from the study or we need to contact you or your GP to report 
blood results. Only the investigators have access to this data. Your GP will only be 
informed of your participation in the study if you would like us to inform them or if 
we find an abnormal blood result, in which case we will communicate this result to 
you, then to your GP and the team at Harrison Wing.  
A summary of the group results of the study will be made available once the study 
is finished. Your personal details will not be identified in this report. Individual 
results will only be provided if you have specifically requested to receive your 
results at the start of the study.  
 
What will happen to your study results? 
We hope to publish the results of the study in a scientific journal. You will not be 
identified in any publication. We will be happy to discuss the overall results with you 
when the study is completed, and will let you know how you can get a copy of the 
published results if you wish. Future studies may investigate other effects of CLA 
using your sample, but in such cases, confidentiality and anonymity will be 
maintained and it will not be possible to identify you from any publication.  
 
Who is organising and funding the study? 
The study is organised by Cathríona Loonam and her PhD supervisor, Dr Anne 
Mullen, at the Diabetes and Nutritional Sciences Division, Kings College London. 
Neither Miss Loonam nor Dr Mullen will be paid for recruiting participants to the 
study. The study is funded by a King’s College London PhD scholarship provided 
as part of the researcher’s PhD programme. The supplements will be provided by 
Stepan Lipid Nutrition, a nutrition company based in the Netherlands. In recognition 
of your time commitment, you will be paid an honorarium of £50 upon completion of 
the study and you will be refunded the cost of travelling to and from the Harrison 





Do you have to take part? 
It is up to you to decide whether or not to take part. If you do decide to take part 
you will be given this information sheet to keep and be asked to sign a consent 
form. You can withdraw from the study at any time by informing one of the 
researchers and you are not obliged to give a reason. You can withdraw your data 
from the study up until the time of publication (December 2014). A decision to 
withdraw at any time, or a decision not to take part, will not affect the standard of 
care you receive.  
 
What if there is a problem? 
If you have a concern about any aspect of this study, you should ask to speak to 
the researchers who will do their best to answer your questions [020 7848 4081]. If 
you remain unhappy and wish to complain formally, you can do this by contacting 




Further information and contact details 
If you would like further information or would like to take part, please contact the 
researcher, Cathríona Loonam, by email (claartstudy@kcl.ac.uk) or by telephone 
(020 7848 4162), or her supervisor Dr Anne Mullen by email  
(anne.mullen@kcl.ac.uk) or by telephone (020 7848 4081). 
 
If you decide to take part please let me know if you have been involved in any other 
study in the last year.  
 














CONSENT FORM FOR PARTICIPANTS IN A NUTRITIONAL STUDY 
 
Please complete this form after you have read the Information Sheet and you are satisfied that the 
research has been fully explained. 
Title of Study: A pilot study to investigate the effects of a novel dairy fat 
(conjugated linoleic acid; CLA) on levels of body fat in men with HIV 
receiving HAART: the CLAART study 
Research Ethics Committee Ref: 13/LO/1145 
 
Thank you for considering taking part in this research. The person organising the research must explain 
the project to you before you agree to take part. If you have any questions arising from the Information 
Sheet or explanation already given to you, please ask the researcher before you decide whether to 
participate. You will be given a copy of this Consent Form to keep and refer to at any time. 











I understand that if I decide at any time during the research that I no longer wish to participate in 
this project, I can notify the researchers involved and be withdrawn from it immediately. 
Furthermore, I understand that I will be able to withdraw my data up to the point of publication. 
I consent to the processing of my personal information for the purposes of this research study. I 
understand that such information will be treated as strictly confidential and handled in accordance 
with the provisions of the Data Protection Act 1998. 
I agree that the research team of Cathriona Loonam and Dr Anne Mullen may use my samples for 
future research. Please note that in such cases, as with this project, confidentiality and anonymity 
will be maintained and it will not be possible to identify you from any publication. 
 
Participant’s Statement: I ______________________________________________________________ 
agree that the research project named above has been explained to me to my satisfaction and I agree to 
take part in the study. I have read both the notes written above and the Information Sheet about the 
project, and understand what the research study involves. 
 
Signed  _________________________ Date  ____________________________ 
 
Investigator’s Statement:  I ______________________________________________________             
confirm that I have carefully explained the nature, demands and any foreseeable risks (where applicable) 
of the proposed research to the volunteer.  
Signed  _________________________ Date  ____________________________ 
 
  
I am a male aged between 18 and 55 years  
I do not have a history of heart disease, stroke, blood clots, diabetes, liver or kidney diseases, 
intestinal problems, hepatitis C or a cancer diagnosis (except basal cell carcinoma)  
I do not consume excess alcohol intake (excess = >21 units per week) or use illicit drugs 
I think I may have a large waist circumference or a high body mass index (BMI) 
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Appendix 8 CLAART study data collection sheet 
 
 
CLAART study data collection sheet 
 
Anthropometric assessment- Visit 01 
 
Measurements 
Height ____________(cm)  
Weight ____________ (kg) 
Reported usual weight __________(kg) / ___________(stones, pounds) 
Reported weight loss in the previous 6 months __________(kg) 
Body mass index (BMI) ____________ (kg/m
2
) 
Waist circumference ____________(cm) 
Upper arm length   ____________(cm) 
Upper arm circumference  ____________(cm) 
Tricep skin fold thickness (1) __________ (2) ________ (3) ________  
(Avg.) _________ (mm) 
Bicep skin fold thickness  (1) __________ (2) ________ (3) ________  
(Avg.) _________ (mm) 
Supra-iliac skinfold   (1) __________ (2) ________ (3) ________ 
(Avg.) _________ (mm) 
Subscapular skinfold  (1) __________ (2) ________ (3) ________  
(Avg.) _________ (mm) 
Total skinfolds: _____________   log Total: _____________ 




): Adult males (16-19y) = 1.1620 – 0.0630 x log10x 
      Adult males (20-29y) = 1.1631 – 0.0632 x log10x 
 Adult males (30-39y) = 1.1422 - 0.0544 x log10x 
      Adult males (40-49y) = 1.1620 – 0.0700 x log10x 
 Adult males (50+)      = 1.1715- 0.0779 x log10x 
____________________________________________________________________ 

















RE:  [Patient Name] participation in clinical trial 
Date of birth: [DOB], NHS number: [NHS number] 
Dear [Doctor Name]: 
 
I am writing to inform you that [Patient Name]  has requested that you should be 
informed of his participation in our research trial: A pilot study to investigate the effects 
of a novel dairy fat (conjugated linoleic acid; CLA) on levels of body fat in men with 
HIV receiving HAART: The CLAART Study. This trial is being conducted at the 
Harrison Wing, St Thomas’ Hospital, as part of a PhD project funded by King’s College 
London.  
 
This is a pilot, randomised, double-blind, placebo-controlled trial investigating the 
effects of CLA supplementation on measures of body fat including waist circumference. 
Participants are required to take four 1g CLA capsules (3g CLA total) per day for 12 
weeks. The primary outcome of the study is a reduction in waist circumference. 
Participants will attend three visits at the Harrison Wing where they will have their 
height, weight, waist circumference and body fat distribution measured, as well as a 
blood samples taken to measure triglycerides, total cholesterol, glucose, liver function, 
oxidative stress, CD4 count and viral load, as measures of the potential side effects of 
CLA. As a measure of adherence, plasma CLA levels will also be measured. Any 
clinically significant findings during this trial will be communicated to you, but if you 





Diabetes & Nutritional Sciences Division 
King's College London 
Franklin Wilkins Building 
150 Stamford Street 
London 
SE1 9NH  
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Appendix 10 Body Density Equations 
 
 





 (16-19y) = 1.1620 – 0.0630 x log10x 
 (20-29y) = 1.1631 – 0.0632 x log10x 
 (30-39y) = 1.1422 - 0.0544 x log10x 
 (40-49y) = 1.1620 – 0.0700 x log10x 
 (50+)      = 1.1715- 0.0779 x log10x 
 































































































































































































































































































































































































Appendix 13 International Physical Activity Questionnaire (Short Version) 
 
PHYSICAL ACTIVITY QUESTIONNAIRE 
 
We are interested in finding out about the kinds of physical activity you do as part of 
your everyday life because it is may affect your waist circumference, weight or body fat 
levels. The questions are about the time you spent being physically active in the last 7 
days. They include questions about activities you do at work, as part of your house and 
garden work, to get from place to place, and in your spare time for recreation, exercise 
or sport. 
Your answers are important. 
 
Please answer each question even if you do not consider yourself to be an active 
person. 
 










1a) During the last 7 days, on how many days did you do vigorous physical activities 
like heavy lifting, digging, aerobics, or fast bicycling? 
 
Think about only those physical activities that you did for at least 10 minutes at a time. 
 
 
________ days per week  
 
   
 




2a. Again, think only about those physical activities that you did for at least 10 minutes 
at a time.  
 
During the last 7 days, on how many days did you do moderate physical activities like 
carrying light loads, bicycling at a regular pace, or doubles tennis? Do not include 
walking. 
 vigorous physical activities refer to activities that take hard physical effort and 
make you breathe much harder than normal. 
 
 moderate activities refer to activities that take moderate physical effort and 
make you breathe somewhat harder than normal. 
 
1b. How much time in total did you usually 










________ days per week  
   
 
or  none 
   




3a. During the last 7 days, on how many days did you walk for at least 10 minutes at a 
time? This includes walking at work and at home, walking to travel from place to place, 








   
 
 
The last question is about the time you spent sitting on weekdays while at work, at 
home, while doing course work and during leisure time. This includes time spent sitting 
at a desk, visiting friends, reading travelling on a bus or sitting or lying down to watch 
television. 
 
4. During the last 7 days, how much time in total did you usually spend sitting on a 
weekday? ____ hours ______ minutes 
  
2b. How much time in total did you usually 
spend on one of those days doing moderate 
physical activities? 
__________hours______minutes 
3b. How much time in total did you usually 





Appendix 14 Determination of serum total cholesterol 
 
 
Sample requirements  
The Roche c8000 cobas c system used 2 μl of sample in the test.  
 
Method 
Serum cholesterol concentration was determined on the Roche cobas c8000 system 
(Roche Diagnostics Ltd., Burgess Hill, West Sussex, UK). Cholesterol esters were 
cleaved by the action of cholesterol esterase (CE) to yield free cholesterol and fatty 
acids. Free cholesterol was oxidised to cholesten-3-one and hydrogen peroxide by 
cholesterol oxidase (CHOD). Peroxidase (POD) catalysed the reaction of hydrogen 
peroxide with 4-aminoantipyrine and phenol to produce a red coloured quinoneimine 
product. Colour intensity is directly proportional to concentration of cholesterol and was 
measured spectrophotometrically at 520 nm. Intra-assay CV was 0.8 % and inter-assay 
CV was 1.5 %.  
 
                                                 
Cholesterol esters + H2O                                                   cholesterol + RCOOH 
                                               
Cholesterol + O2                                                                cholest‑4‑en‑3‑one + H2O2 
                                               







Appendix 15 Determination of serum HDL-cholesterol 
 
 
Sample requirements  
The Roche c8000 cobas system used 2 μl of sample in the test.  
 
Method 
HDL-C concentration in serum was determined using Roche colorimetric assay on the 
cobas c8000 system. The Roche assay for the measurement of HDL-C is an enzymatic 
assay. The cholesterol concentration of HDL-C was determined enzymatically by 
cholesterol esterase and cholesterol oxidase coupled with PEG to the amino group. 
Cholesterol esters are broken down quantitatively into free cholesterol and fatty acids by 
cholesterol esterase. In the presence of oxygen, cholesterol was oxidised by cholesterol 
oxidase to Δ4-cholestenone and hydrogen peroxide. In the presence of peroxidase, the 
hydrogen peroxide generated reacted with 4-amino-antipyrine and HSDA to form a 
purple-blue dye. The colour intensity of this dye is directly proportional to the 
cholesterol concentration and was measured spectrophotometrically at 600 nm. Intra-
assay CV was 0.7 % and inter-assay CV was 0.9 %.  
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Appendix 16 Determination of triglyceride levels 
 
 
Sample requirements  
The Roche c8000 cobas system used 2 μl of sample in the test.  
 
Method  
Triglyceride concentration in plasma samples was determined using the Roche c8000 
system. The Roche assay for the measurement of TG is an enzymatic colorimetric 
assay. Triglycerides in the sample were hydrolyzed to glycerol and free fatty acids by 
the action of lipase. A sequence of three coupled enzymatic steps using glycerol kinase, 
glycerophosphate oxidase, and horseradish peroxidase causes oxidative coupling of 3,5-
dichloro-2-hydroxybenzenesulfonic acid with 4-aminoantipyrine to form a red 
quinoneimine dye. The change in absorbance (520 nm) is directly proportional to the 
concentration of triglycerides in the sample. Intra-assay CV was 0.7 % and inter-assay 









Samples were taken into fluoride-oxalate tubes. The Roche cobas c8000 system used 2 
μl of sample in the test.  
 
Methods 
Glucose concentration in fasting plasma samples was determined using a Roche 
colorimetric assay on a cobas c8000 system. Glucose was oxidised by glucose oxidase 
to gluconolactone in the presence of atmospheric oxygen. The resultant hydrogen 
peroxide oxidised 4-aminophenazone and phenol to 4-benzoquinone-monoimino 
phenazone in the presence of peroxidase. The colour intensity of the red dye is directly 
proportional to the glucose concentration and was measured spectrophotometrically at 








The sample was taken into a serum separator tube. The Roche cobas c8000 system used 





At a pH of 4.1, bromcresol green (BCG), an anionic dye, binds selectively with cationic 
albumin to form an albumin-BCG complex. The colour intensity of the blue-green 
colour was directly proportional to the albumin concentration and determined 
spectrophotometrically at 570 nm. Intra-assay CV was 0.5 % and inter-assay CV was 
0.95 %.  
 
ALT 
ALT catalyzes the reversible transamination of L-alanine and 2-oxoglutarate to pyruvate 
and L-glutamate. Pyruvate is then reduced to lactate in the presence of lactate 
dehydrogenase with the concurrent oxidation of NADH to NAD. The rate of the NAD 
oxidation is directly proportional to the catalytic ALT activity. It was determined by 
measuring the decrease in absorbance at 340 nm. Intra-assay CV was 0.5 % and inter-
assay CV was 2.95 %. 
 
ALP 
P‑nitrophenyl phosphate is cleaved by phosphatases into phosphate and p‑nitrophenol 
in the presence of magnesium and zinc ions. The p‑nitrophenol released is directly 
proportional to the catalytic ALP activity and was determined by measuring the increase 
in absorbance at 480 nm. Intra-assay CV was 0.6 % and inter-assay CV was 1.6 %. 
 
Bilirubin 
Total bilirubin in the presence of caffeine, benzoate, and acetate is coupled with a 
diazonium ion in a strongly acidic medium. The intensity of the colour of the 
azobilirubin produced is proportional to the total bilirubin concentration and was 
measured spectrophotometrically at 520 nm. Intra-assay CV was 1.2 % and inter-assay 
CV was 1.6 %.  
308 
 
Appendix 19 Determination of CD4+ T lymphocyte count 
 
  
Sample requirements  
The sample was taken into an EDTA tube. The Beckman Coulter FP1000 system used 
100 μl of sample in each test.  
 
Method  
Sample preparation was carried out in a closed system using the automated FP1000 cell 
preparation system (Beckman Coulter). 100 μl of the sample was injected into the 
FP1000 system, to which 10 μl of Cyto-Stat® containing a four-colour monoclonal 
antibody panel was added. The addition of CD45 to the tube containing CD4, CD8 and 
CD3 allowed for the identification of lymphocytes based on CD45 and side scatter and 
for enumeration of CD4 and CD8 cells. Using a single platform approach, 100 μl of 
Flow-Count™ Fluorospheres were added to the CD4 stained sample. The fluorospheres 
contain a dye which emits fluorescence when excited at 488 nm. An assayed 
concentration of the fluorospheres allowed for the determination of absolute lymphocyte 
counts. The sample was incubated, fixed, lysed and stabilised on the FP1000 system. A 
no-wash method was used for single platform analysis. Flow-cytometric analysis was 
performed using a 5-colour flow cytometer equipped with FC500 CXP software 
(Cytomics FC 500, Beckman Coulter). A threshold was set according to manufacturer’s 
recommendations, side-scatter was adjusted to identify leukocyte populations and a gate 
was set manually around the CD45 population to allow for analysis within this 
population. Lymphocyte populations were identified based on CD45 fluorescence and 





Appendix 10 Determination of HIV viral load 
 
 
Sample requirements  



















 Analyser. The quantitation of HIV-1 viral RNA was performed 
using HIV-1 Quantitation Standard (QS) Armored RNA. The HIV sequences in the QS 
contain identical primer binding sites to the HIV-1 target RNA, but are distinguished 
from HIV-1 target amplicon through a unique probe binding region. The QS is a non-
infectious Armored RNA construct that was added to the sample at a known copy 
number. Protease, lysis reagent and magnetic glass particles were added to the sample to 
lyse the HIV-1 virus particles, release nucleic acids and protect the released HIV-1 
RNA from RNases in plasma. The HIV-1 RNA and QS RNA bound to the surface of 
the glass particles and unbound salts and proteins were removed by washing. After 
separation and washing, the adsorbed HIV-1 RNA and QS RNA were eluted with an 





 Analyser. HIV-1 RNA and QS RNA were reverse transcribed, 
amplified using PCR and detected using dual-labelled fluorescent probes. The 
COBAS® TaqMan® Analyser compared the HIV-1 signal to the HIV-1 QS signal for 
each sample and control and calculated the HIV-1 RNA concentration (Roche 




Appendix 11 Determination of plasma adiponectin 
 
 
Sample requirements  
The sample was taken into an EDTA tube. The Quantikine Adiponectin ELISA kit (R & 
D Systems) used 50 μl of sample for the test.  
 
Methods  
All samples were pre-diluted 1/100 before performing the assay. 100 μl of proprietary 
assay diluent was added to each well of a microplate. To this, 50 μl of standard, control, 
or sample (pre-diluted) were added to the respective wells. The plate was sealed with an 
adhesive strip. The plate was incubated for 2 hours at room temperature. The contents of 
each well were aspirated and the wells washed four times with 400 μl proprietary wash 
buffer. 200 μl of adiponectin conjugate was added to each well. The wells were covered 
with a new adhesive strip and incubated for 2 hours at room temperature. The aspiration 
and washing step was repeated. 200 μl of substrate solution was then added to each well 
and the plate was incubated for 30 minutes at room temperature protected from the 
light. Stop solution (50 μl) was added to each well inducing a colour change from blue 
to yellow. The optical density of each well was determined using a microplate reader set 




Appendix 12 Determination of plasma cytokines 
 
Sample requirements  
The sample was taken into an EDTA tube. The Evidence Investigator™ Cytokine & 




Proprietary assay buffer was pipetted into each well of a biochip. The calibrator, 
sample, or control was added to their respective wells. The handling tray containing the 
biochip was incubated for 1 hour at 37ºC and 370 rpm. Following this, the wells were 
covered and placed at 2-8ºC for 16-20 hours. Following overnight incubation, the cover 
strips were removed and the reagents discarded. Two quick wash cycles were carried 
out using proprietary wash buffer added to each well. This was followed by four further 
wash cycles and incubation in wash buffer for 2 minutes. After the final wash, residual 
wash buffer was removed from the biochip carrier by flicking the handling tray. 
Conjugate was added to each well and the reagents within the well were mixed. The 
biochip was incubated for 1 hour at 37ºC and 370 rpm. Following incubation, the 
reagents were discarded and washing was carried out as described previously. After the 
final wash, the wells were filled with wash buffer and left to soak for up to 30 minutes 
prior to imaging. The biochip to be imaged was removed from the handling tray. The 
wash buffer was removed and working signal reagent was added to each well. The 
biochip was placed into the Evidence Investigator
™
 automated analyser after exactly 2 
minutes. Images were captured automatically using dedicated software. The light signal 
generated from each of the test regions on the biochip was detected using digital 
imaging technology and compared to that of a stored calibration curve. The 
concentration of analyte present in the sample was calculated from the calibration curve. 
The sensitivity of the assay for each analyte (ng/L) is shown below.  
 
IL2 IL4 IL6 IL8 IL10 VEGF INFγ TNFα IL1α IL1β MCP1 EGF 
0.9 2.12 0.12 0.36 0.37 1.53 0.44 0.59 0.19 0.26 0.66 1.04 
 
 
